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Chronic rhinosinusitis (CRS), a disease of multifactorial aetiology characterised by the 
presence of infection and inflammation. The initial triggering factor/s and the perpetuating 
factor/s in the disease progression of CRS remains a matter of much debate. As a result of 
this, the treatment modalities in CRS is directed against infections using antibiotics and 
against inflammation using oral and topical steroids. Quiet often these therapies are given 
alone or in combinations for varying duration and frequency to bring clinical improvement 
in patients. The most unfortunate outcome is the chronicity of this disease despite multiple 
courses of medical therapies and in many cases, sinus surgeries. 
With the emergence of concepts of the microbiome and its implications in health and 
disease, and many chronic diseases linked to specific microbial alterations, the CRS 
microbiome have been extensively studied. This has led to the understanding that microbial 
richness and abundance are very individual specific and there are probably no clear 
demarcations between a healthy and a diseased sinus. However, a microbial dysbiosis could 
be associated with an inclination towards unhealthy state. Although antibiotics have been 
used to effectively to control a number of infections, their irrational use have led to the 
emergence of multidrug resistant organisms as well as microbial dysbiosis in humans with a 
potential to develop diseases. CRS is the number one reported condition for which 
antibiotics are prescribed at the peripheral general practice.  
Despite providing excellent clinical outcomes, corticosteroids are often combined with or 
are replaced by antibiotics in the treatment of CRS. This thesis, attempted to see if 
corticosteroids in addition to its anti-inflammatory property, had an effect on bacterial 
growth. We also investigated the usefulness and efficacy of antibiotics over corticosteroid 
therapy to determine if antibiotics are warranted as first line therapy in the medical 
management of CRS. Towards this, the aims of the study were: 
7 
 
1. To look at the potential antibacterial action of corticosteroid and the different 
excipients in a commercial preparation of topical nasal steroid in vitro. 
2. To investigate the growth and metabolic response of a common CRS pathogen, 
Staphylococcus aureus in the presence of different concentration of corticosteroid.  
3. Finally, to conduct a double-blinded, randomised placebo-controlled trial to better 
understand the usefulness and efficacy of corticosteroid and antibiotic therapies in 
CRS along with the probable microbiome changes they bring about and its influence 
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1.1 Chronic rhinosinusitis – definition 
 
Chronic rhinosinusitis (CRS) is a common complex clinical syndrome of multifactorial 
aetiology. A large number of guidelines, consensus documents, and position papers have 
attempted to define CRS(1-5). Most of these guidelines define CRS as chronic inflammation 
of the nose and paranasal sinuses lasting for at least 8-12 weeks and having at least two of 
the following clinical symptoms namely, 1. Nasal obstruction, 2. Anterior or posterior nasal 
discharge, 3. Facial pain or pressure, and 4. Reduction or loss of sensation of smell. Along 
with these subjective findings, for a diagnosis of CRS, there should also be objective 
evidence of nasal polyps, mucopurulent discharge or mucosal oedema on nasal endoscopy 
or mucosal changes on computerized tomography (CT) of the paranasal sinuses.  
CRS can further be classified into two phenotypes based on nasal endoscopy as CRS 
without nasal polyps (CRSsNP) and CRS with nasal polyps (CRSwNP)(4). Another 
classification based on the duration of symptoms distinguishes CRS into acute, subacute, 
chronic, recurrent acute and acute exacerbations of chronic CRS(6).   
1.2 Incidence 
Current data from many studies suggests that CRS affects around 5-15 % of the general 
population(7, 8). In the western population, the prevalence ranges from 4.5 to 12.5% and is 
typically less in the developing countries(9). It affects around as 1.8 million (9.2%) 
Australians, utilizes a large amount of health expenditure and adversely affects the quality 
of life of those affected(10). Some studies have even shown that patients with CRS have a 
low health state utility values and is comparable to chronic disease processes such as 
asthma, ischemic heart disease, end-stage renal and liver disease and neurocognitive 
disorders(11). 
1.3 Etiopathogenesis 
The etiopathogenesis of CRS with its heterogeneous presentations is largely unknown, even 
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though a multifactorial mechanism is considered likely.  A number of extensively 
researched hypothesis have been proposed which can be broadly classified into host-derived 
factors (eicosanoid hypothesis and the immune barrier hypothesis) and environmental 
factors (fungal hypothesis(12), superantigen hypothesis(13), the biofilm hypothesis(14),  the 
microbiome hypothesis and intracellular bacterial infection(15). The environmental factors 
are influenced by allergens (16) and toxins(4) and the host factors by genetic predisposition(17) 
and defective local or systemic immune responses(18).  
Inflammation and infection coexist in CRS, questioning the role of either as the initiating 
factor of the disease. While certain studies describe immune dysfunction, inflamed sinonasal 
mucosa and sinus outflow obstruction caused by allergic a nonallergic diseases as the 
triggering elements of inflammation in CRS, other studies demonstrate the role of resident 
commensal and pathogenic bacteria and their byproducts in the establishment and 
continuation of inflammation(19, 20). In a small group of patients with diseases like 
Kartagener’s syndrome, cystic fibrosis, Wegener’s granulomatosis and sarcoidosis CRS 
results due to the disease factors affecting the drainage of secretions in the sinuses leading to 
chronic inflammation(21).  
1.3.1 Anatomical variations 
The identification of the presence of paranasal sinuses dates back in history to the ancient 
Egyptians in the 3700 to 1500 BC(22). A better understanding of the anatomy of the nose and 
paranasal sinuses came about with the basic work describing these structures by Emil 
Zuckerkandl in the 1870s(23). The paranasal sinuses in humans, generally are classified into 
maxillary sinuses located below the eye socket, anterior and posterior ethmoid cells, frontal 
and the sphenoid sinuses. In reality, however, these sinuses are connected to each other or 
are closely related with regard to their drainage pattern. The area where the sinuses are 
located is called the lateral wall of the nose and various terminologies are used to define 
specific cells and spaces. The lateral wall anatomy is exceptionally complicated apart from 
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having a great number of variations. Middle meatus is a space lateral to the middle turbinate 
into which the maxillary, frontal and the anterior ethmoidal cells drain. The posterior 
ethmoidal cells open into the superior meatus and the sphenoid sinus into the 
sphenoethmoidal recess located medial to the superior turbinate(24).  
The majority of the structures of the lateral wall including the sinuses are lined by 
respiratory ciliated columnar epithelium. Scattered in this layer are goblet cells, eosinophils, 
mast cells, neutrophils and lymphocytes(25, 26). The mucosal barrier in the nasal cavity 
comprising IgA and other protective mediators are secreted by the goblet cells (27) and the 
largest production of nasal secretion in the nasal cavity is mostly from the seromucinous 
glands present in the submucosa(25). On the septum, the maximum number of goblet cells 
are seen at the posterior and inferior part. Contrary to this, glands are more abundant in the 
anterior and superior parts(28). Compared to the other sinuses maxillary sinus has the 
maximum density of goblet cells.  
Where certain studies do not support the contribution of anatomical variants such as concha 
bullosa, Haller cells, paradoxical middle turbinate, and deviated nasal septum to the 
development of CRS, certain other studies suggest that anatomical variations may represent 
one of the multiple factors that influence the expression of the disease. This was more so in 
patients who developed CRSsNP(29). 
1.3.2 Physiology and its dysfunction 
Although the exact significance of the presence of paranasal sinuses is debatable, their role 
in the multiple functions of the nose cannot be ignored. These include vocal resonance, 
diminution of auditory feedback, air conditioning, pressure damper, reduction of skull 
weight, flotation of skull in water, mechanical rigidity and heat insulation. However, the 
major relevance of the presence of paranasal sinus lies in its propensity for causing diseases.  
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Mucociliary clearance and mechanical defence of the nasal cavity 
Mucociliary transport is the physiologic process by which secretions and unwanted particles 
are eliminated from the nose. This is essentially brought about by the cilia of the respiratory 
epithelial cells. The cilia consisting of outer nine paired microtubules and an inner paired 
microtubule propel the mucous blanket backward from the nasal cavity to the pharynx. The 
energy for this is derived from the conversion of ATP to ADP by the ATPase located at the 
outer and inner dynein arms of the outer microtubules(30). Particles of size from 3 to 0.5 um 
are filtered by the nasal mucosa and pushed posteriorly and cleared within 10-20 minutes by 
the ciliary beat pattern which consists of an effector propulsive stroke and a slow recovery 
stroke(25). The IgA in the nasal secretions provides the first line of defense against the 
inhaled bacteria and viruses(25, 27). Apart from the cilia the epithelial cells of the nasal 
mucosa also play a part in the mechanical defenses by regulating the permeability of 
mucosa in the event of an inflammatory insult. This is achieved by establishing cell to cell 
contact in a way that may permit the entry of blood plasma to the lumen but prevent any 
foreign particles penetrate the airway tissue(27). The surface receptors like CD14 and Toll-
like receptors on the epithelial cells can also identify microbial pathogen-associated 
patterns(27, 31).   
Apart from this, the drainage of secretions from the different sinuses also follow specific 
patterns. In the maxillary sinus, the mucociliary clearance is spiral towards the natural 
ostium and against gravity. The frontal sinus, ethmoids and sphenoid sinus drainage are 
downward towards gravity(32).  In conditions like cystic fibrosis, Kartagener’s syndrome and 
Youngs disease there is an inherent defect in this mucociliary clearance and so chronic 
infection of the paranasal sinuses in these patients is a common finding. The defective 
mucociliary clearance leads to stagnation of secretions which probably facilitates 
development and persistence of infection in CRS. Outside the genetic conditions, a recent 
study on a rabbit model of sinusitis has demonstrated a decreased periciliary depth and 
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mucous transport on the functional micro-anatomy study using micro-optical coherence 
tomography in the early stages (2 weeks) of CRS development. They also showed that the 
mucous fermenting microbes (Lactobacillales, Bacteroidales) dominated on week 2 and 
there was a significant shift to potential pathogens (e.g., Pseudomonas, Burkholderia) by 
week 14 suggesting that an abnormal mucociliary host defense mechanism could promote 
the growth of pathogens due to the decreased bacterial clearance capacity(33).  
 
 
Figure 1: a Normal mucous blanket, b Pathological mucous blanket with mucous 
hypersecretion(34) 
1.3.3 Immunology 
The sinonasal epithelial cell layer acts as the first line of defence against foreign invasion. 
The structural integrity of this barrier is maintained by tight junctions which also control the 
epithelial permeability. Apart from being a structural barrier, they provide immunological 
protection through innate toll-like receptors and secretory IgA transport. Tight junctions 
consist of a number of scaffold adaptors and transmembrane proteins(35). A defect in these 
structures has been shown to be associated with polyp formation in CRSwNP. Soyka et al. 
in their study showed a defective barrier function with a decreased expression of TJ proteins 
and decreased mRNA levels in CRS patients when equated with normal subjects(35).  
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The composition of the mucous and innate immune response in the nose 
Around 80% of the dry weight of the mucous is constituted by glycoproteins.  These include 
sialomucins, fucomucins, and sulphomucins and they can be acidic or neutral. They are 
responsible for the viscosity and elasticity of the mucus(36). Water and ions enter the mucous 
through transudation and active ion transport(37). Proteins form another component in the 
mucus. They are procured from the circulation (complement, α-2rmacroglobulin, C reactive 
proteins) or are produced by the nasal mucosa and surface cells. Antiproteases like α-
antitrypsin, αl-antichymotrypsin, α 2macroglobulin produced by leukocytes are seen to be 
increased during infection.  Lactoferrin found only in the nasal secretions bind to heavy 
metal ions like iron thereby preventing the growth of facultative and aerobic gram-positive 
and -negative bacteria and also Candida albicans, which depend on iron for their 
metabolism (27, 38). Lysozymes are potent bacteriostatic agents against certain bacteria 
without a capsule and also increases the lysis potential of antibody-activated complements 
on gram-negative bacteria like E-coli(27, 38). Lactoperoxidases also form toxic molecules to 
eliminate bacteria(38). The enzymes lysozyme and lactoferrin are however not effective 
against viral infections(27). Complement system with an array of proteins is involved in the 
opsonization of pathogens by phagocytes(27).  Other notable molecules are secretory 
leukoprotease inhibitor, uric acid, peroxidase, aminopeptidase, secretory phospholipase A2, 
and defensins(27). In the event of an insult, the resulting inflammation leads to increased 
blood flow to the mucosa and also recruitment and activation of inflammatory cells such as 
neutrophils and macrophages. Immunoglobulins, complement, and proteases are carried to 
the site to clear the pathogens(39). Neutrophils with toxic granules create an oxidative burst 
also leading to an increase in the level of nitric oxide in the sinuses which is an important 
agent in the defense mechanism against pathogens(27).  
Adaptive immune response in the nose 
Apart from the secretory immunoglobulin Ig A released in response to exposure to antigens, 
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immunoglobulins are also released against polysaccharide capsule of bacteria like 
Haemophilus influenza B and Streptococcus pneumoniae(27). Specific cellular responses 
occur as a result of presentation and activation of T and B lymphocytes by foreign 
antigens(38). A delayed IgE mediated allergic response occurs following initial antigen 
exposure. Subsequent subjection to the same antigen leads to the release of preformed (like 
histamine, platelet activating factor) and newly formed (like leukotrienes, prostaglandins) 
bioactive mediators. The resulting neural and vascular responses lead to allergic symptoms 
like nasal congestion, postnasal drip, watery rhinorrhoea, nasal and ocular itching, and 
sneezing(40).  
Immunology in CRS 
The inflammatory pattern seen in CRSsNP is TH1 predominant and neutrophil biased. 
Whereas in CRSwNP a Th2 dominant an eosinophil rich inflammation is seen(41). The 
eosinophilic pattern seen in CRSwNP, however, is found to vary among the different human 
races and for example, a non-eosinophilic inflammation is seen in more than half of Chinese 
patients with CRSwNP(42). This suggests the involvement of genetic or epigenetic 
mechanisms in the development of the disease and polyposis. The understanding of innate 
immune responses and epithelial barrier functions of the host would help us better 
understand the inflammatory profile seen in the disease and also the mechanisms by which 
various medical therapies alter these profiles.  
Tissue remodelling in CRS 
Remodelling is a reorganization or restoration of tissue by extracellular matrix (ECM) 
production and degradation which occurs following an injury. The end result of this process 
could be a return to normalcy or a change to pathologic tissue(43). There are indications of 
remodelling in CRS and a distinctive histological feature of CRSwNP is albumin 
accumulation, oedema, eosinophilic infiltration, and pseudocyst formation. Whereas in 
CRSsNP there is neutrophilic inflammation and marked fibrosis(43, 44). Presence of collagen 
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in CRS detected with picrosirius staining of the tissue showed an increase in collagen in 
CRSsNP compared to CRSwNP(45). ECM breakdown is modulated by a family of matrix 
metalloproteinases (MMPs) and their inhibitors, called the tissue inhibitors of 
metalloproteinases (TIMPs). Both their levels are increased in CRSsNP whereas only 
MMP-9 is increased in CRSwNP. This might be another reason for the different overt and 
histopathological differences seen in the CRS phenotypes(46). In another study comparing 
early polyp with mature ethmoidal polyp showed that epithelial loss was much pronounced 
in early polyps. Whereas, in mature polyps junctional proteins E-cadherin, zonula 
occludens-1 (ZO-1), and occludin showed greater deficits(47).  According to Takabayashi et 
al.(48), deposition of fibrin mesh in tissue leads to polyp growth. Due to the impaired 
epithelial expression of tissue plasminogen activator (tPA) polyps have a decreased 
fibrinolytic activity. Factor XIIIA from M2 macrophages in the tissue is the cause for to 




Figure 2: Role of host immune response in chronic rhinosinusitis(49) 
Steroids (oral and topical) with their anti-inflammatory properties and antibiotics like 
Doxycycline with their anti MMP-9 effects potentially intervene with remodelling and 
affect the pathological sequelae in CRS(50).  
1.3.4 Fungus 
 
Fungal elements as an etiological agent were described when positive fungal cultures and 
eosinophilia was demonstrated in CRS patients. It was hypothesized that fungal elements 
could become trapped in the nasal mucous secretions and trigger an immune reaction. This 
would then lead to the recruitment of eosinophils that attacked the fungi and released 
inflammatory toxic mediators. This whole inflammatory process would then result in the 
observed polyposis in CRS. The fungal hypothesis, however, failed to hold and currently, 
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fungi are recognized as physiologic flora of the upper respiratory tract and “innocent 
bystanders in the majority of cases of CRS. However, fungal colonization does play an 
important role in patients where the fungus is seen either on microscopy or culture in the 
thick eosinophilic mucous.  This subset of patients is now recognized as “allergic fungal 
sinusitis”(51). The burden of fungal elements in CRS patients identified using next generation 
sequencing (NGS) showed that fungal biomass estimated through ITS amplicon 
concentration correlated with traditional fungal detection techniques and CT double 
densities thus asserting the current understanding that fungal dysbiosis occurs only in a 
selected subgroup of CRS patients(52). 
1.3.5 Bacteria 
Bacteria are prokaryotic organisms which are unicellular. They have a rigid cell wall but 
they lack nucleus and membrane bound organelles. Usually, a spherical bacterium will have 
an average diameter of 0.5 to 2 μm and rod or filamentous bacteria 0.25 to 1 μm. The length 
varies from 1 to 10 μm in the rod-shaped bacterium. 
The human body is colonized with a multitude of different microorganisms including 
bacteria, fungi, and virus. It is considered that the interaction between these microbes is 
responsible for the balance of various bodily functions. The commensal bacteria are thought 
to interfere with the pathogenic bacteria through mechanisms like competing for cell surface 
receptors, thus inhibiting adherence of pathogens, producing antibacterial peptides and other 
antibacterial metabolites like hydrogen peroxide. An abundance of commensal bacteria may 
also starve the pathogens for nutrients (exploitative competition)(53).  A disruption or shift in 
the microbial community resulting in dysbiosis could cause an imbalance of the delicate 
mutual interactions between bacteria and bacteria and host. This is thought to contribute to 
disease onset, progression, or duration of conditions like antibiotic-associated diarrhoea, 
bacterial vaginosis, celiac disease, colorectal cancer, cystic fibrosis, oesophageal disease, 
Crohn’s disease and ulcerative colitis (collectively referred to as inflammatory bowel 
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diseases [IBD]), irritable bowel syndrome, necrotizing enterocolitis, non-bacterial 
prostatitis, pre-term birth, obesity, pouchitis, and psoriasis where culture-independent 
sequencing technologies have shown the presence of significant dysbiosis(54). 
Despite a large number of studies describing several species of bacteria being abundant in 
CRS when compared to that of control, there is much debate on the contribution of bacteria 
in the pathogenesis of CRS. This is due to the number of other studies which fail to identify 
a specific type of organism with CRS compared to control. It further supports the theory of 
an ongoing paradigm shift in infectious diseases away from one causative biological agent 
to a pathogen-dysbiotic microbiome interaction determining the disease outcome(55). 
1.3.6 Other factors 
 
Allergic rhinitis (AR)has often been associated with the development of CRS. Their 
symptoms mostly overlap and hence make the distinction between the conditions difficult. 
AR and CRS are thought to share come common cellular and molecular mechanism in their 
pathophysiology. This is mostly through eosinophil and mast cell infiltration and IgE 
expression. Inflammation of the nose in AR would affect the sinuses and show changes on 
CT as well as endoscopy. However, only AR shows a positive reaction with the nasal 
challenge of allergens and responds to treatment with allergen immunotherapy. Although 
current data support a role of on-going allergic inflammation in the development of acute 
bacterial rhinosinusitis, the data supporting interaction between CRS and AR are 
insufficient to come to any conclusion(29).  
Immune deficiency arising from congenital and acquired causes, chemotherapy in 
malignancies, hyper immunoglobulin E syndrome, use of biologics like anti-TNF can all 
cause a sinus infection. These patients almost always have the most refractory and difficult 
to treat disease. A metanalysis of recurrent uncontrollable rhinosinusitis showed a pooled 
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IgG, IgA, and IgM deficiency prevalence of 12.7% in patients with recurrent CRS and 
22.8% in patients with difficult-to-treat CRS(56). 
Dental diseases are known to cause maxillary sinusitis secondary to perinodal infection or 
dental manipulations.  
Gastro-oesophageal reflux disease (GORD) and CRS are often seen to exist together in 
patients. It is proposed that gastric contents could reflux into the nasal cavity causing 
mucosal inflammation. Prospective studies have demonstrated the co-existence of GORD 
and CRS in children and also the improvement in CRS symptoms when patients were 
treated for GORD(57).  
Autoimmune disorders like Churg-Strauss syndrome and selective IgE deficiency have been 
associated with the development of CRS 
Tobacco smoke has been known to adversely affect the sinonasal mucosa in multiple ways. 
Apart from causing irritation of the eye and nose, nasal congestion, rhinorrhoea, and 
increased nasal resistance smoke can reduce mucociliary transport, alter innate immune 
effector proteins, suppress toll-like receptor-mediated pathways, increase squamous 
metaplasia, and decrease olfactory function(58). Individuals exposed to second-hand smoking 
during childhood or currently have an increased risk of developing CRS compared to 




Figure 3: Etiopathogenesis of CRS - the interplay of multiple factors 
1.4  Bacteriology in CRS 
 
1.4.1 Bacteria isolation and culture techniques 
 
The prior understanding was that the sinuses were sterile in healthy people. This was, 
however, proved wrong when bacteria were cultured from the middle meatus and maxillary 
sinus of healthy individuals(60). These findings led to the theory that bacteria could be 
present in health and disease of the sinuses.  
The isolation of bacteria from the sinuses is using standard laboratories techniques have 
evolved over the years. Culture-based techniques yield information about the role of the 
individual organism and their causative mechanisms eliciting disease in the host.  There is 
however a large disparity between various studies trying to isolate the common pathogenic 
organisms in CRS. The issues could be attributed to the different sampling methods, 





contamination from the adjacent nasal sites, presence, and absence of polyps, time and 
method of culture after sample collection, variability in the patient selection including age, 
recurrent disease, and multiple surgeries. Again, most studies do not quantify the amount of 
each species of bacteria identified and this would make it difficult to assess the contribution 
of the organism in the inflammatory milieu. The isolation of anaerobic bacteria requires 
specific, laborious and more expensive techniques and they are, therefore, often undetected.  
Never-the-less, culture based bacteriological isolations remain the standard practice to 
identify microbes in most clinical settings as it is easy to perform, cost-effective and gives a 
species level identification and the ability to assess biophysiological responses of the 
bacteria. Vigorous culture-based techniques in a study were able to identify around 139 
distinct bacterial species within most subjects, regardless of disease status. This included 
Staphylococcus epidermidis (S. epidermidis), Propionibacterium acnes (P. acnes), 
Corynebacterium accolens (C. accolens), Corynebacterium tuberculostearicum, 
Staphylococcus aureus (S. aureus), Propionibacterium avidum, Propionibacterium 
granulosum, and Finegoldiamagna. Other common taxa included Staphylococcus 
haemolyticus (S. haemolyticus), Staphylococcus capitis (S. capitis), Staphylococcus hominis 
(S. hominis), Staphylococcus warneri (S. warneri), Staphylococcus lugdunensis (S. 
lugdunensis), Streptococcus mitis-S. oralis, Streptococcus parasanguinis, as well as strict 
anaerobes from the genera Clostridium, Anaerococcus, Finegoldia, Parvimonas, 




Figure 4: MALDI-TOF mass spectrometry for identification of microbes from positive 
cultures(62) 
1.4.2 Bacteria in health 
The bacterial profile of the paranasal sinuses has been extensively studied and a number of 
studies have come out with conflicting reports. Axelsson and Brorson in the study showed 
that Staphylococci and Diphtheroid species predominated in the nose of healthy controls 
and Pneumococci and Hemophilus influenza (H. influenza) in sinus aspirates from acute 
maxillary sinusitis. Staphylococci were considered a nasal contaminant rather than a 
pathogen. However, many of their cultures were growth negative(63).  In a study by 
Jousimies-Somer et al (64)it was seen that in healthy subjects, H. influenza, Streptococcus 
pneumoniae (S. pneumoniae), Staphylococcus pyogenes (S pyogenes), and Branhamella 
catarrhalis were infrequently isolated. A Pilot study by Allen et al (65)looking at the 
bacteriology of the nose by analysing nasal lavage fluid samples using traditional bacterial 
culture methods and microarray techniques showed that there was no change in the bacterial 
load when the healthy volunteers were infected with rhinovirus. The microarray technique 
moreover, identified a few bacteria that could not be cultured in the lab. All recruits had S. 
epidermidis/coagulase negative staphylococcus in their nasal sample. Doyle PW and 
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Woodham JD(66)analysed the nasal biopsy specimens from the ethmoid sinuses using 
aerobic and anaerobic culture techniques. They saw that the non-pathogenic and the most 
common clinical isolate was Coagulase negativestaphylococcus (CNS). The most common 
pathogenic organism isolated was S. aureus and this was followed by members of the 
Enterobacteriaceae family. This was quite different from the other studies which showed 
that H. influenza and S. pneumonia as the predominant bacteria. Most of these studies, 
however, looked at the microbiology of the maxillary sinus. Some of these studies also had 
anaerobes as the predominant organism isolated (67-70). 
1.4.3 Bacteria in CRS 
A recent study by Zheng-Wei et.al(71) comparing the microbiology of the middle meatus in 
patients with CRSwNP, CRSsNP and controls found that the most common bacterial species 
in CRSwNP were CNS, Corynebacterium, and S. epidermidis. In CRSsNP it was S. 
epidermidis, Corynebacterium, CNS, and S. aureus and in the control group, S. epidermidis, 
CNS and S. aureus were frequently isolated.  Another interesting finding was that they 
identified a relatively high proportion of Citrobacter in the CRSwNP group. This study also 
tried to categorize the samples into subgroups according to the percentage of eosinophils 
present in the peripheral blood study. They found that in patients with CRSwNP, the 
isolation of S. aureus was higher in the subgroup which had an increased percentage of 
eosinophils (>5) whereas S. epidermidis was higher in the subgroup with a low percentage 
of eosinophils. The study concluded that S. aureus may promote an eosinophilic 
inflammatory response, while S. epidermidis a non-eosinophilic inflammatory response.  A 
retrospective analysis of the culture results from 513 CRS patients was done by Cleland et 
al.(72) to determine the impact of surgery and factors like the presence of polyps, asthma, and 
aspirin sensitivity on the bacteriology in CRS. The study demonstrated that revision patients 
were more likely to have a positive culture with S. aureus and P. aeruginosa being 
predominant pathogens. The increase in P. aeruginosa was also demonstrated in the Zheng-
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Wei et.al(71) study suggesting that surgical procedures with the concomitant use of 
antibiotics promote the colonization of opportunistic organisms. There was also a 
significantly higher rate of S. aureus in CRS patients undergoing revision surgery.  
When bacterial isolation was done from sinus tissue biopsy in CRSwNP, S. epidermidis and 
S. aureus was found to be a most prevalent organism. This was followed by S. haemolyticus, 
P. aeruginosa, Moraxella catarrhalis (M. catarrhalis), S. pneumoniae, S. warneri and S. 
lugdunensis(73).  
The systematic review by Brook I(74) identifies S. aureus, S. epidermidis, and anaerobic 
Gram-negative bacteria as the predominant isolates in CRS. The true prevalence of the 
anaerobe is however questionable as most studies employed inadequate methods for 
isolation. The isolation rates of anaerobes among twenty studies reviewed were in the range 
of 8 % to 93%. Despite this, anaerobes as a major pathogen have been supported by a 
number of studies(75). It is proposed that the aerobes and facultative organisms in CRS are 
gradually replaced by anaerobes because of the use of antibiotics which will favour the 
development of resistant organisms. This leads to persistent oedema and swelling of the 
sinus cavity resulting in reduced oxygen tension and increased acidity which is an ideal 
condition for the growth of anaerobes.  
CRSwNP is often considered as a separate clinical entity because of the severity of 
presentation, high recurrence after surgery and recalcitrance. The bacteriology however in 
these subsets of patients appears to be similar to that seen in CRSsNP with S. aureus, H. 
influenzae, and S. pneumoniae among the common organisms(74). 
These results show that in both health and disease there are a group of organisms that can be 
isolated by traditional techniques from the paranasal sinuses and these differ in the 
frequency of them of their predominance in the different studies making it difficult to 
attribute a particular organism in health and in disease.  
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1.4.4 Biofilms in CRS 
Biofilms are bacterial communities embedded in a self-produced polymeric extracellular 
matrix and attached to biotic or abiotic surfaces or could exist in a floating state (pellicle). In 
the initial stage of biofilm formation, bacteria switches from planktonic mode to biofilm 
mode. A rapid phenotypic change and small molecule signalling lead to adhesion and 
coaggregation of microbes and secretion of a polysaccharide matrix which eventually 
encapsulates the clusters of bacteria. The process by which a single planktonic bacterium 
attach to each other is called auto-aggregation. A biofilm is usually polymicrobial, 
providing the organisms the advantage of passive resistance, synergistic metabolic 
cooperation, by-product influence, shielding of beta-lactam susceptible organisms by beta-
lactamase-producing ones, quorum sensing systems, an enlarged gene pool with more 
efficient DNA, and many other synergies, giving them a competitive advantage(76). Apart 
from this the bacteria in the biofilms exist in a low metabolically active state and is often the 
preferred state of the bacteria in the human body(77).  
Biofilms were identified and strongly implicated in the pathogenesis of CRS since 2004(78). 
Studies have also shown that in the sinonasal cavities biofilms are 10-1000 times less 
susceptible to antibiotic killing when compared to the planktonic counterpart(18). Although 
several bacterial species especially occurring as a polymicrobial biofilm formation have 
been identified in the context of CRS, their exact role in the pathophysiology of CRS is 
debated due to the identification of similar biofilms in the absence of the diseased state(79). 
Nevertheless, studies in favour of the biofilm theory in CRS pathogenesis have shown an 
increased rate of S. aureus biofilms and their superantigens in CRS compared to controls. 
The biofilms in CRS patients tend to co-locate with disruption of the epithelial barrier and 
have an increased presence of T cells and macrophages(76, 80). Among the CRSwNP patients, 
S. aureus is known to produce the most robust and higher amount of biofilms than CNS(73).   
While the direct role of biofilms in CRS remains unclear, patients who have biofilm 
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formation also tend to have a worse prognosis, are more likely to have poorer surgical 
outcomes and exhibit an increased immune response.  
1.4.5 Staphylococcus aureus 
S. aureus has been identified as a persistent colonizer of the nasal cavity in 20% of the 
population and an intermittent carrier in another 30%. It could exist as a benign commensal 
or could be the major pathogen in many chronic infections including CRS. The 
pathogenicity is attributed to the various virulence factors expressed by S. aureus. These 
include enterotoxins and toxic shock syndrome toxin which acts as superantigens, cell wall 
associated proteins, antimicrobial genes, Agr and capsule type and genes involved in 
biofilm formation, exotoxins that degrade epithelial barrier integrity, affecting complement, 
antimicrobial peptide production, and adhesion and chemotactic processes(81, 82). In-vitro 
exposure of human nasal epithelial cells to S. aureus or its secretory proteins can induce 
apoptosis and alter cytokine signaling and nitric oxide production(83). These effects may be 
responsible for the S. aureus-mediated immune modulating effects and the mucosal injury 
seen due to epithelial damage in CRS. This organism also has the capacity to survive inside 
the epithelial cells evading the host immune response and antibiotic killing. This is possible 
by the phenotype switching to metabolically less active small-colony variants (SCVs) which 
becomes a reservoir of putative pathogens in recurrent recalcitrant CRS resistant to 
treatments. The intracellular form of S. aureus have been identified in up to 75% of CRS 
patients compared to a 12.5% in controls and have an increased risk of relapse of the disease 
even after surgery(76). However, there is a recent study which shows no association between 
S. aureus SCVs and CRS with comparable isolation rates of the bacteria in both CRS and 
controls(84).  
Thungberg et al.(81) study found a statistically significant increase in the frequency of S. 
aureus in nares samples from CRS patients than from controls. This they suggested reflects 
as a risk factor for developing the disease. In this study, however, the prevalence of genes 
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encoding virulence factors between isolates from patients with CRS and healthy control was 
not found to be statistically significant.  
Despite much controversies in its potential role in the development and progression of CRS, 
the pathogenicity and virulence of S. aureus make it an undesired bacterium in the 
recalcitrant sinus diseases.  
1.4.6 Methicillin resistantstaphylococcus aureus (MRSA) 
Methicillin-resistant Staphylococcus aureus (MRSA) was first isolated in England in 1961 
and has since then disseminated worldwide with a progressive increase in its incidence. 
They are also known to form robust biofilms and thus recalcitrant infection. Although its 
incidence from the anterior nares has been reported to be as high as 53%, it mostly 
represents colonisation rather than pathogenicity. A retrospective case-control study by 
Casey et al(85) reported an MRSA incidence of 9.22% in CRS in their study population. The 
study, however, did not show any association between antibiotic use frequency of previous 
endoscopic sinus surgery with the incidence of MRSA. To the contrary, MRSA has been 
associated with recalcitrant disease, revision surgeries and multiple courses of antibiotic 
use(86).   
The treatment of MRSA infection is primarily with a beta lactam compound. Topical 
therapies have also been proven beneficial in treating MRSA. Topical mupirocin has been 
shown to eradicate MRSA infection in acute exacerbations of CRS. This can be used as 
irrigation with Ringer lactate to improve penetration. There is however a concern with the 
bacteriological profile after mupirocin irrigation as was seen in a study which showed a shift 
towards an increase in other pathogenic gram negative and positive culturable bacteria(87). 
Surfactants (baby shampoo) are also effective in removing MRSA colonisation and is 
shown to have synergistic activity when combined with mupirocin or gentamicin. Another 
interesting and novel agent which effectively reduces mature biofilms without toxic effect is 
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Manuka honey which contains methylglyoxal (MGO- identified as the dominant 
antimicrobial component). Other beneficial topical therapeutic modalities include topical 
ofloxacin eye drops (0.3%) used intranasally, nasal irrigation containing hypochlorite super-
oxidized solution, diluted iodine saline rinse, colloidal silver nanoparticle irrigation, and 
antimicrobial photodynamic therapy(88).  
1.4.7 Staphylococcus epidermidis (Coagulase negative staphylococcus -CNS) 
S. epidermidis is considered as a commensal identified in the nasal cavity of healthy 
controls and having a low virulence. This, however, could be potentially pathogenic when 
identified as the sole and highly abundant organism. The incidence of their isolation from 
cultures of CRS can vary from 0% to 60%. This organism is now being more and more 
recognised as a major pathogen especially if isolated from mucopurulent discharge and 
represents a single isolate on cultures(89).  
1.4.8 Corynebacterium species (sp.) 
Corynebacterium sp. is among the most frequently isolated bacteria in both healthy controls 
as well as CRS patients. While certain studies attribute its presence to the pathogenicity of 
the disease, certain others associate it with a healthy microbiome(90, 91).  Corynebacterium is 
one of the dominant species in both health and CRS patients. Its reduction in postoperative 
CRS patients was found to be associated with an increase in the sinus symptom scores(92).  
C. accolens, a common skin commensal, metabolizes triacylglycerols in nasal secretions to 
oleic and linoleic acid, which can inhibit the growth of Streptococcus pneumoniae(93). 
1.4.9 Bacterial co-occurrence 
Different bacterial communities show a plethora of interspecies metabolic exchanges 
leading to a large number of co-occurrence and co-exclusion relationships. In CRS S. aureus 
is more frequently seen along with S. epidermidis and P. acnes. While C. accolens and S. 
aureus have been seen to mutually facilitated the growth of each other, Corynebacterium 
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pseudodiphtheriticum (C. pseudodiphtheriticum) and S. aureus were mutually inhibitory. C. 
accolens is capable of metabolizing triglycerols into free fatty acid and oleic acid which in 
turn inhibits the growth of Pneumococcus(76).    
1.5 Microbiome 
As opposed to the previous assumption that the  human body harbours from 10 to 100 
trillion microbes which greatly outnumber our own human cells, recent studies have shown 
that the number of bacteria in a 70 kg reference man (3.8.1013) is similar to the number of 
bacterial cells in the body (3.0.1013)(94). The combined genetic material of the 
microorganisms in a particular environment is referred to as the microbiome. This mini 
ecosystem of communities of symbiotic, commensal and pathogenic organisms can interact 
with each other and also the host. A microbiome is unique to the host organism and changes 
in its composition can lead to imbalances in homeostasis. Alteration in the microbiome has 
been linked to many chronic diseases including inflammatory bowel disease, diabetes 
mellitus, certain conditions of the skin and some lung diseases.  A study(95) from the Danish 
birth registry which compared 2 million term deliveries either by natural birth or caesarean 
section showed an increased risk of asthma, systemic connective disorders and 
inflammatory bowel disease in the cesarean section cohort.  A number of other 
epidemiological studies also demonstrate a link between exposure to microorganisms early 
in life and a lower incidence of chronic inflammatory disorders later in life(53).  
The microbiome of the upper airway and paranasal sinuses is an area of recent research. To 
date, the studies are relatively small in number, underpowered and differ in terms of 
sampling technique and site as well as bioinformatic analysis. This has led to a discrepancy 
in the results obtained with no real consensus achieved on the specific microbiome in health 




Figure 5: Highly personalised human microbiome.(96) 
1.5.1 Microbiome isolation techniques 
The microbiome of the nasal cavity has been studied both from swabs and tissue specimens 
obtained from the sinuses. There are now multiple studies which show that the bacterial 
DNA load obtained from nasal swabs is comparable to tissue specimens and that the 
microbiome within the nasal cavity of the same individual remains relatively consistent 
irrespective of the location from where it was taken. For this reason, the middle meatus is 
most commonly used as a surrogate for the sinuses and is now the most commonly sampled 
location in sinus microbiome studies(97). 
Recently, there have been significant technological advances in the field of microbiology. 
Culture-independent techniques have emerged as a much more sensitive and superior 
modality for understanding the entire micro-ecology of local environments. These 
techniques allow the detection of previously “un-culturable” bacteria and provide new 
information on the diversity and relative abundance of resident microbes and potential 
pathogens. (98). Bacterial detection through culture-independent techniques demonstrate an 
increased diversity of bacterial species by a magnitude of 109 when compared to standard 
cultures and this is also consistent with other reports in which it is proposed that only 1% to 
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10% of bacteria encountered in the environment are able to be cultured in the laboratory(99).  
These culture-independent techniques rely on matching bacterial DNA isolated from a 
specimen to libraries of known bacterial sequences. They include quantitative polymerase 
chain reaction (qPCR), fluorescence in situ hybridization (FISH), mass spectrometry, DNA 
microarray, and next generation sequencing (NGS) central to the technique. 
Next generation sequencing (NGS) emerged in the mid and late 1990s and early 2000s 
leading to the release of the first commercially available second-generation sequencing 
system in 2005 thus making it widely available and cost effective(98). NGS relies on 
sequencing by synthesis design by amplifying the DNA through PCR in the initial step. This 
is followed by DNA sequencing to determine the DNA sequence. There are several methods 
of sequencing, each reliant on a different type of chemistry.  Pyrosequencing is a method 
which relies on the production of light when pyrophosphate is released after nucleotide 
incorporation into a DNA strand. The intensity of light emitted is proportional to the number 
of specific nucleotides incorporated in a given area and this method can now read DNA 
sequences of up to 1000 base pairs. Another method is Reversible Terminator Sequencing 
where DNA is denatured into single strands and washed with the 4 different nucleotides 
tagged with fluorescent dye and a reversible blocking group. As each base is added at a time 
this technique is more accurate compared to pyrosequencing. It also has a large output and 
low reagent cost although the read length is shorter and takes longer run time. Amplicon 
sequencing is used for an in-depth investigation of the sinonasal microbiome. This involves 
amplifying and sequencing regions of highly conserved bacterial genes which could then be 
compared to an existing database to determine the sequence from which the bacterial 
organisms came. These regions are also called markers (e.g. 16S ribosomal ribonucleic acid 
subunit -16sRNA, elongation factor). 16s RNA subunit gene is one of the most commonly 
used regions in view of its cost effectivity and ease of use(100). Although the 16sRNA 
subunit is conserved amongst all bacteria, there are numerous hypervariable regions within 
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the subunit which differ among different bacteria. It is these regions that are further 
sequenced to differentiate the different bacterial genus or species from each other. The 
sequences obtained through the amplification process are then compared to known genetic 
sequences in bacteria “banks” or “libraries” to allow identification to occur.  
The major downside of 16sRNA is that as some bacteria have multiple copies of the 16S 
rRNA gene which artificially increase their abundance in a sample. Also, the multiple 
copies of the 16S rRNA within 1 bacterial genome can be highly divergent and, thus, can be 
falsely identified as coming from different bacteria, which impacts reported diversity(101). 
These chimeric sequences can now be identified and removed using tools such as UCHIME 
and Chimera Slayer. Following this, the sequences identified are designated to operational 
taxonomic units (OTUs). OTUs refer to clusters of organisms, grouped by DNA sequence 
similarity of a specific taxonomic marker gene. This grouping allows further community 
analysis by computational methods to determine abundance, richness, and diversity both 
within one single population (alpha diversity) and between populations (beta diversity).  
Another popular method used is Whole Metagenome Shotgun (WMS) and 
Metatranscriptomic Sequencing. In this, all the DNA from a given sample (unlike selected 
portions in 16sRNA sequencing) is sequenced and analysed. This technique is useful in 
determining the functions of the community(98).    
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Figure 6: Microbiome analysis using NGS technique and WMS sequencing 
1.5.2 Comparison of bacteria by traditional isolation techniques and NGS 
Although culture-based approaches can isolate bacterial species accurately, they have only a 
limited range of defined conditions for bacterial growth. As a result, a number of slow 
growing, viable but unculturable or difficult to culture organisms often fail to be 
identified(76). However, analysing species level community differences is not always 
accurate in next-generation sequencing based studies, which reliably identify taxa only to 
the genus level.   
A cross-sectional study by Fazel et al.(102) on 21 nasal swabs (15 patients with CRS, 5 non 
CRS, 1 repeat swab from a patient)  aiming to compare microbiological culture-based and 
culture-independent (16S rRNA gene sequencing) methodologies to identify the pathogens 
in CRS showed that while sequencing generally identified the same pathogens as culture, 
the opposite was not the case, as culture techniques failed to detect potentially pathogenic 
members of many genera. The most prevalent organisms in both groups were CNS (75%), S. 
aureus (50%), and P. acnes (30%). The common isolatesfromgene sequencing was CNS 
(100%), Corynebacterium sp. (85.7%), P. acnes (76.2%), and S. aureus (66.7%). They 
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concluded that DNA pyrosequencing revealed greater biodiversity than culture, particularly 
in the anaerobic groups although in most cases culture results represented a subset of the 
abundant DNA sequence types.   
Despite many studies reporting similar dominant bacteria being identified using culture-
based and NGS techniques, there are studies which show that dominant bacteria identified 
on sequencing were identified by culture only approximately half of the time(103). It is 
known that microbial genetic potential and activity, virulence, and involvement in disease-
associated processes can vary significantly at the level of the species and at times even 
between bacteria of the same genus(104). Hence to fully understand the complexity of 
bacterial community interactions both overall and at the bacterial species or strain level, 
studies combining both molecular and culture-based approaches are probably necessary.  
1.5.3 Microbiome in health 
There are nine published studies using NGS which examine the microbiome in sinuses of 
healthy control patients (75, 102, 105-111). To date, no consensus on the microbiome composition 
of a normal healthy sinus exists. This is largely because of the differences in study design, 
including sampling site and method used, different primer selection, sequencing 
methodology, and bioinformatics analysis. Nevertheless, a systematic review by Andersen 
et al. (112) showed that members of the phylum Firmicutes, Actinobacteria, and Bacteroides 
phyla were identified in every sample of control patients and patients with CRS. The total 
bacterial burden and bacterial diversity was similar in both healthy controls and CRS 
patients. There was also no single phylum that was seen to be particularly enriched in 
controls. Wagner Mackenzie et al.(113) reviewed all published sinonasal genomic studies and 
reanalysed the raw data from the available studies in an attempt to standardize the 
bioinformatic analysis. Although their study did not address the differences in sampling 
method/site or population differences of the enrolled patient cohorts, it did allow analysis of 
a much larger patient series facilitating some meaningful comparison.  
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Their meta-analysis demonstrated an increase in the relative abundance and diversity of 
some members of the phylum Actinobacteria and the genera Propionibacterium in healthy 
sinuses when compared to the inflamed sinuses in CRS patients. Another interesting but 
previously unreported finding was their observation that the absence of Burkholderia and 
Propionibacterium phylotypes appeared to be correlated with an increased network 
fragmentation of a healthy bacterial community. They postulated that these phylotypes may, 
therefore, act as possible gatekeepers in the maintenance of a stable sinonasal bacterial 
population. The potential protective effects of unclassified Corynebacterium species borne 
out from this study is also supported by other studies in the literature. Corynebacterium, 
when applied to the nasal cavity of persistent nasal carriers of S. aureus, resulted in a sizable 
reduction in nasal load of S. aureus. Yet another similar study found an eradication of 
facultative pathogen with no recolonization on follow up(55).  An analysis of microbiome in 
control patients undergoing trans-sphenoidal pituitary surgery when compared to CRS 
patients undergoing surgery showed a significant prevalence of Acinetobacter johnsonii 
(82% versus 26%,), Corynebacterium confusum (73% versus 26%)(114). 
1.5.4 Microbiome in CRS 
Jason et al. (115)study proposed that microbial colonization of the gut produces a host 
antibody response which in turn could influence the microbiome composition and function 
to benefit the host health through a process they referred to as antibody-mediated immune 
selection (AMIS).  Studies showed that naturally occurring polymorphisms in MHC genes 
resulted in differences in microbiota composition between different lines of MHC-congenic 
mice, and this influenced colonization resistance against an enteric pathogen. This 
emphasize that defects or naturally occurring variability in AMIS among individuals lead to 
the establishment of unique microbial communities that can influence host susceptibility to 
inflammatory and infectious disease in the gut. Further studies of germ-free mice also 
reinforce the hypothesis that bacteria are needed for the development and maintenance of 
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normal tissue and immune function(116). In one of the studies, the formation of isolated 
lymphoid follicles which are induction sites for intestinal immune reactions failed to 
develop in the absence of specific microbial stimulus. The ability of the microbiota to 
promote substantial changes in gut morphology, including villus architecture, crypt depth, 
stem cell proliferation, blood vessel density, mucus layer properties and maturation of 
mucosa-associated lymphoid tissues have also been well described. Invariant NK T cells 
which are promoters of inflammation is found more abundant in the colon of germ-free 
mice compared to the NK- like cells suggesting that the gut microbiota promotes 
homeostasis by decreasing the number of these pro-inflammatory cells. It has been thus 
proposed that in health a symbiosis between pathogenic bacteria and non-pathogenic 
bacteria is needed to maintain homeostasis and normal tissue functioning. In chronic 
diseases it has been shown that a dysbiosis exists (117),  leading researchers to postulate that a 
similar alteration in the sinus microecology may also be responsible for the inflammation 
seen in CRS. 
A number of studies have examined the microbiome of CRS, and similar to the studies in 
health, no consensus regarding the composition of the microbiome in diseased patients 
exists.  
 




A common finding of most of the studies however is that although there is no difference in 
the degree of bacterial burden between the healthy sinus and a diseased sinus, there is a 
consistent observation of a relative reduction in the markers of bacteria biodiversity, 
richness and evenness(75, 107, 110, 113, 119). This finding supports the dysbiosis hypothesis as 
having a possible role in CRS as well.  A review of this topic, based on the findings of 
studies from six independent centers around the world, (120)  found a consistent relative 
reduction in the abundance of commensal bacteria and augmentation of pathogenic strains 
in the microbiome of CRS. Within the subgroups of CRS, there appeared to be no 
significant difference in the most commonly isolated bacteria on 16s sequencing between 
polyp and non-polyp patients, a finding which was different to previously culture dependent 
studies, that observed bacterial differences between the two phenotypic groups. 
Apart from this, various comorbid conditions and patient demographics and habits could 
also influence the sinus microbiome and the disease profiles. Its observed that CRS subjects 
are more often asthmatics compared to controls and also CRSwNP is more likely to develop 
in asthmatics compared to non-asthmatics. Cystic fibrosis patients with CRS with or without 
polyps are found to have a reduced bacterial community diversity and increased bacterial 
load compared to healthy controls(90). A history of smoking has been consistently associated 
with a decrease in bacterial diversity and poor treatment outcomes. However, variables like 
patient age, allergies, diabetes, ethnicity, gender, polyposis, antibiotic usage in the 6 months 
prior to surgery, saline washing, intranasal steroid use, and previous surgery was not found 
to be associated with changes in the bacterial community(91). To better understand the 
microbiome influence on CRS pathogenesis it might be important to take into account the 
coexistent comorbidities apart from classifying CRS on the standard phenotypic basis of 
presence or absence of polyps.  
While single gene-based approaches identify the taxonomic diversity of the bacterial 
community, they do not provide information of the functional capacity of the community. 
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This can be investigated using computational approaches such as PICRUSt (Phylogenetic 
Investigation of Communities by Reconstruction of Unobserved States(121). These 
approaches that sequence all DNA (metagenomics) or all transcribed RNA 
(metatranscriptomics) or that identify proteins (metaproteomics) or metabolites 
(metabolomics) will provide greater insights into the true diversity and structure, the full 
genetic potential and in situ functional activity, of the microbiota. In an attempt to explain 
the CRS patient heterogenicity on the basis of the presence of distinct sinus microbiota, 
Cope et al.(122)examined the sinus mucosal microbiome and parallel host immune responses 
of a cohort of CRS and healthy subjects and related these findings to clinical outcomes of 
nasal polyposis development. For this, they used an unbiased probabilistic model, Dirichlet-
multinomial mixtures (DMM) which identifies clusters of samples based on bacterial 
communities. Three distinct sample clusters termed Dirichlet states (DSI-III) were 
identified. All the healthy controls and a few CRS patients clustered into DSI which 
exhibited relative enrichment of Streptococcus. This group was depleted of polyketide and 
folate biosynthesis and enriched for a pathway responsible for ansamycin biosynthesis, 
amicrobial secondary metabolite with a broad range antimicrobial activity. DSII (only CRS 
patients) were the least functionally diverse, the most immunologically active, had the 
greatest proportion of cystic fibrosis and asthma patients, and was predominated with 
Pseudomonadaceae with relative enrichment for Fusobacterium, Aggregatibacter, 
Achromobacter, and Prevotella. This group was specifically depleted of 67 KEGG 
pathways for lipid, carbohydrate, terpenoid, and xenobiotic metabolism. DSIII containing 
CRS patients were further classified into a or b depending on the species dominating the 
cluster, Corynebacteriaceae (DSIII a) and Staphylococcaceae (DSIII b). DSIII(a) was 
characterized by both peroxisome proliferator-activated receptor-γ and retinoic acid-
inducible gene-1signaling pathways both of which have been shown to be increased in 
eosinophilic polyp tissue in CRS patients. DSIII(b) along with DSII was significantly 
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enriched in bacterial virulence pathways, including two-component response systems, and 
for fatty acid and tryptophan metabolism pathways associated with inflammation.  
It was suggested that patients with Corynebacteriaceae-dominated (DS III a) state were 
uniquely associated with increased IL-5 and IFN-γ gene expression and increased the 
tendency for development of nasal polyposis and induced TH2-skewed immune responses. 
On the other hand, IL-1β gene expression was increased in DSI, II, and III(b), which may 
indicate a role for inflammasome activation in CRS patients with TH1-skewed disease. The 
study is however limited by the significant number of CRS patients who were on antibiotics 
prior to their nasal swabs.  
 
Figure 8: Future directions in microbiological techniques.(118) 
 
In-spite-of all these advances in technology, the exact role of microbiota in the pathogenesis 
of CRS remains unclear. This is largely because of the substantial technical variation in the 
methodological approaches used in different studies. The differences in sampling sites and 
techniques, target gene regions, sequencing platforms, bioinformatics pipelines, and 
taxonomic assignment databases can all make a meaningful comparison difficult. The 
present-day consensus from the literature is that specific genera or species of bacteria or 
bacterial communities may not be directly associated with the development of CRS, rather it 
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is more common to observe an overall shift away from an apparent “healthy microbiota” 
which leads to disease. These findings suggest that it is important to identify the possible 
dysbiosis occurring in sinuses leading to CRS and also to see if the changes are reversible 
and exhibit long term stability in spite of multiple surgical or medical therapies. Dysbiosis 
and instability in the community as a whole are likely reflected in the dominance of 
particular microbes (single pathogen hypothesis) or clusters of microbes (co-occurrence 
hypothesis), intramucosal invasion and persistence (intramucosal hypothesis), or changes in 
the membership and activity of the biofilms present(76). 
1.5.5 Significance of the different bacteria in health and disease 
Identifying and categorizing bacterial communities to different disease entities alone might 
not be sufficient to understand the significance of the presence or absence of these 
communities in disease pathogenesis. This would require various metagenomics, 
metatranscriptomics, and metabolomics/metaproteomic methods to identify the composition 
and function of host-associated microbiota. Thus, identifying specific microbiome derived 
molecules that promote the selection of pathogenic microbial communities and drive 
specific inflammatory responses to help in better understanding of host-microbe 
interactions.  
In all these, the role of commensal bacteria in the sinuses cannot be underestimated. They 
act as a competitor to pathogenic strains in regard to space, nutrient cell surface receptor and 
also actively secrete antimicrobial agents like hydrogen peroxide, lactic acid,and bacitracin. 
It has been shown that bacitracin secreted by P. acnes, a commensal isolated from healthy 
nose possess antibacterial and antifungal properties and also modulate immune responses to 
pathogenic bacteria. Apart from these properties, commensal bacteria also have important 
structural and metabolic functions. Studies have established their involvement of regulation 
of epithelial health and the reinforcement of tight junctions. They are also involved in the 
sequestration of metals, synthesis of vitamins and fermentation of undigested 
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polysaccharides and mucus.  Even among the patients with CRS, an increased preoperative 
bacterial diversity has been associated with an improved surgical outcome.  
Although it is unclear if dysbiosis drives the initial aetiology or subsequent exacerbation of 
the disease, the loss of epithelial integrity and inflammations seen in CRS subsequently 
promotes secondary bacterial, fungal and viral invasion which results in persistent 
inflammation. The microbial milieu may, therefore, be important in exacerbations and the 
progression of the CRS, even though not primarily responsible for the initial aetiology. The 
resident microbiome, host immune responses, therapeutic interventions and the interactions 
between these factors all eventually contribute to the chronicity of this condition.  
 
Figure 9: Multifaceted interactions in the development and progression of CRS.(118) 
1.6 Medical therapy in CRS 
A recent systematic review by Rudmik(123) et al attempted to summarize the highest-quality 
evidence on medical therapies for adult chronic sinusitis and to provide an evidence-based 
approach to assist in optimizing patient care. They examined a total twenty-nine studies 
which met their strict inclusion criteria, including 12 meta-analyses (examining >60 RCTs), 
13 systematic reviews, and 4 individual RCTs that were not included in any of the meta-
analyses. The results of this well performed systematic review will be detailed in the 
following section. Topical nasal steroids, oral corticosteroids, oral antibiotics, and saline 
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nasal irrigations form the main stay of medical therapy in CRS (described below).  
 Other treatment modalities which are not widely used includes anti-IgE therapy. This 
involves delivery of recombinant DNA-derived IgG monoclonal antibody which will bind to 
free IgE preventing its binding to mast cell and basophil receptors. This is given in patients 
with high serum IgE level(124). Yet another mode of treatment involves the Anti–Interleukin 
5 Therapy. Humanized IgG monoclonal antibody is delivered which binds free IL-5 and 
impairs eosinophilic-mediated inflammation. A systematic review by Soler et al (125)looked 
at the effect of topical antibiotics like Fosfomycin, N-chlorotaurine, bacitracin, tobramycin, 
mupirocin, and neomycin for CRS without polyps and evaluated the symptom, quality of 
life, and endoscopy. The study, however, did not demonstrate any difference in clinical 
outcomes compared with placebo. It has been shown that there is fungal colonization in the 
nasal cavity of 96% of CRS patients and healthy controls. Against this background, it was 
thought that abnormal immunological response to fungi may cause chronic sinusitis. 
However, studies failed to demonstrate any benefits with topical antifungal (amphotericin) 
compared to placebo(126). Leukotriene pathway antagonist such as Montelukast had no 
additional benefit to topical steroids and antihistamines and allergy immunotherapy results 
in significant symptom relief in CRS(127, 128). 
1.6.1 Saline irrigations 
The use of saline nasal irrigation as a treatment for nasal ailments can be traced back many 
centuries. The benefits of saline irrigation are believed to be due to the removal of 
environmental allergens, clearing excess mucus, and improving mucociliary clearance. A 
report from pooled data of three RCTs shows that saline nasal irrigations can significantly 
improve symptom scores and disease-specific quality of life as compared with no 
treatment(129). Moreover, a review of sixteen RCTs concluded that saline is very beneficial 
even as a single treatment modality in the treatment of post-surgical CRS(130). Intranasal 
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saline irrigations also appeared to have a beneficial adjunctive effect on symptom relief for 
patients(131). 
The concentration of saline recommendation varies from hypotonic, isotonic to hypertonic. 
The efficacy of all the three concentrations remains comparable although it is argued that 
hypertonic saline may result in nasal irritation. In terms of delivery of the saline, most 
distribution studies agree that large volume irrigation is superior to sprays or low volume 
washes in terms of sinus penetration and symptom score improvements.(130).  
Saline washes are generally well tolerated by most patients, although reported side effects 
include nasal irritation/burning, sore throat, otalgia or aural fullness, epistaxis, postnasal 
drainage, and headache.  
1.6.2 Oral antibiotics 
Sinusitis was found to be the most common condition for which an antibiotic was prescribed 
in surveys conducted in 2003 and 2013 in the United States. Despite being widely used as 
the first line medical therapeutic agent in many clinical practices there is little evidence to 
support its efficacy in treating CRS. This is because the organisms commonly isolated in 
sinus disease are also present as harmless commensals in the oropharynx, nasopharynx, and 
skin. Antibiotic use and benefits are also debatable between CRSsNP and CRSwNP with A-
11 grade evidence for use in CRSsNP and B-111 grade evidence for use in CRSwNP from 
multiple randomized controlled studies(123). Furthermore, a current study suggests that 
recent antibiotic exposure may be implicated in the development of allergic disease and 
chronic inflammation in the sinonasal cavities. It is hence argued that CRS is a disease of 
inflammation alone and not of infection. The propagators of this theory emphasis on the 
antibiotic use only in cases of acute sinusitis or an acute exacerbation of CRS. 
In this contest, amoxicillin-clavulanic acid and second- or third-generation cephalosporins 
are considered the first-line antibiotic choice. Quinolones are helpful second-line agents for 
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refractory cases, followed by trimethoprim-sulfamethoxazole, doxycycline, telithromycin, 
and macrolides(132). The macrolide group (erythromycin, clarithromycin, and 
roxithromycin), have received special interest among the CRS research due to its anti-
inflammatory effects along with having anti-infective properties. Macrolides inhibit the 
production of a number of inflammatory cytokines, decrease Pseudomonas biofilm 
formation, decrease secretion of mucous in the airways, blocks transcription factor nuclear 
factor ĸB (NF- ĸB) activation, and facilitates the apoptosis of neutrophils(133, 134).These 
properties of macrolides may improve clinical outcomes in CRS. Moreover, the presence of 
biofilms in CRS would also encourage the use of antibiotics early in the disease aiming 
disease eradication. 
 In vivo and in vitro studies with macrolides, amoxicillin-clavulanic acid and levofloxacin 
have all shown potent antibiofilm activity of these compounds against S. aureus and 
Coagulase negative staphylococcus in nasal polyposis patients(135). A study by Zeng et al(136) 
showed that Clarithromycin at 250mg daily given for a period of 12 weeks produces 
significant changes in the subjective and objective clinical outcomes in patients, which is 
comparable to that when Mometasone furoate nasal spray given at 200mcg puff once daily 
for the same time duration. Moreover, the study also showed significant and similar clinical 
improvement in both groups at 4weeks of treatment. However, the maximum benefit was 
seen at the end of 12 weeks in the Clarithromycin group, whereas it was seen earlier in the 
steroid group. 
Doxycycline a bacteriostatic agent under the Tetracycline group of antibiotics is 
increasingly being used in CRS due to its broad spectrum of action, safety and good 
tolerability in patients, excellent penetration into tissue and sinus secretions and most 
importantly the additional anti-inflammatory action of the compound(137). The other actions 
include suppression of cytokine production, inhibition of metalloproteinases (MMPs), 
suppression of hydrolases, and reduction of pathological tissue damage from reactive 
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oxygen species(138). In contrast, studies comparing two antibiotics for 3 weeks or less 
without a placebo group have shown no difference in outcome between the groups(139). 
Antibiotic therapy could potentially destabilise the microecosystem and could facilitate the 
growth of antibiotic-resistant bacterial strains. Exacerbation of infection following antibiotic 
therapy has been documented outside CRS in cystic fibrosis. Antibiotic therapy has also 
demonstrated a predominance of resistant strains in the sinonasal microbiota(140). This shift 
in the bacterial diversity was highly individualised from patient to patient and highly 
variable, again questioning the complex interactions between the microbiota and host 
leading to disease progression.  
1.6.3 Topical antibiotics 
Topical antibiotics have been increasingly used in CRS as the biofilm theory of 
pathogenesis emerged. The theory behind their use in this manner is that higher doses can 
be delivered directly to the nasal cavity, circumventing first pass clearance and systemic 
side effects. Although they are still used in acute exacerbations of CRS there is a growing 
concern for the development of multidrug-resistant bacteria(141).  Despite this, topical 
antibiotics have a role in treating MRSA positive CRS exacerbations with studies showing 
90% eradication at five days and 60% at long term follow up(142). Its activity against S. 
aureus biofilms has been shown to be superior to that of the oral ciprofloxacin and 
vancomycin.  
Adverse effects of topical antibiotics include postnasal drainage, nasal irritation, dryness, 
burning, itching, otalgia, and sore throat. Although RCTs do not support the routine use of 





Although early low-level evidence studies initially suggested a role of antifungal 
medications in the management of CRS, more recent metanalysis have conclusively 
demonstrated that such agents confer no significant benefits in the management of CRS(143) 
Adverse drug effects of topical antifungals include local irritation (nasal burning, dryness, 
bleeding, itching), muscle aches, facial pain, nasal congestion, rhinorrhoea, and respiratory 
symptoms (asthma attack, bronchitis, cough)(144). 
1.7 Corticosteroids 
Corticosteroids are synthetic or naturally occurring compounds structurally related to 
hydrocortisone and bind to a single group of endogenous corticosteroid receptor mediating 
an anti-inflammatory action. The basic chemical structure of the corticosteroids contains 3 
rings of 6 carbons each and 1 ring of 5 carbons. They also contain a ketone oxygen at 
position 3, the unsaturated bond between carbons 4 and 5, the hydroxyl at position 11, and 
the ketone oxygen at carbon 20. Many of the intra nasal corticosteroids (INCS) have 
halogen groups attached to position 6 and 9. Variations of the corticosteroid at carbon ring 
D at positions 16, 17, and 21increase topical activity while minimizing systemic adverse 
effects. In case of mometasone furoate (MF) which is 21-chloro 17(2´ furoate), the chloride 
at position 21 makes MF resistant to degradation by esterases, and the addition of chloride 




Figure 10a: Methylprednisolone, 3b: Mometasone fumarate 
The effects of steroids are brought about by genomic and non-genomic actions(146). The 
classic genomic or delayed mechanism of action of steroids is mediated through 
intracellular receptors. The lipophilic steroid molecule is thought to enter the cell by simple 
diffusion. Once the steroids bind to the ligand binding domain of the steroid receptors the 
affinity of the receptor for the DNA increases and the glucocorticoid receptors complex is 
translocated into the nucleus. They then act as transcription factors regulating gene 
expression by recognizing palindromic hormone response elements (HRE) at the DNA and 
binding to them. This ligand-receptor complex dependent transcription is initiated in 
conjunction with the basal transcription complex, different coactivators, repressors, and 
transcription regulators and is sensitive to inhibitors of transcription and translation(147). 
Apart from this, gene expression may be modulated by a non-transcriptional action by the 
interaction of nuclear receptors with sequence-specific transcription factors. This is seen 
with glucocorticoids, which can affect the activity of NFκB (a modulator of cytokine-
induced inflammation). Glucocorticoids genomically can increase the level of inhibitor IκB, 
which traps NFκB in the cytoplasm(148). In addition, glucocorticoid receptor interacts with 
p65, a transcriptionally active subunit of NFκB, by protein-protein interaction(149). 
Glucocorticoids can thus elicit direct actions at the transcriptional level and effects mediated 
by direct protein-protein interactions, which should be termed non-transcriptional activities 
of classic steroid receptors.  
In contrast to this, the non – genomic effect of steroids has a rapid onset of action (within 
seconds to minutes) and is insensitive to inhibitors of transcription and protein synthesis. 
These actions are, however, not uniform and a number of potential mechanisms have been 
proposed and hypothesized. The Mannheim classification scheme (150)has classified this to 
better describe and understand the non-genomic actions. This includes 1. Direct steroid 
action (A) which is nonspecific -A1, 2. Direct steroid action which is specific (AII) and is 
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mediated through a classic steroid receptor - AIIa, 3. Direct steroid action which is specific 
(AII) and is mediated through a non-classic steroid receptor – AIIb, 4. Indirect steroid action 
(B) which is nonspecific – BI, 5.  Indirect steroid action which is specific (BII) and is 
mediated through a classic steroid receptor – BIIa, and 6. indirect steroid action which is 
specific (BII) and is mediated through a non-classic steroid receptor – BIIb.  The receptors 
responsible for these actions, when present are thought to be located on the cell membrane 
and are considered structurally similar to the classic intracellular receptors. Direct steroid 
actions in the absence of a receptor are thought to occur at high concentrations and are 
considered to occur due to change in membrane fluidity(151).  
Most of the adverse effects of oral corticosteroids result from the suppression of the 
hypothalamic–pituitary–adrenal (HPA) axis function. This leads to the development of 
iatrogenic Cushing’s syndrome (cardiovascular disease, thromboembolic events, weight 
gain, glucose intolerance, osteoporosis/avascular necrosis of bone, obesity, skin changes, 
neuropsychological changes, immune deficiency, cataracts, serous chorioretinopathy, and 
increased intraocular pressure)(130). The modifications created on the carbon ring D at 
positions 16, 17 and 21 are responsible for increasing the topical activity while reducing 
systemic side effects of corticosteroids.  
In CRS, these actions of steroid can be summed up to its multiple mechanisms by which it 
decreases the mucosal inflammation, decrease vascular permeability, and reduce 
glycoprotein release. Corticosteroids thus can reverse histone acetylation of activated 
inflammatory genes. This leads to a decreased production of cytokines, chemokines, 
adhesion molecules, inflammatory enzymes, and receptors. Corticosteroids promote 
transcription of anti-inflammatory proteins and reduce lymphocyte activation, 
differentiation, and cytokine release by inhibiting macrophage presentation of antigens to 
lymphocytes(130). Oral and topical steroids can also significantly decrease the expression 
levels of IL-1, Il-6,and TNF-alpha in nasal polyps(152).  
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Corticosteroids are known to reduce host immune responses and could potentially affect the 
body’s ability to fight infection. Recent studies, however, provide significant evidence for 
their use in a wide range of infections, especially in the early stages. Diseases like acute 
bacterial meningitis, pneumocystis pneumonia, croup, tuberculous meningitis, tuberculous 
pericarditis and tuberculous pleurisy all have level 1 evidence and grade A recommendation 
for the use of steroids in the treatment protocols(153). The indications for corticosteroids in 
rhinosinusitis recommended by the European Position Paper on Rhinosinusitis (EPOS) 
guidelines include acute rhinosinusitis (ARS), prophylactic treatment of recurrent ARS, 
CRSsNP, CRSwNP, postoperative treatment of CRS with or without nasal polyps(4).  
1.7.1 Oral steroid 
The most common oral steroid used in CRS is methyl prednisolone. The utility of oral 
corticosteroid has been widely acknowledged in cases of CRSwNP while current literature 
is increasingly showing the benefits of short course oral steroid in CRSsNP cases also. 
Steroid therapy in CRSwNP has also been described as medical polypectomy due to its 
remarkable ability to reduce the size of polyps in a sizable number of patients. These 
patients also report a significant improvement in their sinonasal symptom score as the nasal 
polyps obstructing the nasal cavity and the sinus drainage reduces. The symptom relief 
however, tend to return back to the pre-treatment stage after a few weeks of steroid therapy 
as the polyps have been shown to recur once the anti-inflammatory benefits of oral steroids 
taper off.  The recommended dosage of oral prednisolone over 3 weeks is 25mg every day 
in the first week followed by 12.5 mg every day for the next week and 12.5mg on alternate 
days in the third week(154). Oral steroids are however considered superior to antibiotics in 
the treatment of CRSwNP symptoms. An RCT by Van et.al (155) compared the effect of 
200mgofdoxycycline once, followed by 100 mg daily for 20 days with methylprednisolone 
and placebo for nasal polyposis. They showed that there was an improved polyp score at 12 
weeks for the doxycycline group compared to placebo. Methylprednisolone had a larger 
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improvement in polyp score at 2 weeks compared with doxycycline and placebo. However, 
after discontinuing the treatment for 12 weeks there was no difference in the symptom score 
in both the steroid or the doxycycline group. 
1.7.2 Topical nasal steroids 
Topical nasal steroids are currently the most popular treatment modality for CRS globally. 
This is due to the advantage of providing high concentrations of localized therapy 
preventing systemic toxicity, ease of administration, cost efficacy and particularly the 
clinical benefits observed.  
INCS can be delivered through Freon-propelled aerosols, metered dose pumps, aqueous 
pump sprays, pressurized aerosols, or even as nasal drops and nasal rinses in saline or 
applied directly into the sinuses in a carrier medium (e.g. chitosan gel). It is estimated that 
after topical nasal application around 80% of the steroid is available for absorption from the 
mucosal surface. About 20% of the drug has been shown to remain in the frontal cavity and 
turbinates for up to 1.5 hours after application. The efficacy of INCS is measured in terms 
of the therapeutic ratio. An optimal INCS will have the highest ratio of topical to systemic 
activity as this increases the potential for therapeutic effects relative to undesired systemic 
effects(156). A portion of INCS applied topically is swallowed and subsequently absorbed at 
the gastrointestinal tract and also could be absorbed in the circulation at the nasal mucosa. 
The amount of drug reaching target tissues and exerting therapeutic effect relative to the 
amount reaching the systemic circulation is a measure of safety of topical drugs. Fluticasone  
propionate (FP) and Mometasone furoate (MF) are highly lipophilic compounds and are 
poorly absorbed into the systemic circulation whereas, Budesonide (BUD) which is 
relatively less lipophilic is better absorbed(157). The systemic availability is however further 
reduced due to the first pass metabolism of the steroid by the liver.  
Once administered the compounds cortisone and prednisone are metabolised into their 
active form cortisol and prednisolone respectively by the reduction of the ketone group at 
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position 11. When compared to the corticoid receptor affinity of 1 for dexamethasone the 
relative binding affinity of beclomethasone dipropionate (BDP) is 0.53, beclomethasone 
monopropionate (BMP) is 25, BUD is 258, FP is 813 and MF is 1235(145). Half-life (t1/2) is 
a function of the volume of distribution and the clearance rate of a drug. When multiple 
doses of a drug are administered the plasma concentration of the drug steadily increases till 
it reaches a steady state concentration. The highest reported half-life is for FP (7.8) followed 
by MF (5.8) and then BUD (2.3).Reviews of intranasal administration of BDP, BUD and FP 
and MF indicate no detectable effects on measures of HPA axis function at recommended 
doses, which is in agreement with rapid hepatic metabolism of these INCS.(145, 158).  
Intranasal corticosteroids currently in use for CRS have a high ratio of topical to systemic 
activity(159). They are delivered into the nose as aerosols or metered dose pump sprays or 
aqueous spray pumps or pure powder formulations. Of these, the latter two have a more 
favourable intranasal drug distribution(160). Lipworth and Seck(161) estimated that around 
80%of the drug is available for absorption from the nasal mucosa following intranasal 
administration. This is because of the nasociliary clearance into the throat. Yet another study 
using positron emission tomography showed that 10% to 20% of the drug remained in the 
anterior nasal cavity and inferior turbinate for up to 1.5 hours(162).   
As maintenance therapy, topical steroids showed the most benefit in CRS patients with and 
without polyps. There is also early evidence which shows that high volume nasal irrigations 
(e.g. BUD rinses) are more effective than the low volume applications (i.e. meter-dosed 
spray, atomized, or nebulized solutions). A meta-analysis of 6 RCT (all double-blinded) has 
shown that CRSwNP treated with either mometasone or budesonide showed a significant 
decrease in polyp size which was directly correlated with a decrease in symptom scores(123). 
Most of these studies report an improvement in the nasal symptoms of congestion and 
rhinorrhoea while the improvement in the symptom of altered smell sensation is 
controversial. There is now increasing evidence supporting the use of nasal steroids for 
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CRSsNP(163). Unlike the previous belief that steroids might exacerbate the infection in 
CRSsNP, studies suggest that the benefits of topical steroids treatment for CRSsNP 
outweighed the minor adverse effects of epistaxis and headache. The improvement of 
symptom score seen in these patients was significantly higher than in patients treated with 
placebo. A recent Cochrane review by Chong et al(164) analysing the use of nasal steroids in 
CRSwNP and CRSsNP concluded that there was not much information about the quality of 
life (very low-quality evidence), however, the disease severity for all symptoms improved 
(low-quality evidence). There was a moderately sized benefit for nasal blockage 
(congestion) and a small benefit for rhinorrhoea (moderate-quality evidence). Although 
many studies mentioned the risk of local irritation, the risk could not be quantified (low-
quality evidence). The risk of epistaxis was increased (high-quality evidence), but the 
clinical relevance was unclear. 
INCS have been identified as the mainstay of treatment in post-surgical cases of CRS due to 
their potential to reduce the formation of adhesions and also recurrent mucosal oedema. 
This has also been demonstrated in molecular biological studies where INCS treatment 
reduce the expression of cytokines and other growth factors(165, 166). Fluticasone propionate, 
a higher generation INCS compound has been shown to reduce the production of type I, III 
and V collagens and the expression of profibrotic cytokines IL-11 and IL-17 in an RCT 
where nasal polyp biopsies were analysed before and after treatment(167). Whereas in another 
double-blindedplacebo-controlled trial, the same INCS compound was shown to decrease 
the expression levels of IL-4, IL-13, TNF-alpha and IL-1beta, but with no effects on the 
expression of endothelial vascular cell adhesion molecule (VCAM)-1 and P-selectin(168).  
The reported incidence of side effects of topical nasal steroids in literature is quite a few. 
The most common symptom is mild epistaxis and this is usually due to incorrect positioning 
of the sinus rinse bottle towards the nasal septum instead of towards the eye and also the 
intrinsic vasoconstrictor activity of steroid. The bioavailability of fluticasone and 
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mometasone is determined to be at 1%, whereas that for budesonide and triamcinolone is 
closer to 40% to 50%. There is however no evidence currently to show that topical nasal 
steroids cause HPA suppression at the typical doses given for CRS(130, 169).  
1.8 Types of intranasal steroids 
1.8.1 Hydrocortisone 
Silcox L E used intranasal hydrocortisone alcohol in patients with allergic rhinitis, allergic 
rhinitis with polyps and acute rhinitis. Formulas with different concentrations of 
hydrocortisone were used (50mg/100ml,2mg/100ml, 22mg/100mland 20mgmg/100ml with 
and without vasoconstrictors). The study showed that all the concentrations of 
hydrocortisone had satisfactory effects on allergic rhinitis with or without polyps. Of the 
preparations, 20mg/100ml with vasoconstrictors was the most beneficial in the anti-
inflammatory action and providing subjective relief(170). 
The preparations of hydrocortisone, dexamethasone, and methylprednisolone, are currently 
only used off-label to treat refractory cases of CRS.  
1.8.2 Beclomethasone 
Beclomethasone dipropionate (BDP) was the first clinically active aerosolized corticosteroid 
discovered in 1972. The use of BDP nasal spray especially in children is now not 
recommended since it was shown to affect the growth rate in children when used for one 
year.  
1.8.3 Fluticasone 
Fluticasone propionate (FP) has been approved as a commercial INCS in 1990 for use in 
adults and children above 4 years of age. The indications include seasonal and chronic 
allergic and non-allergic rhinitis, perennial rhinitis and CRSsNP and CRSwNP. It is one of 
the more potent glucocorticoids available for intranasal use. The formulations are available 
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as metered dose nasal sprays and nasal drops. The daily adult dose of fluticasone is 200 to 
400 μg/day in both nostrils.  
FP has been used in the treatment of CRSsNP and CRSwNP. Most of the studies focus on 
CRSwNP with many of them showing improvement on the polyp scores and disease 
severity(171, 172). FP, when used as nasal drops, has been shown to decrease the disease 
recurrence in CRSwNP patients following surgical clearance of the disease. The 
requirement for surgery in patients with severe polyposis was also found to be significantly 
reduced following the use of intranasal FP drops(173). A recent study has shown that 
fluticasone delivered through an exhalation delivery system significantly improves 
subjective and objective measures of disease and quality of life scores in CRSsNP 
patients(174). A comparison between FP and BDP showed similar effectiveness in terms of 
disease severity and epistaxis(172).  
1.8.4 Mometasone 
Mometasone furoate (MF) is among the more recently introduced topical INCS with 
potency equivalent to FP and almost undetectable systemic availability(145) and was first 
introduced as a nasal spray in 1998.Its efficacy in the treatment and prophylaxis of seasonal 
and perennial rhinitis, asthma, ARS and adenoid hypertrophy has been well documented in 
the literature. In patients with CRSwNP, a daily administration of MF decreases nasal 
congestion and the size of polyps. It causes minimal or no adverse effects while providing 
an improvement in the quality of life score and the sensation of smell(171, 175).  
A Cochrane review comparing different corticosteroids and their efficacy found no 
significant difference in the clinical outcomes of nasal obstruction, postnasal drip, anterior 
rhinorrhoea when FP and MF were used for CRS. The study also found no significant 
difference between the two drugs for most of the parameters assessed. The analysis also 
showed that the effectiveness of high and low doses of FP (800μg and 400μg) and MP 
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(400μg and 200μg in adults, 200μg and 100μg in children) were comparable. However, all 
the studies reported an improvement in the polyp score with high dose(172).  
MF has been shown to be safe for use in pediatric population and in pregnancy. Compared 
to BDP,  MF showed no suppression of bone growth in children after one-year 
treatment(145). The long-term administration of MF attenuates the inflammatory process 
decreasing the extent of inflammatory cell infiltration (especially eosinophils) without 
affecting the epithelial thickness or causing atrophy. 
1.8.5 Budesonide 
Budesonide was initially developed for use as a respiratory suspension for bronchial asthma. 
This preparation is now being increasingly used in CRS in an atomizer or drop formulation 
or in large-volume irrigations to treat uncomplicated as well as recalcitrant CRS. There is 
now increasing evidence in the literature supporting its use in pre and post-surgical cases of 
CRS with benefits being superior to traditional nasal sprays in post-operative cases. This is 
largely due to the ease of administration as a large volume rinse through saline apart from 
the clinical benefits it offers in the absence any systemic side effects. It is also well tolerated 
by the patients while giving a high localized concentration of steroid (176).  
Budesonide is a glucocorticoid structurally related to 16αhydroxy prenisolone. It is non-
halogenated and contains carbon rings. The chemical name of this molecule is 16α, 17α -
22R, S-propylmethylenedioxy-pregna-1, 4-diene-11ß, 21-diol-3, 20-dione. It is a white 
powder with free solubility in chloroform and sparing solubility in ethanol. It is insoluble in 
water and heptane. The melting point is 226⁰Celcius. It is available as powder inhalers, 
nebulizing suspensions as respules, metered dose inhalers, metered nasal sprays, ointments, 
and creams. The two main metabolites of budesonide include 6 beta-hydroxy budesonide 
and 16 alpha-hydroxy prednisolone. 
Budesonide is used in CRS as a pressured dosed nasal spray (e.g. Rhinocort) or as respules. 
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The respules can be directly instilled into the nasal cavity or used as rinses by dissolving 
them in saline water or can be applied directly into sinus cavity dissolved in sinus dressings 
like chitosan gel or gel foams. There is also early evidence which shows that high volume 
nasal irrigations (e.g. Budesonide rinses) are more effective than the low volume 
applications (i.e. meter-dosed spray, atomized, or nebulized solutions)(123).  
The safety profile of budesonide with regards to HPA axis suppression is currently being 
investigated. A small prospective study using intranasal budesonide did not show any 
significant change in intraocular pressure over 22 months although the study reported 
subclinical HPA axis suppression on prolonged budesonide use(177). A recent prospective 
cohort study reported low stimulated cortisol levels in 23% of the patients after at least 6 
months of treatment with topical budesonide despite being asymptomatic(130). There was 
also no bone suppression in children after 1-year treatment with budesonide (145). The US 
Food and Drug Administration (FDA) has classified intranasal steroids as category C with 
the exception of budesonide, which is category B in early pregnancy.  
Table 1: Topical nasal applications 
Topical steroid preparations used in nasal application reproduced(130) 
Name  Dose (per spray) Frequency  Notes  
Beclomethasone 
dipropionate 
40 or 80 μg 
1 spray per nostril 
bid 
 
Budesonide spray  32 μg 
1–4 sprays per 
nostril once daily 
For CRSwNP – 128 
μg (2 sprays per 
nostril) once daily 
Budesonide respules 0.5–1 mg 
1. Direct drops (1 




3. Mucosal atomizer 
device, 1 mL (0.25 
mg) in each nostril 
For irrigation, 
dissolve 1 mg in 240 
mL of normal saline 
and irrigate 60 mL 




Ciclesonide 50 μg 













2 drops bid per 
nostril twice daily 
Can be tapered to 
once daily and then 
every other day 
Flunisolide 25 μg 






2 sprays per nostril 
bid 
 
Fluticasone furoate 27.5 μg 
2 sprays per nostril 
once daily 
May decrease to 1 
spray per nostril 
once daily after 
symptoms controlled 
Mometasone furoate 50 μg 






1–2 sprays per 
nostril once daily 
 
 
bid- two times a day, tid- three times a day 
1.9 Pulmicort in CRS 
Pulmicort (Budesonide) respules are commercially marketed in the concentration of 
0.5mg/2ml and 1mg/2ml. The other ingredients in the formulation include disodium edetate, 
sodium chloride, polysorbate 80 (E 433), citric acid - anhydrous (E 330), sodium citrate (E 
331) and water for injections. These are also known as inactive ingredients or excipients. 
Excipients are compounds used in pharmaceutical preparations to solubilize or suspend a 
drug, for preservation and for the stability of the drug composition for optimal action of the 
drug. The excipient as such is not considered to be involved in the treatment process as it is 
present only in very minute quantity.  
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Pulmicort is widely used off label in the management of CRS and has shown many 
promising results in comparison to many of the new generation high potency INCS. When 
treatment with fluticasone nasal spray (group A) or budesonide directly instilled into the 
nostril using a mucosal atomizing device (group B) or budesonide instilled into the nose in a 
vertex-to-floor position of the head ( group C) was given in post-surgical patients with 
CRSwNP, the patients in group B showed greater reduction in sinonasal outcome test 
(SNOTT-22) and Lund -Kennedy scores at six months postoperatively which was closely 
followed by group C(178). A recent double-blinded RCT on adult patients to evaluate the 
incremental effect of adding budesonide to large-volume, low-pressure saline sinus 
irrigation found that the budesonide group experienced a clinically meaningful reduction in 
their SNOT-22 scores as well as improvement in the objective endoscopic scoring compared 
with the control group(179).  
The major limitation in the use of budesonide respules in the treatment of CRS (apart from 
being not FDA approved for use in the nasal cavity) is the cost expense on patients when the 
treatment has to be given over a prolonged period of time. Intranasal budesonide has been 
shown to not suppress the hypothalamic-pituitary-adrenal (HPA) axis or affect intraocular 
pressure when used in sprays, rinses, or respules(178, 180).  
1.10 Influence of therapy on sinonasal bacterial profile 
Therapy with medications including topical steroids, saline irrigations, oral steroids, and 
oral antibiotics form the first line of management in CRS. Surgery is indicated as a second 
line option in patients who do not respond to medications. A number of studies have 
evaluated the effect of the different medical therapies and surgery on the microbial pattern 
in CRS.  
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1.10.1 Invitro studies 
The growth of P. aeruginosa, S. aureus, H. influenzae, S. pneumoniae, M. cattharalis, B. 
cepaciae, and C. albicans on petri dishes were inhibited in the presence of budesonide 
200μg doses and not with fluticasone and beclomethasone. The study attributed this killing 
effect on the excipients present in budesonide(181).  
1.10.2 Animal models 
In an attempt to determine whether intranasal steroids help in the elimination of bacteria and 
thereby modulate the mucosal changes in a rabbit model of acute sinusitis, Cheng You et 
al(182). showed that intranasal corticosteroids may lessen infiltration by inflammatory cells. 
The study suggested that steroids could not be a substitute as a single therapy for antibiotics 
and the combined application of steroid and antibiotic did not decrease the effect of 
antibiotic but provided better efficacy. Transmission electron microscopic examination of 
the nasal mucosa in this study showed significant ultrastructure changes in the intranasal 
corticosteroids group and control group compared to the antibiotic group and hence they 
concluded that a prompt therapy including an antibiotic is essential to restore the mucosal 
changes occurring in acute sinusitis. The antibiotic used in the study was ampicillin as 
intramuscular injection and the steroid budesonide as a nasal spray. S. pneumoniae which 
were used to inflict the acute sinusitis was not detected in the bacterial cultures of all the 
four groups of rabbit maxillary sinus secretions in the study. The cultures instead, showed 
different kinds of Gram-negative bacteria which suggested that an original infection could 
be replaced by opportunistic pathogens.  
1.10.3 Clinical trials 
1.10.3.1 Pre-surgical  
A few studies have evaluated the effect of medical therapy on the sinonasal microbiome in 
patients who have not had prior sinus surgery. A recent study by Jain et al.(137) compared the 
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effect of treatment with oral Doxycycline and oral prednisolone for 7 days in patients with 
uncomplicated CRS. Bacterial communities of Corynebacterium and Staphylococcus were 
found in the pre-treatment swabs of all their patients. The average relative abundance of 
Propionibacterium was significantly increased in the doxycycline group and 
Corynebacterium significantly reduced in the prednisolone group following treatment. They 
found no significant differences in clinical scores, endoscopic scores, changes in bacterial 
profiles, and changes in bacterial burden within or between treatment arms.  
The administration of nasal steroid spray for allergic rhinitis did not change the S. aureus 
carrier state in these patients(183). The steroid used in this study was triamcinolone acetonide 
aqueous intranasal spray. When the effect of intranasal fluticasone on the bacterial culture 
rate and drug sensitivity was assessed in patients with CRSwNP, no significant difference 
was observed in the bacterial isolation and drug sensitivity of oxacillin and cephazolin 
before and one month after nasal steroid use. The most common bacteria isolated at both 
time points were S. aureus, CNS, and S. pneumonia. The study suggested that nasal steroids 
did not facilitate colonization and possible super-infection and antibiotic sensitivity in CRS 
patients(184).  
1.10.3.2 Surgical 
Quite a number of studies have evaluated the effect of endoscopic sinus surgery on the 
microbiota of CRS. Cleland et al.(114) examined the nasal swabs from 23 patients with CRS 
undergoing surgery and 11 non-CRS patients undergoing transsphenoidal pituitary surgery. 
Further postoperative swabs were collected in the CRS group. Bacterial identification was 
done using16S ribosomal DNA bacterial tag-encoded FLX amplicon pyrosequencing. The 
study showed a higher mean relative abundance of Acinetobacter (22 vs 4%) while a lower 
relative abundance of S. aureus in non-CRS controls. In the CRS patients, S. aureus was 
also the most abundant species, followed by S. epidermidis (10%), P. acnes (8%), 
Anaerococcus hydrogenalis (5%), and P. aeruginosa (4%) at the time of surgery. However, 
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when an analysis of the temporal change of mean relative abundance was done on these 
patients, there was a significant increase in A. johnsonii, from 4% during surgery to 37% at 
the late postoperative time point and Acinetobacter schindleri, which increased from 1% 
during surgery to 5% at the late postoperative time point. Jain et al.(92)in their longitudinal 
cohort of 23 patients also reported shifts in bacterial community composition post-surgery. 
Staphylococcus (pre: 95.7%, post: 100%), Streptococcus (pre: 95.7%, post: 100%), 
Corynebacterium (pre: 100%, post: 95.7%), and Propionibacterium (pre: 95.7%, post: 87%) 
were the most prevalent genera detected in the 23 patients both before and after surgery. 
They observed an increase in the number of operational taxonomic units (OTU) in spite of 
all the patients receiving oral antibiotics for at least two weeks following surgery. This was 
primarily due to the large increase in Staphylococcus (an increase of average relative 
abundance of 24.7%) while most other genera had reductions in average relative abundance 
after surgery which was seen consistently with and Streptococcus and Corynebacterium. A 
reduction in Corynebacterium was seen to be associated with an increase in symptom scores 
and qPCR replicates postoperatively. A similar result was observed by another study where 
bacterial burden but not the complexity was highest just after two weeks of antibiotics 
following surgery suggesting that antibiotics did not eliminate the commensals but in fact 
increased the bacterial load. A Principal coordinate analysis (PCoA) plot illustrated that the 
ethmoid microbiota shifted after surgery (day-1) and antibiotic administration (2 weeks) but 
returned toward the original baseline in many of the patients at 6weeks. The study also 
compared the nasal swabs from different sites and found that bacterial communities 
colonizing the ethmoid at 6 weeks postoperatively were most similar to anterior nasal cavity 
and pre-treatment bacterial profiles, suggesting that these sites may be a likely source for 





Liu et al(140). recruited a small longitudinal cohort study with six patients with patent 
maxillary antrostomy and active sinus inflammation, and who had not received medical 
therapy in the form of antibiotics or corticosteroids in the previous eight weeks. Evaluation 
of the pre and post microbiome after maximal medical treatment showed a consistent 
decreased total number of unique bacterial taxa among the participants. Patients had a 
highly specific microbiome pattern both before and after treatment and there was no 
tendency to incline to a specific microbiota in response to specific therapy. The authors 
underscore the potential futility of the search for a universal antimicrobial strategy. An 
interesting finding, however, was that post-treatment, participants frequently became 
colonized by taxa that are less susceptible to the prescribed antibiotics. Yet another larger 
study by the same group examined the effect of topical treatments with nasal saline 
irrigation, topical steroid sprays, or corticosteroid rinses on the microbiota of CRS patients 
with nasal polyps and controls without active symptoms and signs of sinusitis but with 
patent antrostomy. The microbiome analysis of the patients showed no association with the 
use of nasal saline irrigation, with or without added budesonide to a significantly distinct 
sinonasal microbiota composition. Nevertheless, the use of topical steroid sprays was 
associated with a distinct microbiota in control subjects(186). In an analysis by Fazel et al.(102) 
to examine the factors influencing bacterial biodiversity in CRS patients, they found that 
asthma and antibiotic use were both associated with reduced microbial diversity and 
increased S. aureus abundance, as measured by specific qPCR. They suggested that asthma 
and antibiotic use promoted a higher abundance of S. aureus in the middle meatus, leading 
to a decrease in biodiversity.  
Many of the studies show a change in the microbial pattern after medical or surgical 
intervention. It is also seen that while some patients recover from this bacterial community 
change to return to an initial pretherapy state, others continue to shift toward a new and 
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different microbial community. These effects possibly depend upon the treatment used and 
patient immune responses.   
1.10.4 Effect of steroids on microbiome or bacteriology of CRS 
There are a few studies in the literature which evaluated the effect of steroid therapy on the 
sinonasal bacteriology. Most of them have focused on the biofilm forms of bacteria. Biofilm 
formation has been found to be significantly reduced in the presence of corticosteroids 
mometasone and fluticasone. The reduction was more pronounced when treated with 
fluticasone. In the same study, isotonic saline was found to be superior to fluticasone in 
reducing biofilm formation. Among the bacterial strains S. aureus, P. aeruginosa and S. 
pneumoniae appeared to be more sensitive to the antibiofilm action of corticosteroids and 
isotonic saline(73).A study by Goggin et al.(187) investigated the antibacterial potential of 
corticosteroids like fluticasone, mometasone, and budesonide on S. aureus biofilms grown 
on pegs. Biofilm biomass quantification done using confocal scanning laser microscopy 
showed a biofilm biomass reduction with the higher doses (clinically significant) of the 
corticosteroids tested. Both these studies however determined the bacterial biofilm biomass 
which includes both live and dead bacteria. Hence the different metabolic responses and 
activity of bacteria to corticosteroids could not be established in the studies. A similar 
antibacterial action of nasal corticosteroids and saline irrigation was also seen on the 
planktonic form of bacteria by Liu et al.(186)in subjects with CRSwNP. The study by Nadal 
et al(89) indicated that P. aeruginosa was also more common in those who received systemic 
steroids.  
Presence of biofilms has been associated with significant epithelial destruction and 
metaplasia which is independent of INCS use in CRSwNP patients. INCS, however, 
influence the type of inflammatory cell infiltrate seen in the sub-epithelial layers of polyps 
with a predominant lymphocyte and plasmocytic infiltration seen with INCS use and a 
predominant polymorphonuclear cells infiltrate seen in the absence of INCS use(166). A 
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persisting microbial biofilm causes subepithelial inflammatory reaction and consecutive 
extracellular matrix production in CRSwNP(165). This effect is not affected by INCS use 
where no significant associations were found with biofilm positivity, biofilm thickness or 
microscopic architecture of the respiratory mucosa(166).  
There has been some concern regarding the long-term use of INCS especially in post-
operative cases where the ability of steroids to cause immunosuppression and decrease 
cytokine production was proposed to facilitate colonization and superinfection by 
pathogenic bacteria. Contradicting this hypothesis, studies have shown that the use of 
topical INCS resulted in a decrease in isolation of bacteria from ethmoid sinuses undergoing 
functional endoscopic sinus surgery(184, 188). The study showed that although the rate of 
recovery of bacteria, as well as isolation of S. aureus, was higher in revision surgery cases 
compared to primary surgery, the use of INCS preoperatively decreased the bacterial 
isolation, especially in the revision cases. The presence of purulent nasal secretions was also 
less in the group of patients who were on INCS. It was suggested that the anti-inflammatory 
property of INCS prevented mucosal oedema and sinus obstruction thus decreasing the 
chance of recurrent bacterial infections after the initial surgical clearance of the disease. 
The exact mechanism by which topical steroids and bacteria interact remains unclear. The 
steroid molecule, as well as the different excipients used in commercial topical steroid, 
could potentially influence bacterial growth in multiple ways. From a microbiome 
perspective, if topical steroids are considered to promote bacterial growth due to their 
immunosuppressive property it could potentially promote both protective and pathogenic 
bacteria. The final microbial milieu would then be in favour of the bacterial communities 
which thrive better on steroids and other compounds in topical nasal preparations. This also 
leads to the potential for development of bacterium that could have steroid resistance and 
hence could explain the inadequate response to steroids in many patients.  
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1.10.5 Corticosteroids on microbiome outside the sinonasal cavity 
Pragman et al., in their study of the lung microbiome in patients with Chronic Obstructive 
Pulmonary Disease, demonstrated the separation of microbial clusters based on the use of 
inhaled corticosteroids (189). Other studies have also shown distinct microbiome profiles in 
patients with corticosteroid-sensitive vs corticosteroid-resistant asthma, that they attribute to 
the presence of specific bacteria that degrade corticosteroids and modulate the 
responsiveness to corticosteroids of inflammatory cells  (190)Bacterial colonization with S. 
aureus in lesions of atopic dermatitis has been shown to be eradicated using topical therapy 
with topical corticosteroid (betamethasone valerate)(191).  
An animal study to delineate the functional characteristics of glucocorticoid-mediated 
changes on gut microbiota and their subsequent repercussions on host mucin regulation and 
colonic inflammation found a phylogenetic shift in the gut microbiota following treatment 
with dexamethasone both acutely (10days) and chronically (4 weeks) in healthy SPF mice. 
This was found notably in the Actinobacteria genus, where Bifidobacterium and 
Lactobacillus were significantly elevated after dexamethasone treatment when compared to 
controls while the colonic mucin degrader, Mucispirillum, was noticeably absent 
aftertreatment. Thus, suggesting a possible relationship between glucocorticoids, altered gut 
microbiota, and mucin regulation in the intestine. The study also showed a significant 
decrease in mucin gene expression after dexamethasone treatment. This the authors 
suggested was protective in the settings of inflammation to maintain the intestinal 
homeostasis. Further findings in this study were that gut microbiota is necessary and 
sufficient to regulate mucin gene expression while dexamethasone treatment in the absence 
of microbes could not produce such effects. Further, they concluded that dexamethasone 
mediated shifts in gut microbiome confer a protective effect on the development of colonic 




1.10.5.1 Influence of steroids on the antimicrobial activity of antibiotics: 
A study by Plotkin et.al. investigated the action of androgens, testosterone, and 
dihydrotestosterone, and of glucocorticoids, hydrocortisone and dexamethasone, on growth 
kinetics and antibiotic susceptibility of Escherichia faecalis, Escherichia coli, P. 
aeruginosa, and S. aureus. They found an increased sensitivity of S. aureus to Erythromycin 
and P. aeruginosa to tobramycin in the presence of steroid hormones. The antibiotic 
susceptibility changes were not related to the growth kinetics of the organisms(193). 
However, other studies show that the rate of bacterial growth is inversely proportional to the 
minimum inhibitory concentration (MIC) of antibiotics, especially those which act on cell 
functions(194). Ernest Jawetz(195) evaluated the quantitative effects of cortisone on the results 
of antimicrobial therapy in experimental lethal infections in mice with Klebsiella 
pneumoniae (K. pneumonia) and S. pyogenes. The study showed that cortisone significantly 
reduced the therapeutic efficacy of penicillin G potassium, streptomycin sulphate, and 
chlortetracycline hydrochloride. However, in their invitro studies, cortisone did not have 
any direct effect on the bacterial growth rate and also failed to show any influence on the 
bactericidal or bacteriostatic action of antimicrobial agents. They hence concluded that the 
depressive effect of cortisone on antibiotics is mediated through a host dependent 
mechanism.  
1.11 Bacterial and steroid metabolic interactions 
Steroids are important signalling molecules essential in many biological processes. In 
eukaryotic cells, adrenal steroids like mineralocorticoids and glucocorticoids help in 
electrolyte and glucose homeostasis. Sex hormones like androgens, oestrogens and 
progesterone help in reproduction. Certain steroid molecules like cholesterol play an 
inevitable role in the stabilization of the cell membrane in eukaryotes. Steroids are however 
not known to occur in primitive eukaryotes and prokaryotes like bacteria. These vertebrate 
steroid compounds (such as sex steroids, cholesterol) and bacterium are ubiquitous in the 
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environment and has been proposed to serve as a natural source of carbon for the microbes. 
The literature on the effects of steroids and related compounds on bacterial growth or 
metabolism is very limited. The complex interactions between bacteria and steroids have 
been observed in soil and aquatic bacterium and an impressive data on the steroid 
degradation pathway in terms of steroid intermediate and metabolite identification, as well 
as the characterization of the diverse enzymes involved, has been reported in the literature. 
The best-described steroid degrading bacteria is Comamonas testosteroni (C. testosteroni) 
which was done by Horinouchi et al.(196). Steroid transformation and metabolism are often 
performed by specific hydroxysteroid dehydrogenases (HSDs) that belong to the short-chain 
dehydrogenase/reductase (SDR) superfamily. Studies on 3α-hydroxysteroid dehydrogenase 
(3α-HSD) lead to the identification of a novel SDR gene (SDRx) which was found to code 
for 7α-hydroxysteroid dehydrogenase (7α-HSD) that is involved in steroid degradation in C. 
testosteroni. The 7α-HSD is also known to catalyse the dehydrogenation of the hydroxyl 
group at position 7 of the steroid skeleton of bile acids found in mammalian liver(197, 198).  
A study aimed at identification of classified functional HSDs and the bioinformatic 
annotation of these proteins in all complete sequenced bacterial genomes as well as a 
corresponding phylogenetic analysis found that the dominating phyla that express HSDs 
were that of Actinobacteria, Proteobacteria, and Firmicutes and also some evolutionary 
microorganisms like Cyanobacteria and Euryachaeota. The authors suggested that steroid 
metabolism is an evolutionarily conserved mechanism that might serve different functions 
such as nutrient supply and signalling(199). A similar bioinformatics study which looked at 
the distribution of aerobic steroid catabolism pathways among over 8,000 microorganisms 
whose genomes are available in the NCBI RefSeq database identified 265 putative steroid 
degraders within Actinobacteria and Proteobacteria, which mainly originated from the soil, 
eukaryotic host, and aquatic environments. In many of the actinobacterial genera, 
particularly in members of the Corynebacterium, a pathway for cholesterol degradation was 
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conserved and for the members of genus Rhodococcus, a cholate degradation pathway was 
present. A pathway for testosterone and, sometimes, cholate degradation had a patchy 
distribution among Proteobacteria. Growth experiments done to confirm this bioinformatics 
prediction found nine bacterial strains (Pseudomonas resinovorans, Cupriavidus necator, 
Sphingomonas wittichii, Shewanella pealeana, Thermomonosporacurvata, Actinoplanes 
missouriensis, Salinisporaarenicola Amycolicicoccus subflavus, Amycolatopsis sp.) capable 
of steroid metabolism. A single ancestral 9,10-seco-steroid degradation pathway was found 
to be involved in the bacterial steroid metabolisms(200).  
Durham et al.(201) examined the effect of different steroids on the growth of Aerobacter 
aerogene(A. aerogene) and found that stilbestrol, oestradiol, and progesterone in a 
concentration-dependent manner enhanced its growth when starch but not glucose, maltose, 
or raffinose was present as a source of carbon and energy. Cholesterol, estrone, and 
testosterone did not significantly affect the rate of growth in these experiments. They also 
suggested that progesterone and oestradiol exerted this effect by influencing the metabolic 
process of the bacteria while stilbestrol exerts its activity on the enzyme system to enhance 
bacterial growth. It was also seen that A. aerogene was unable to oxidize the steroid 
compounds or stilbestrol as a sole source of energy.  
Raboaun et. al (202)compared the degradation of topical hydrocortisone 17 butyrate in the 
presence of six different bacteria found on psoriatic skin. The degradation products were 
analysed using high-performance liquid chromatography (HPLC). They observed that the 
cocci (S. aureus, S. epidermidis, Streptococcus agalactiae) did not change the degradation 
of hydrocortisone when compared to the 16·6 +/- 7·1% degradation seen in the absence of 
microbes. Three bacilli, however, increased degradation, Escherichia coli 59·1+/-19·4%, K. 
oxytoca 62·1+/-6·7% and P. aeruginosa 56·0+/-17·9%.  
Steroid compounds are constantly discharged into the environment and act as a substrate for 
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many organisms. The metabolism of steroid by environmental (soil and aquatic) as well as 
human pathogenic and commensal bacteria potentially have implications in many disease 




















































Effect of commercial nasal steroid preparation on bacterial growth 
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2.2 Abstract 
 
Background: Topical Pulmicort (Budesonide) is commonly used in the management of 
chronic rhinosinusitis (CRS).  Although this is due to their perceived anti-inflammatory 
effect, previous studies suggest that they may also have anti-bacterial properties. To make 
the hydrophobic steroid molecule suitable for topical administration, pharmaceutical 
excipients are used in commercial steroid formulations. Here we investigated the 
antibacterial action of commercial budesonide and its excipients. 
Methods: Planktonic and biofilm forms of S. aureus and methicillin-resistant S. aureus 
(MRSA) were treated with Pulmicort or its excipients at clinically relevant concentrations. 
Bacterial growth was determined by optical density, Resazurin assays, colony forming unit 
counts and Giemsa staining. Minimum inhibitory concentration (MIC) studies assessed 
excipients’ potentiation of antibiotics. Experiments were conducted in triplicates and results 
analysed using one-way ANOVA. 
Results: There was significant reduction in planktonic and biofilm growth of S. aureus and 
MRSA on exposure to budesonide (p <0.0001) and its excipients (p <0.0001). The excipient 
EDTA demonstrated antibacterial property even at the low concentrations used in topical 
preparations (p<0.0001). With Amoxicillin, excipients exhibited a potential 




Conclusion: The commercial product Pulmicort has a direct antibacterial effect on the 
planktonic and biofilm forms of S. aureus and MRSA. This effect is at least in part mediated 
through the excipient EDTA in the product. Excipients also influenced the antimicrobial 
activity of antibiotics depending on the bacterial strain and antibiotic tested. 
2.3 Introduction 
 
Corticosteroids together with antibiotics form the mainstay of medical therapy for chronic 
rhinosinusitis (CRS) although the specific regimen may vary. Among these, topical 
corticosteroids are popular due to their absence of systemic side effects(123).Most therapeutic 
effects of steroids result from their anti-inflammatory action mediated through 
glucocorticoid receptors which suppress inflammatory gene transcription. They also inhibit 
nuclear factor-κB and activating proteins causing a down regulation of cytokines and 
inflammatory molecules(146, 203). This action is responsible for decreased mucosal 
inflammation, improved symptom scores and reduced recurrence after surgery. It is, 
however, unclear how sinonasal bacteria respond to topical steroids.  
In an evaluation of the effect of fluticasone, mometasone and budesonide on S. aureus 
biofilms, Goggin et al(187)reported a significant biofilm biomass reduction in the presence of 
steroids. Since biomass measures both dead and live bacteria together, the metabolic activity 
and exact response of bacteria to steroids remained unexplored. Similar antimicrobial 
effects have been identified in other chronic inflammatory conditions, like atopic dermatitis, 
where topical steroids reduced S. aureus colonization.(204)Another study has suggested an 
indirect antibacterial action in which hydrocortisone increased S. aureus sensitivity to 
erythromycin, without changing the bacterial growth kinetics.(193) 
Commercial preparations of topical nasal steroids also contain non-therapeutic compounds 
known as excipients. In Pulmicort, these include disodium edetate (EDTA), sodium citrate 
tribasic dihydrate, citric acid anhydrous, polysorbate (tween) 80 and sodium chloride.  The 
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exact concentration of these excipients in Pulmicort and most commercial preparations are 
unknown. There is, however, a standard guideline for the maximum permissible amount of 
each excipient that can be used in a pharmaceutical preparation.(205)Excipients are not 
actively involved in disease treatment but are utilised for preservation, stabilisationand 
suspension of the active agent. Nevertheless, studies have demonstrated the ability of 
excipients to reduce bacterial load. EDTA has been shown to eradicate bacterial biofilms 
from abiotic surfaces.(206, 207)Studies have also shown that combining EDTA with 
antimicrobials like ethanol complements its killing activity.(208)Tween 80,  has been shown 
to increase the planktonic growth and biofilm biomass of S. aureus and slow the growth rate 
of P. fluorescens.(209)Saturated citric acid solution decreased bacterial load on dental 
plaques(210)and sodium citrate has been found to inhibit growth of many oral cavity 
bacteria.(211) 
Despite being widely used in CRS, the action of excipients on bacteria at the concentration 
present in commercial nasal steroids and the interaction between excipients and traditional 
antibiotics currently remains unexplored. We, therefore, hypothesized that steroids and 
excipients could indirectly modulate inflammation through a direct antibacterial action. We 
aimed to look at the effect of a commercial nasal steroid and the various excipients both as a 
preparation and individually on S. aureus and MRSA planktonic and biofilm forms. We also 
investigated the effect of combining the excipients with antibiotics on MIC values against S. 
aureus and MRSA.  
2.4 Methods 
 
Bacterial strains:  
Staphylococcus aureus ATCC 25923 and methicillin-resistant Staphylococcus aureus 
MRSA JE2 (USA300JE2) were purchased from American Type Culture Collection 
(Manassas, VA, U.S.).  
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Drugs and chemicals:  
Budesonide 1mg/2ml (Pulmicort respules) was purchased from AstraZeneca AB, Sodertalje, 
Sweden. The maximum concentration excipient solution (Ex-max) was prepared by 
combining the maximum permissible food and drugs administration (FDA) approved 
dosage for each ingredient for topical nasal application in sterile Milli-Q water in the 
following concentrations: Citric acid anhydrous 0.027% (HOC(COOH)(CH2COOH)2, 
≥99.5%), ethylenediaminetetraacetic acid, 0.02% ((HO2CCH2)2NCH2CH2N(CH2CO2H)2, 
99%), sodium citrate tribasic dihydrate, 0.1% (HOC(COONa)(CH2COONa)2 · 2H2O, 99%), 
Polysorbate (Tween) 80, 0.04% (C64H124O26, average Mw∼ 79 000), sodium chloride, 1.7% 
(NaCl, ≥99%). Antibiotics Amikacin, Amoxycillin, Ciprofloxacin, Doxycycline, 
Erythromycin, Gentamicin, and Vancomycin (all purchased from Sigma-Aldrich, 
Steinheim, Germany). Water used in the experiments was prepared in a three-stage Milli-Q 
Plus 185 purification system (Merck Millipore, Darmstadt, Germany).  
Determination of presence of budesonide in centrifuged Pulmicort with liquid 
chromatography- mass spectrometry (LC-MS).  
Commercial Pulmicort respule at 1mg/2ml is a cloudy suspension of budesonide in 
excipients and cannot be used for optical density (OD) measurements.  To allow accurate 
and reliable OD measurements, Pulmicort was centrifuged 10 times for 10 minutes at 
4000rpm at room temperature resulting in a transparent supernatant. Pulmicort was diluted 
50 fold in acetonitrile and both samples were analysed for the presence of budesonide using 
a Beckman (Fullerton, CA, USA) liquid chromatograph, consisting of a 126 pump and a 
168-diode array detector. A Quattro II, triple-quadrupole mass spectrometer (Micro mass) 
was used for mass spectrometric analysis. Pulmicort supernatants were used for all 
treatments measuring the OD for planktonic bacterial growth. For all the other experiments, 
commercial Pulmicort was used.  
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The LC-MS analysis showed identical budesonide peaks after removal of insoluble particles 
in the Pulmicort respules, indicating the presence of budesonide even in the clear 
supernatant. (Figure 16).  
Cytotoxicity assay 
The local institutional Human Research Ethics Committee approved the study and primary 
human nasal epithelial cells (HNEC) were harvested from the inferior turbinate of consented 
non-CRS control patients. Cell cytotoxicity was determined by measuring the amount of 
lactate dehydrogenase (LDH) in the medium at 24 hours using the Cytotox Homogeneous 
Membrane Integrity Assay (Promega, Australia). Briefly, HNECs were grown in Bronchial 
Epithelial Cell Growth Medium(BEGM, Lonza, Walkersville, MD, USA) in 96-well flat-
bottom plates and incubated for 24 hours (37°C, 5% CO2) as described 
previously,(212)followed by treatment with different concentrations of commercial Pulmicort 
(5,100 and 200ug/ml) and excipients (starting at a maximum FDA permitted ). Cells were 
incubated for 24 and 48 hours before supernatant collected. 50ul of this supernatant was 
added to 50ul of LDH reagent, incubated for 30 minutes, and absorbance recorded at 490nm 
on a FLUOstar Optima plate reader (BMG, Labtech, Ortenberg, Germany). Negative 
controls included untreated cells and positive controls, cells exposed to Triton X-100 
(Sigma Aldrich, Steinheim, Germany). 
Pulmicort and excipient effect on planktonic growth of S. aureus/MRSA:  
Single colonies of bacteria from a 24-hour growth on nutrient broth agar plate at 370C, 5% 
CO2was transferred into 10 ml nutrient broth (NB) and was incubated on a shaking platform 
(180 rpm) at 370C for 14 to 16 hours. A dilution factor was calculated from this overnight 
broth culture to obtain a starting OD 600 of 0.05. Prior to incubation, this volume was added 
to tubes containing treatments and NB (making a final total volume of 10ml) in the 
following proportions.  
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For the excipient treatment, a solution with maximum FDA approved concentration of the 
excipients (Exmax) used in Pulmicort was prepared. From this, 2ml of the maximum, half 
maximum (Ex1/2max) and one fourth maximum (Ex1/4max) concentration was added to 8ml of 
NB. For the Pulmicort experiments, treatment A contained two respules of Pulmicort (each 
1mg/2ml) in 6ml of NB, treatment B had one respule of Pulmicort in 8ml NB. The controls 
for A and B contained an equal volume of phosphate buffered saline (PBS; Sigma Aldrich, 
Steinheim, Germany) in the place of Pulmicort. In the OD measurement experiments, this 
Pulmicort was the clear centrifuged supernatant (sample 2) and for colony forming unit 
(CFU) determination and Giemsa staining, it was commercial Pulmicort as is.   
i.  Growth curve determination by OD measurements: OD readings at 600nm were 
taken every hour for 7 hours and then at 24 hours from each tube to plot a 
bacterial growth curve. The growth curve plotting was done as 9 independent 
experiments.  
ii. CFU determination: Briefly, at the end of 24 hrs, a 20μl volume taken from the 
tubes with the above-mentioned treatments and serially diluted in PBS and 
spotted on nutrient agar plates in triplicates. Colony morphology was also 
determined. The CFU plating was done as three separate experiments.  
iii.  Giemsa staining: Another 20μl from each tube was spread on a glass slide and 
air dried. This was fixed in methanol for 7 minutes and then stained with 1:20 
dilution of Giemsa stain (Sigma-Aldrich, Steinheim, Germany) in sterile Milli Q 
water for one hour. The slides were rinsed with distilled water, dried and 
examined under light microscope (Eclipse 90i, Nikon, Japan) at 60 x 
magnification under oil immersion.  
Commercial Pulmicort and excipient effect on S. aureus/MRSA biofilm formation:  
Alamar blue or Resazurin assay 
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Single bacterial colonies suspended in 0.9% saline were adjusted to 1.0 ± 0.1 McFarland 
units (approximately 3 × 108 CFU/mL) and diluted 1:15 in NB. The resazurin assay (Life 
Technologies, Scoresby, Australia), was done by inoculating a black 96-well microtiter 
plate (Costar, Corning Incorporated, Corning, U.S.) with this bacterial suspension. 
Commercial Pulmicort was added to the wells starting at a concentration of 250μg/ml in the 
first well and then serially diluted. The excipients were added at a starting concentration of 
Ex1/2max and then serially diluted.  Each excipient at different concentrations was also used 
individually to treat the biofilms. The final volume in each well was 150μL and this 
incubated at 37°C for 48 h on a rotating platform (3D Gyratory Mixer, Ratek Instruments, 
Boronia, Australia) at 70 rpm. Biofilms were then rinsed twice with phosphate buffered 
saline (PBS) and the viability (metabolic activity) assay was done. For this, 200μL of a 
freshly prepared 10% resazurin dilution in NB was added to each well, protected from light, 
and incubated for 7 h at 37 °C on a rotating platform. The fluorescence was measured 
hourly on a FLUO star OPTIMA plate reader at λexcitation = 530 nm/λemission = 590 nm.  
Maximum fluorescence was typically reached after 4 h for both S. aureus and MRSA. 
Antimicrobial activity of the treatments used was quantified according to equation 1: 
%BK = FC-FT x 100 % 
               FC 
Antimicrobial activity of commercial Pulmicort and excipient solution was expressed as the 
percentage of biofilm killing (% BK), where FC was the fluorescence of the untreated 
control biofilms (100% bacterial growth) and FT was the fluorescence observed in the 
treated biofilms. Both FC and FT were corrected for background fluorescence (sterile 




Effect of excipients on S. aureus and MRSA minimal inhibitory concentration (MIC) of 
antibiotics:  
The MIC values of antibiotics (Amikacin, Gentamicin, Amoxicillin, Ciprofloxacin, 
Doxycycline, Erythromycin and Vancomycin) and the excipient mixture was assessed 
against the planktonic S .aureus and MRSA using standard methods(213)The MIC value 
which is the lowest concentration of the drug preventing bacterial growth was determined 
both visually and also quantitatively by OD measurements. Antimicrobial activity was 
quantified as: 
% Killing = (ODc-ODt) x100 
ODc 
Where, ODc was the optical density of the untreated control wells (maximum bacterial 
growth) and ODt was the optical density in the treated wells. Both ODc and ODt were 
corrected for background absorbance (sterile medium). Viability studies were performed as 
six independent experiments.  
The effect of consecutive treatment with excipients and antibiotics were done in a similar 
way at their sub-inhibitory concentrations.  
Statistical analysis:  
All the experiments were conducted at least in triplicate and were presented as mean ± 
standard deviation (SD) unless stated otherwise. The results were analysed using one-way 
analysis of variance (ANOVA) following Sidak test (GraphPad Prism version 7.00, 
GraphPad Software, La Jolla, U.S.). Statistical significance was assessed at the 95% 






Effect of Pulmicort and excipients on planktonic growth of S. aureus (ATCC 25923) and 
MRSA (JE2) 
OD measurements after 24 hours co-culture with Pulmicort (100 and 200 μg/ml) indicated a 
significantly reduced S. aureus and MRSA growth compared to appropriate volume controls 
in a dose dependent manner (Figure 11A, P<0.001). The maximum concentration excipient 
solution (Exmax) also showed significant reduction of bacterial growth of S. aureus and 
MRSA (Figure 11B, P<0.0001) whilst Ex1/2max reduced growth of the MRSA strain only 
(P<0.01) (Figure 11B). These results were confirmed on CFU counts which demonstrated a 
similar pattern of anti-Staphylococcal effect from both Pulmicort and its excipients (Figure 
11C and 11D). Giemsa staining of the Pulmicort and excipient treated tubes further 
confirmed findings with a visible reduction in the number of the bacteria when compared to 




Figure 11: Effect of Pulmicort and excipients on planktonic growth of S. aureus (ATCC 
25923) and MRSA (JE2) 
(A-D) Log optical density (OD) at 600nm for planktonic growth of S. aureus (SA) and 
MRSA (A-B) or Colony forming unit counts (CFU) (C-D) in the absence (maximum 
growth) or (A, C) presence of Pulmicort at 200ug/ml and 100ug/ml [4 ml or 2 ml Pulmicort 
in 6 or 8 ml nutrient broth (NB)] compared to volume controls [4 ml or 2 ml phosphate 
buffered saline (PBS) in 6 or 8 ml NB]; or (B, D) 2 ml excipients at different concentrations 
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(Exmax-maximum concentration, Ex1/2max-half concentration, Ex1/4max-one fourth 
concentration) in 8 ml NB compared to 2 ml PBS in 8 ml NB (control). Data represent the 
mean ± SD of three (C, D), six (B) or nine (A) biological replicates. E, F & G: Light 
microscopic image at 60x magnification of Giemsa stained SA after treatment with 
200ug/ml (E), 100ug/ml Pulmicort (F) or excipients (G) compared to control. One-way 
ANOVA, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; SD, standard deviation. 
 
Effect of Pulmicort and excipients on biofilm formation of S. aureus (ATCC 25923) and 
MRSA (JE2) 
We then assessed the effect of commercial Pulmicort or excipients on the formation of S. 
aureus biofilms. Formulations were co-incubated with S. aureus or MRSA for 48 hours in 
plastic plates on a rotating platform followed by in vitro resazurin viability assays. 
Pulmicort incubation showed S. aureus biofilm reduction of 91% with 250 μg/ml and 81% 
with 125 μg/ml compared to maximum biofilm growth (no-treatment control) (p<0.0001, 
Figure 12A). With the MRSA strain the killing was 97%, 99% and 7% when incubated with 
250 μg/ml and 125 μg/ml and 62.5μg/ml Pulmicort respectively, compared to the no-
treatment control (p<0.0001, Figure 12A).  
Excipients showed a killing of 92% with Ex1/2 max, 91% with Ex1/4 max and 57% with Ex1/8max 
for S. aureus compared to the no-treatment control (p<0.0001, Figure 12B). For the MRSA 




Figure 12: Effect of Pulmicort and excipients on biofilm formation of S. aureus (ATCC 
25923) and MRSA (JE2) 
Biofilm killing (%) of S. aureus(SA) and MRSA on exposure to different concentrations of 
(A) commercial Pulmicort (250, 125, 62.5, 31.2 μg/ml) or excipients (Ex1/2max-half 
concentration, Ex1/4max-one fourth concentration, Ex1/8max-one eighth concentration, 
Ex1/16max- one sixteenth concentration) compared to untreated control. Data represents the 
mean ± SD of three biological replicates. One-way ANOVA, ****, p < 0.0001; SD, 
standard deviation.  
Effect of individual excipients on biofilm formation of S. aureus (ATCC 25923) and MRSA 
(JE2) 
We then repeated the experiments using different concentrations of individual excipients, to 
identify the agent responsible for the bacterial killing. Results showed EDTA significantly 
reduced biofilms of S. aureus at concentrations that are approved by the FDA for use in 
nasal formulations (86% at 0.02%, P<0.0001), and also at much lower concentrations (95% 
at 0.005%and 65% at 0.0025%, P<0.0001, Figure 13A). MRSA biofilms also responded 
similarly to EDTA (98% killing at 0.02%, 99% at 0.005% and 61% at 0.0025%, Figure 
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13B). Furthermore, the compound SCDT at an FDA approved concentration significantly 
reduced MRSA biofilms (76% at 0.1%, P<0.01, Figure 13B).  
 
Figure 13: Effect of individual excipients on biofilm formation of S. aureus (ATCC 25923) 
and MRSA (JE2) 
Biofilm killing (%) of S. aureus (A) or MRSA (B) on exposure to different concentrations 
of individual excipients compared to untreated control. Data represents the mean ± SD of 
three biological replicates. One-way ANOVA, *p < 0.05; **p < 0.01; ***p < 0.001, ****p 
< 0.0001; SD, standard deviation, CA-Citric acid anhydrous, EDTA- 
ethylenediaminetetraacetic acid, T80- Polysorbate (Tween) 80, SCTD-sodium citrate 
tribasic dihydrate, NaCl-sodium chloride. 
MIC of excipients 
The MIC of the excipients was found to be Ex1/2max for both S. aureus and MRSA with > 
85% killing. For S. aureus, a concentration of Ex1/4max showed 26% killing and for MRSA 
Ex1/8max showed 44% killing (Figure 14). These concentrations of the excipients that gave 
less than 50% bacterial killing were combined with antibiotics at concentration lower than 




Figure 14: MIC of excipients 
MIC of excipients expressed as % killing of S. aureus (SA) and MRSA. Exmax- maximum 
excipient concentration, Ex 1/2max – half concentration, Ex 1/4max - one fourth concentration, 
Ex 1/8max - one eighth concentration and Ex 1/16max – one in 16 concentration. Data represents 
the mean ± SD of three biological replicates. 
 
Effect of excipients on antibiotic sensitivity of S. aureus ATCC 25923 and MRSA JE2 
The combination of Amoxicillin with excipients had synergistic effects on the percentage 
killing of planktonic S. aureus (from 43% at ½ MIC amoxicillin and 26% with Ex1/4max to 
82% killing when ½ MIC amoxicillin and Ex1/4max were combined, P<0.05, Figure 15A).  
With the planktonic MRSA, a similar significant increase in killing was seen with the 
combination of Amoxicillin and excipients (from 55% at ½ MIC amoxicillin and 44% with 
Ex1/8max to 97% killing when ½ MIC amoxicillin and Ex1/8max were combined, P<0.01, 
Figure 15B). The antibiotic-excipient combination with Amikacin, Gentamicin and 
Erythromycin on MRSA at ½ MIC however, did not increase bacterial killing. Rather, the 
combinations demonstrated a potential antagonistic action (from 75% at ½ MIC of 
100 
 
Amikacin to -0.9% killing when ½ MIC Amikacin and Ex1/8max were combined, P<0.0001; 
from 56% at ½ MIC Gentamicin to -4% killing when ½ MIC Gentamicin and Ex1/8max were 
combined, P<0.0001; and from 57% at ½ MIC Erythromycin to 8% killing when ½ MIC 
Erythromycin and Ex1/8max were combined, P<0.001. In all the cases, killing with Ex1/8max 
alone was 44%, Figure. 15B). This antagonism on MRSA was also found to be significant at 
higher antibiotic concentrations (1 MIC) for Gentamicin and Erythromycin (from 93% at 
MIC Gentamicin to 50% killing when MIC Gentamicin and Ex1/8max were combined, 
P<0.001; and from 90% at MIC Erythromycin to 31% killing when MIC Erythromycin and 
Ex1/8max were combined, P<0.0001. In all the cases, killing with Ex1/8max alone was 44%, 
Figure. 15C).  
 




MIC expressed as % killing of S. aureus (SA) (A) or MRSA (B-C). The blue bars are 
antibiotics alone and red bars are antibiotic-excipient combinations. Ex1/4max and Ex1/8max - is 
1/4th and 1/8th maximum concentration of excipients. Ami 4- Amikacin 4ug/ml, Amox 0.125 
– Amoxicillin 0.125ug/ml, Cip 0.25-Ciprofloxacin 0.25ug/ml, Dox 0.0625- Doxycycline 
0.0625ug/ml, Ery 0.5- Erythromycin 0.5 ug/ml, Gen 0.25- Gentamycin 0.25ug/ml, Van 0.5- 
Vancomycin 0.5ug/ml. Ami 8- Amikacin 8ug/ml, Ery 0.5- Erythromycin 0.5 ug/ml, Gen 1- 
Gentamicin 1ug/ml. Data represent the mean ± SD of six biological replicates. * p < 0.05, 
**p < 0.01; ***p < 0.001; ****p < 0.0001; SD, standard deviation. 
 
Cytotoxicity assay 
A 24 and 48-hour exposure of HNEC from non-CRS patients (n=3, 2 males and 1 female, 
aged 35-65 years old) to Pulmicort and excipients showed no significant cell toxicity 
(Supplementary Figure 17A &17B). 
2.6 Discussion 
 
The presence of biofilms in CRS and their influence on disease severity and treatment 
outcomes is well established.(214-216)Previous research from our department has shown that 
topical steroids may directly reduce biofilm production in an in vitro environment outside of 
the inflammatory milieu.(187)This study builds on this research, demonstrating that 
Pulmicort’s non-therapeutic excipients have independent antibacterial actions on both 
planktonic and biofilm forms of S. aureus and MRSA. Moreover, our study shows that those 
excipients influence the antimicrobial activity of commonly used antibiotics. 
The excipients used in commercial preparations help to suspend the active drug and act as a 
preservative and stabilizing agent. Because they are used in minimal concentrations, they 
are largely considered as non-therapeutic. Previous studies do suggest however that when 
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used at higher concentrations these agents may have an effect on bacterial growth.  EDTA 
for example can potentiate the cell walls of bacteria and destabilize biofilms by sequestering 
calcium, magnesium, zinc, and iron.(217)Unlike previous studies which suggest this only 
occurs at higher concentrations(218, 219)our study demonstrated EDTA to reduce S. aureus 
and MRSA biofilm formation at FDA approved and much lower concentrations. A similar 
antibiofilm effect on an MRSA strain was also seen for sodium citrate dibasic trihydrate 
(SCDT), another commonly used excipient. Like EDTA, SCDT acts as a metal chelator 
inhibiting biofilm formation. (211)Although the other excipients in Pulmicort such as NaCl, 
citric acid and tween 80 have all been shown to influence bacterial growth independently in 
other research,(209, 220, 221)none of them had any effect on bacterial growth in our study. This 
is most likely secondary to the low concentrations used. For example, although NaCl has 
been shown to cause physical damage to the cells at high concentrations, (222)S. aureus has 
been reported to be osmotolerant at low and moderate concentrations of NaCl due to its 
ability to accumulate osmoprotectants such as proline and glycinebetaine in the cells.  
Budesonide, when used in mucosal atomiser device (MAD) or incorporated into gel (e.g. 
Pulmicort respules mixed with saline or chitosan gel) for application into the sinuses deliver 
concentrations from 0.25mg to 1mg and when used as a nasal spray (e.g. Rhinocort) delivers 
a maximum of 256μg/day into the nasal cavity. These concentrations of the steroid with its 
excipients are comparable to that used in our study. However, when budesonide is used as a 
large volume nasal rinse, the concentration of the drug and excipient is much lower and did 
not demonstrate the antibacterial action which was seen at the higher concentrations in this 
study. A study by Thamboo et.al.(180)comparing the effect of budesonide nasal rinses (high 
volume, low concentration) with budesonide delivered through MAD (low volume, high 
concentration) in post-operative CRSwNP patients found that the patients using MAD had 
significant improvement in the SNOTT-22 scores compared to baseline when used for a 
short term (up to 60 days) without causing any adrenal suppression. This clinical 
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improvement could be due to the additional antibacterial action of the commercial topical 
nasal steroid and the excipients used in them which was demonstrated in our study. Each 
topical nasal preparation of budesonide contains different excipients, but most of them have 
compounds like tween 80 and EDTA. The FDA concentrations of the EDTA found in the 
different products can vary from 0.5% to 0.0001%, which is also in the range of the 
concentrations analysed in our study.(205) 
Antibiotics are often given in combination with topical steroids in CRS.  When drugs or 
compounds are combined, they could produce desirable or undesirable interactions. 
Additive effect in a combination is the sum of individual effects. Synergism occurs when 
the combination effect is higher than the additive effect and antagonism refers to an 
opposite action where the combination effect is lesser than additive effect.(223)Here, the 
steroid or the excipient could potentially interact additively, synergistically or 
antagonistically with antibiotics influencing the MIC values. To demonstrate these 
interactions, we used a sub-inhibitory concentrations of both excipient and antibiotic as per 
previous studies.(224)In our study, we found that although the excipient solution 
demonstrated an inhibitory effect on the growth of both S. aureus and MRSA, the 
combination of antibiotic-excipient showed an antagonistic trend on MIC for all the 
antibiotics tested except amoxicillin.  
For the Amikacin/Gentamicin-excipient combination in our study, the antagonistic action 
seen could be due to the divalent and monovalent ions in the excipient solution competing 
with the antibiotics at the receptors for uptake into bacteria as have been shown in previous 
studies.(225, 226)Compounds like sodium chloride and citric acid also influence cell viability 
at the transport level affecting aminoglycoside action.(226)EDTA, however, synergises the 
activity of Gentamicin against S. aureus biofilms by sequestering the divalent and 
monovalent cations.(227)This effect was not seen in our study and is attributed to the low 
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EDTA concentrations compared to that of the total divalent and monovalent ions in the 
excipient solution.  
Our results also demonstrated that the addition of excipients to Erythromycin reduced its 
antibacterial effect on MRSA whilst leaving its effect on S. aureus unchanged. This finding 
was consistent with previous MIC studies that combined Erythromycin with plant-based 
products,(228)compounds targeting bacterial fatty acid biosynthesis(229)and other protein 
synthesis inhibitors.(230) 
Antagonistic effects while combining bactericidal and bacteriostatic compounds have been 
reported by previous studies.(231)Bacteriostatic compounds could inhibit cell activity 
rendering them less susceptible to the bactericidal compounds. It is possible that in our 
study, the excipient solution has a bacteriostatic property inhibiting the action of most of the 
antibiotics tested. 
Amoxicillin inhibits cell wall penicillin binding proteins (PBP) 1 and 3 which is required for 
the formation of the cross linkage between peptidoglycan polymer chains in bacterial cell 
wall. MRSA utilises PBP 2a to perform essential cell wall crosslinking functions. PBP2a in 
turn requires teichoic acid to locate and orient the enzyme onto bacterial cell.(232)It has been 
shown that the enzyme lipoteichoic acid synthase, responsible for the production of 
lipoteichoic acids in S. aureus is inhibited by EDTA.(233)This mechanism could explain the 
synergistic effect of Amoxicillin-excipient combination on S. aureus and MRSA seen in our 
study.  
No evidence of cytotoxicity was observed in this study for the excipient or Pulmicort 
concentrations tested. Many of the excipient used in commercial preparations have however 
been shown to be cilio-toxic to varying degrees. This depends on the compound, its 
concentration and also the combination with other agents. Previous studies have shown that 
budesonide based nasal sprays with EDTA at a concentration of 0.1% are  notcilio-toxic and 
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had no hazardous effect on ciliary beat frequency(234)We can also, therefore, assume that it 
would be unlikely that at the lower concentrations used in this study, the excipients would 
have an adverse effect on the cilia.  
A number of limitations within this study raise questions for further investigation. The 
direct effect of budesonide on bacteria could not be ascertained due to its insolubility in 
physiological media. The exact mechanism of antibiotic-excipient effect on MIC could not 
be explained as the excipients used in the study, and commercially, are usually 
combinations of different compounds. The possibility of multiple combination effects and 
the species of bacteria targeted should be considered before concluding whether the 
antibiotic-excipient combination is potentially synergistic or antagonistic on MIC.  
2.7 Conclusion 
In conclusion, topical application of low volume, high concentration of Pulmicort had an 
antibacterial effect on S. aureus and MRSA. This action was mediated through the excipient 
EDTA for S. aureus and EDTA and SCDT for MRSA used in its commercial topical 
preparation. This implicates that antibiotic-resistant strains like MRSA are more susceptible 
to excipient killing, possibly through multiple mechanisms.  
The combination of excipients with antibiotics like Amikacin, Gentamicin and 
Erythromycin appeared to have an antagonistic trend on MRSA killing. Nevertheless, the 
action of Amoxicillin, the most commonly used antibiotic in CRS against gram positive 
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Figure 16:  
 
Figure 16: Determination of presence of budesonide in centrifuged Pulmicort with liquid 
chromatography- mass spectrometry (LC-MS). 
Mass chromatograms of the molecular ion of budesonide from sample 1 or uncentrifuged 
pulmicort  and sample 2 or centrifuged pulmicort . Peaks at 5.30 minutes (sample 1) and 
5.34 minutes (sample 2).  




Figure 17: Cytotoxicity assay for Pulmicort and excipients 
2A: Cell viability using LDH assay after 24-hour treatment with commercial Pulmicort (5,100 
and 200 ug/ml) and Maximum concentration excipient solution (Exmax). Negative control is 
untreated cells and positive control is HNECs + 10% Triton X-100. Data represents the mean ± 
SD of three biological replicates.; LDH, lactate dehydrogenase; SD, standard deviation.2B: Cell 
viability using LDH assay after 48-hour treatment with Pulmicort (250,125 and 62.5 ug/ml) and 
concentration excipient solution (Ex1/2max-half concentration, Ex1/4max-one forth concentration, 
Ex1/8max-one eighth concentration). Negative control is untreated cells and positive control is 
cells +10% Triton X-100. Data represent the mean ± SD of three biological replicates.; LDH, 
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Background- Glucocorticoids are used in a wide range of inflammatory conditions 
including infections. Although the anti-inflammatory action of steroid is fairly well 
understood, the effect of steroids on the metabolic function of human pathogens is unclear. 
Here, we investigated the metabolic responses of planktonic and biofilm forms of S. aureus 
at different concentrations of hydrocortisone 21-hemisuccinate (HCHS) 
Methods- The effect of HCHS at different concentrations on planktonic and biofilm growth 
of S. aureus ATCC 25923 was evaluated using optical density, colony forming units (CFU), 
Giemsa staining, Resazurin assays and confocal laser scanning microscopy. Minimum 
biofilm inhibitory concentration was determined to assess the influence of HCHS on 
antibiotic killing of S. aureus biofilms. High performance liquid chromatography (HPLC) 
was used to determine the bacterial degradation of HCHS. The effect of HCHS in the 
presence and absence of bacteria on poly (I:C) induced IL-6 production by Primary Human 
Nasal Epithelial Cells was evaluated using Enzyme Linked Immunosorbent Assays.  
Results- There was a dose-dependent increase in CFU counts in HCHS treated planktonic S. 
aureus compared to untreated control. Bacterial biofilms were found to be less susceptible 
to antibiotics at low steroid concentrations and more susceptible at high concentrations. The 
degradation of HCHS to active cortisol was found to be accelerated by S. aureus and this 
was associated with a significant reduction in poly (I:C) induced IL-6 secretion.  
Conclusion- HCHS influenced S. aureus multiplication, aggregation, biofilm formation, 
antibiotic susceptibility and metabolic activity in a concentration dependent manner. S. 
aureus was capable of metabolising HCHS to its active compound cortisol thereby 





Glucocorticoids are a class of steroid hormones secreted by the adrenal cortex and are 
involved in the carbohydrate metabolism and regulation of various cellular functions like 
growth, homeostasis, metabolism, cognition and inflammation.(235)Due to their wide range 
of actions spanning from anti-inflammation to immune suppression, glucocorticoids are 
universally prescribed in a number of clinical conditions. These actions make 
glucocorticoids the mainstay of treatment for conditions like asthma, allergy, septic shock, 
rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.(236)The main 
clinical benefit of steroids is thought to be due to its anti-inflammatory action. They 
decrease vascular permeability and reduce the migration of lymphocytes to the site of 
infection, inhibit the transcription of inflammatory genes and promote the encoding of anti-
inflammatory proteins.(235, 236)Apart from these, corticosteroids have been shown to be 
beneficial and at times life-saving when used in certain infections. In infections, steroids 
have been shown to reduce the painful erythema in cellulitis, joint swelling in bacterial 
arthritis, reduce the inflamed lymph node in tuberculous lymphadenopathy and accelerate 
the resolution of effusion in tubercular pleurisy, pericarditis and chronic middle ear 
effusion.(237)Contrary to this, literature also shows that there is a dose dependent increase in 
serious and opportunistic infections especially with long term steroid use.(238) Although the 
beneficial effects of steroids could be due to their perceived anti-inflammatory effect, their 
influence on the bacteria present in these infections is unclear.   
Steroid compounds are ubiquitous in the environment as they are excreted by humans and 
animals. They thus provide an easily available substrate for microorganisms. It has been 
shown that certain soil and aquatic bacteria have highly specialised mechanisms by which 
they can utilise steroids as a carbon source for growth and multiplication.(200)This could be 
true with many pathogenic and non-pathogenic bacteria in humans as well, where 
administration of steroids has a positive or negative outcome on disease progression.  When 
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applied as a topical cream for atopic dermatitis, hydrocortisone reduced the bacterial 
colonisation of Staphylococcus aureus in eczema and atopic dermatitis.(239)Steroids have 
also been shown to increase the sensitivity of bacteria to erythromycin.(193)Some bacteria are 
also capable of metabolizing sex steroid hormones through the activity of distinct enzymes, 
thereby playing a role in the regulation of sex hormone levels.(240)Given the important role 
of sex steroid hormones in regulating the activity of immune cells, altering the balance 
between active and inactive steroids by steroid-degrading bacteria might therefore have both 
physiological and pathological implications.(240)The effect of sex steroid hormones on 
infectious diseases varies depending on the infective species where men are more 
susceptible to certain pathogens such as Mycobacterium tuberculosis, whilst women are 
more susceptible to infections with for example Pseudomonas aeruginosa or Salmonella 
typhimurium.(240, 241) 
The effect of glucocorticoids on the growth dynamics of S. aureus, a common human 
pathogen, is however not known. The objective of this study was to determine metabolic 
responses of planktonic S. aureus and their biofilm counterparts to hydrocortisone 21-
hemisuccinate (HCHS, a water-soluble steroid). We also determined the effect of steroid at 
different concentrations on the antibiotic susceptibility of biofilms. 
3.4 Methods: 
Bacterial strains and tissue:  
Staphylococcus aureus ATCC 25923 (S. aureus) was purchased from the American Type 
Culture Collection (Manassas, VA, U.S.). Human nasal epithelial cells (HNEC) were 
obtained from patients in accordance with guidelines approved by the Human Ethics 
Committee of the Queen Elizabeth Hospital and the University of Adelaide. All patients 
gave written informed consent (reference HREC/15/TQEH/132) and all samples obtained 




Drugs and reagents: 
Hydrocortisone 21- hemisuccinate sodium salt (HCHS), and sodium succinate were 
purchased from Sigma-Aldrich, Steinheim, Germany. Giemsa stain (Sigma-Aldrich, 
Steinheim, Germany), Resazurin dye/ Alamar blue (Life Technologies, Scoresby, Australia) 
and Methyl thiazolyl diphenyl-tetrazolium bromide (MTT; Sigma Aldrich, Missouri, USA) 
were obtained from their respective suppliers. Antibiotics used in minimal inhibitory 
concentration (MIC) and minimal biofilm inhibitory concentration (MBIC)assays were 
Amikacin, Amoxycillin, Ciprofloxacin, Doxycycline, Erythromycin, Gentamycin, and 
Vancomycin (all purchased from Sigma-Aldrich Steinheim, Germany). 
Effect of Hydrocortisone 21- hemisuccinate (HCHS) on planktonic growth of S. aureus:  
Bacteria were grown on a 2% nutrient broth agar plate (NBA) for 24 hours at 37°C. A single 
colony from this plate was transferred into 10 ml nutrient broth (NB) and incubated at 37°C 
for 14 to 16 hours with shaking at 180 rpm. The overnight culture was subsequently diluted 
into NB to obtain a starting OD 600 of 0.05. Prior to incubation, this volume was put in 
50ml falcon tubes containing the treatments and NB (making a final total volume of 10ml). 
HCHS was added to NB at concentrations of 5, 2.5and 0.625mg /ml.  
Growth determination and Colony forming unit (CFU) determination:  
To identify the bacterial growth pattern in the presence of HCHS, OD 600nm of the tubes 
was measured at 0-hours and then hourly for 7 hours before a final measure at 24 hours for 
each condition. A colony forming unit (CFU) count was also performed at 24 hours from 
both the supernatant and the sediments. Briefly, at the end of 24 hours, the tubes were left to 
stand for one hour at room temperature. A 20μl volume taken from the supernatant without 
disturbing the pellet at the bottom was serially diluted in phosphate buffered saline (PBS) 
and then spotted on NBA plates in triplicates. The supernatant from the tubes was then 
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carefully aspirated and the pellet resuspended in 500μl of PBS to be used for CFU counting 
as mentioned above. In addition, colony morphology was also determined. All experiments 
were carried out 3 times independently.  
Giemsa staining:  
Giemsa staining was performed on the sedimented pellet at the bottom of each falcon tube 
(from the above experiment). In brief the pellet was resuspended in 500μl of PBS before 
20μl was taken from each tube, spread on a glass slide and air dried. This was followed by 
fixing in methanol for 7 minutes and then staining with a 1:20 dilution of Giemsa stain in 
sterile Milli Q water for one hour. The slides were rinsed with distilled water, dried and 
examined under a light microscope (Eclipse 90i, Nikon, Japan) at 60 x magnification under 
oil immersion.  
Effect of HCHS on S. aureus biofilm formation:  
1. Alamar blue or Resazurin assay 
Resazurin assay was performed as per the protocol described previously.(224, 242)In brief, 
single colonies of bacteria suspended in 0.9% saline were adjusted to 1.0 ± 0.1 McFarland 
units (approximately 3 × 108 CFU/ml) and were diluted 1:15 in NB. The resazurin assay 
was done by inoculating a black 96-well microtiter plate (Costar, Corning Incorporated, 
Corning, U.S.) with the diluted bacterial suspension. HCHS was added to the wells at a 
starting concentration of 22.8mg/ml and was serially diluted till 0.71mg/ml.  Sodium 
succinate in concentrations comparable to that present in HCHS was measured and used as 
control treatment for each concentration of HCHS tested. The final volume in each well was 
150μl and this incubated at 37°C for 48 h on a rotating platform (3D Gyratory Mixer, Ratek 
Instruments, Boronia, Australia) at 70 rpm. Following the incubation with treatments, 
biofilms were rinsed twice with PBS and the viability (metabolic activity) assay performed. 
For this, 200μL of a freshly prepared 10% resazurin dilution in NB was added to each well 
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and was incubated, protected from light, at 37 °C on a rotating platform. The fluorescence 
was measured every 30 minutes on FLUO star OPTIMA plate reader at λexcitation = 530 
nm/λemission = 590 nm till maximum fluorescence of the untreated well was attained.  
Bacterial metabolic activity (viability) following the treatment was quantified after one-hour 
incubation with resazurin dye according to the equation: 
%MA = 100- (FC-FTx 100 %) 
FC 
The viability of bacteria on coincubation with HCHS was expressed as the percentage of 
metabolic activity (% MA), where FC was the fluorescence of the untreated control biofilms 
and FT was the fluorescence observed in the HCHS treated biofilms. Both FC and FT were 
corrected for background fluorescence (sterile medium).  
The reads were taken and plotted one hour after exposure to Alamar blue dye. The increased 
metabolic activity of the biofilms expressed as % viability (metabolic activity) was plotted 
above or below 100% activity of the untreated well. These studies were performed as three 
independent experiments with three wells per treatment 
1. Methythiazol tetrazolium (MTT) assay 
The methythiazol tetrazolium (MTT) assay was done to complement the findings of the 
metabolic activity of steroid-treated bacteria from the Alamar blue assay. In this, biofilms 
were prepared in the same manner as described for Alamar blue assay, but in a 96 well clear 
bottom cell culture microtiter plates (Cellstar, Greiner Bio-One GmbH, Frickenhausen, 
Germany). After washing the biofilms twice with PBS, the wells were filled with 150μl of 
PBS. To this, a 50μl of 0.3% MTT dye prepared in PBS was added and the plate incubated 
for 2 hours at 37°C. The dye was then suctioned out and 150μl of dimethyl sulfoxide 
(DMSO; Sigma Aldrich, Missouri, US) and 25μl of glycerine buffer (0.1 M, pH 10.2) was 
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added into the wells. This was then incubated for 15 minutes at room temperature with 
gentle agitation. The absorbance of the solution was measured at a wavelength of 540nm 
using a Microplate Reader Model. 
2. Quantification of viable bacteria:  
To quantify the biofilms in the HCHS treated wells, a CFU count was done. Briefly, 
biofilms were grown with different concentrations of HCHS on a clear 96 well flat bottom 
plate in the rotating chamber for 48 hours. After a washing step with PBS, the wells were 
filled with 200μl of PBS and sonicated for 15 minutes. A 20μl aliquot was then taken from 
each well and serially diluted and plated on NBA plates and incubated for 24 hours followed 
by CFU counting and colony morphology determination.  
3. Giemsa staining of biofilms 
Giemsa staining was done to visually demonstrate the morphology and density of the HCHS 
and sodium succinate treated biofilms. Briefly, a 20μl aliquot was taken from the wells of 
the above experiment (CFU count) after the sonication and spread on a glass slide, air-dried, 
methanol fixed and then stained with Giemsa to be examined under a light microscope as 
described previously. 
5. Confocal scanning laser microscopy for live/dead staining of S. aureus biofilms 
S. aureus ATCC 25923 were grown on an 8-chamber Falcon Culture Slides (In Vitro 
Technologies, Noble Park, Australia) in NB in the presence and absence of HCHS for 
48hours at 37°C and with shaking. Following a wash with 0.9% saline, the wells were 
treated with 5% glutaraldehyde fixative (Sigma Aldrich, Steinheim, Germany) for 45 
minutes at 210C. After one more wash to remove the excess fixative, the slides were 
immersed in MilliQ water (Millipore, Billerica, MA, USA) containing 1.5 μl/ml each of 
both LIVE/DEAD BacLight stains SYTO9 and propidium iodide (Invitrogen Molecular 
Probes, Mulgrave, Victoria, Australia). The slide was incubated in the dark at 21°C for 15 
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minutes and then washed with 0.9% saline to remove excess stain, mounting oil (Invitrogen 
Molecular Probes, Mulgrave, Victoria, Australia) applied and then covered with coverslips. 
Samples were visualized by using an LSM700 confocal scanning laser microscope (Zeiss 
Microscopy, Jena, Germany). The excitation/emission wavelengths of the BacLight staining 
were 485/530 nm and 485/630 nm, respectively.  
Effect of HCHS on S. aureus planktonic minimal inhibitory concentration (MIC) to 
antibiotics: 
The minimal inhibitory concentration (MIC)of antibiotics was assessed by measuring the 
optical density (OD) at 595nm for different concentrations of the tested antibiotics as 
described in previous published protocols.(213)MIC was also measured in the presence of 
different concentrations of HCHS. 
Effect of HCHS on S. aureus biofilm minimal biofilm inhibitory concentration (MBIC) to 
antibiotics:  
S. aureus inoculate was prepared in 0.9% saline at a density that was adjusted to a 0.5 
McFarland turbidity standard (108 colony-forming units [CFU]/ml) and diluted 1:100 in NB. 
From this 100μl was put into wells of a 96-well black microplate followed by incubation on 
a rotating platform for 48 hours at 37°C for biofilm formation. Following incubation, the 
supernatant was aspirated and wells were washed twice with PBS to remove planktonic 
bacteria. Treatments consisting of 60μl of Miller Hinton broth (MHB) and 60 μl of various 
antibiotics at different concentrations prepared in MHB were subsequently added to the 
wells. The wells were then incubated for 20 hours and washed once to remove the excess 
treatment. To these wells, Alamar blue staining was applied at 10% in MHB and 
fluorescence measured as describe above.  
To determine the effect of HCHS on the biofilm MBIC, the above experiment was done 
with HCHS (22.8mg/ml and 1.4mg/ml) added to the broth at the time of incubation for 
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biofilm formation and the rest of the experiment was the same as described above. The 
MBIC was then determined by doing an Alamar blue assay and the result was represented as 
a percentage biofilm killing and a cut off value of 90% was taken, as was described 
previously.(243, 244) 
 
Harvesting and Culturing Primary Human Nasal Epithelial Cells 
The local institutional Human Research Ethics Committee approved the study 
(HREC/15/TQEH/132) and primary human nasal epithelial cells (HNEC) were harvested 
from the inferior turbinate of consented non-CRS control patients and all samples were 
anonymised and coded before use according to a previously described protocol.(245)Briefly, 
the nasal brushings were suspended in PneumaCult-EX Plus basal medium (05008, Stem 
cell Technologies, Cambridge, UK). The nasal brushes were flicked against each other 
with force to extract the cells, which were then depleted of monocytes using anti-CD68 
(2021-04, Dako, Glostrup, Denmark) coated culture dishes. This was followed by the 
expansion of HNECs in routine cell culture conditions of 37 °C humidified air with 5% 
CO2 in collagen coated flasks (156367, Thermo Scientific, Walthman, MA, USA). 
Lactate dehydrogenase (LDH) assay 
Cell cytotoxicity was determined by measuring the amount of lactate dehydrogenase (LDH) 
in the medium after 24 hours treatments using the Cytotox Homogeneous Membrane 
Integrity Assay (Promega, Australia). Briefly, HNECs were grown in in 96-well flat-bottom 
plates for 24 hours (37°C, 5% CO2). Then HNECs were treated with different 
concentrations of HCHS (22.8mg/ml and 1.4mg/ml) in the presence or absence of bacteria 
(S. aureus ATCC 25923). A 50 μl sample of the supernatant was added to 50 μl of LDH 
reagent and incubated for 30 minutes at 37°C. The absorbance was recorded at 490nm on a 




Determination of bacterial degradation of HCHS using High-performanceliquid 
chromatography (HPLC)  
The amount of residual HCHS and cortisol produced in the presence or absence of S. aureus 
ATCC 25923 was determined using High-performanceliquid chromatography (HPLC).  
Briefly, HCHS was incubated in the presence or absence of S. aureus ATCC 25932 at 37°C 
and at room temperature for 48 hours. This was then centrifuged briefly at 3000 rpm for 3 
minutes to separate the bacterial pellet. The supernatants obtained were analysed on a HPLC 
system (HPLC, Agilent 1200 series, USA) with diode array UV detector on a Luna C18(2) 
column (150x3mm, 5u, Phenomenex, Torrance, CA, USA) based on a modified method 
described by Zhang et al.(246)Gradient conditions were 10%B (0-5min), 30%B (5-15min), 
40%B (15-20min) and 100%B (20-35min) with mobile phases A and B consisting of 15% 
and 70% acetonitrile respectively in 0.1% formic acid/water. Mobile phase flow rate was 
1ml/min. Peak data was collected at 245nm with cortisol eluting at 11.9min and  HCHS at 
18.8min. 
Enzyme-Linked Immunosorbent Assay (ELISA) 
The supernatant was collected from HNECs that were treated for 24 hours with different 
concentrations of HCHS (22.8mg/ml and 1.4mg/ml) in the presence or absence of S. aureus 
ATCC 25923. The Interleukin-6 (IL-6) protein levels were estimated with an ELISA kit 
using rat anti-human IL-6 antibodies (BD Biosciences, New Jersey, USA), according to the 
manufacturer’s instructions. All measurements were performed in duplicate using a 
FLUOstar OPTIMA plate reader (BMG Labtech, Ortenberg, Germany). 
Statistical analysis 
All experiments were conducted at least in triplicate and are presented as mean ± standard 
deviation (SD) unless stated otherwise. The results were analysed using one-way analysis of 
variance (ANOVA) with Sidak test. MIC analysis was performed using two-way ANOVA 
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(GraphPad Prism version 8.00; GraphPad Software, La Jolla, CA). Planktonic growth assays 
were done using Kruskal-Wallis analysis with Dunn’s correction. Statistical significance 
was assessed at the 95% confidence level. 
 
3.5 Results 
Planktonic bacterial growth with HCHS 
To determine the effect of steroids on planktonic growth of bacteria, S. aureus ATCC 25923 
was grown in NB containing differing concentrations of Hydrocortisone21 hemisuccinate 
(HCHS)or control with NB in the absence of HCHS for 24 hours. HCHS was found to be 
completely soluble in NB and did not precipitate when incubated at similar conditions. 
There was a non-significant increase in total CFU (sediments CFU + supernatant CFU) for 
the highest concentration of HCHS treated S. aureus compared to control (Figure 18Ai). 
After incubation of S. aureus with HCHS for 24 hours however, an increasing sedimentation 
of the bacteria was observed with supernatants becoming clearer. A CFU count was done to 
further evaluate the bacterial numbers in the sediments and supernatants. This confirmed 
these observations with increased CFU counts of bacteria in the sediments (significant at 
5mg/ml, p=0.01) and decreased CFU counts in the supernatants (significant at 5mg/ml, 
p=0.02), compared to the control, as the concentration of steroids increased (Figure 18Bi 
&ii). In line with this, the CFU counts of HCHS treated S. aureus samples were higher in 
sediments compared to supernatants at the highest concentration(p=0.001) whereas in 
control samples, CFU counts were non-significantly higher in supernatants than in 
sediments (Figure 18Aii). Giemsa staining of the sediments showed aggregation of bacteria 




Figure 18: Effect of Hydrocortisone 21 hemisuccinate (HCHS) on the planktonic growth of 
S. aureus ATCC 25923. 
24-hour planktonic growth of S. aureus ATCC 25923 treated with different concentrations 
of (HCHS) followed by CFU counts of supernatant + sediments(1A) sediments vs 
supernatants (1Aii), sediments (1Bi) or supernatants (1Bii).  Giemsa staining of control 
(1Ci), 2.5mg/ml HCHS treated S. aureus (1Cii) or 5mg/ml HCHS treated S. aureus (1Ciii). 
CFU- colony forming units, HCHS-Hydrocortisone 21 hemisuccinate, Control-maximum 
growth (untreated), Sup-supernatant, Kruskal- Wallis analysis with Dunn’s correction *p < 
0.05, **p < 0.01. 
 
Effect of HCHS on the metabolic activity of S. aureus 25923 biofilms 
A resazurin assay (Alamar blue) was performed to assess the effect of HCHS on S. aureus 
biofilm metabolic activity. Compared to sodium succinate control, the different 
concentrations of HCHS had variable effects on the metabolic activity of biofilms.   
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We found a significant increase in metabolic activity of S. aureus biofilms in a 
concentration dependent manner. At the highest concentration tested, (22.8mg/ml), there 
was a 2.4-fold increase in metabolic activity (p<0.0001). At the intermediate concentrations, 
the metabolic activity showed an increase of 1.6 and 2-fold for the 5.7 mg/ml (p<0.05) and 
11.4 mg/ml (p<0.0001) respectively (Fig.19). In the presence of HCHS all the bacterial 
strains showed aggregation at the higher concentrations tested, which was seen as 
sedimentation formation at the bottom of the wells and was demonstrated using Giemsa 
staining (Fig. 20C).  
We then did MTT assays and CFU counts to confirm the findings of increased metabolic 
activity and determine the number of viable bacterial cells in the presence of increasing 
HCHS concentrations. MTT assays mirrored Alamar Blue assays showing a dose-dependent 
increase in the metabolic activity of biofilms in the presence of HCHS (Fig20A). A 
significant increase in CFU (to 1.6 x106) was seen in bacteria treated with 1.4mg/ml HCHS 
compared to control (2.2X105, p=0.0002) (Fig 20B). However, CFU counts gradually 
decreased with increasing HCHS concentrations and at the highest concentration, CFUs 
were similar to the untreated control. Giemsa staining showed increased cell numbers when 
bacteria were treated with HCHS at a concentration of 1.4mg/ml with increasedbacterial 




Figure 19:Metabolic activity of S. aureus ATCC 25923 on exposure to increasing 
concentrations of HCHS compared to succinate as determined by Resazurin assay 
All values are relative to untreated controls, normalised to 100%. Data represent the mean ± 
SD of three biological replicates. One-way ANOVA, *p < 0.05; ****p < 0.0001; SD, 
standard deviation; Succ, sodium succinate salt; HCHS- hydrocortisone 21 hemisuccinate; 
MG, maximum growth. 
 
Figure 20:MTT assay (A), CFU count (B) and Giemsa staining (C) of S. aureus ATCC 
25923 biofilms 
Biofilms treated with different concentrations of HCHS. Control in experiment A and B is 
sodium succinate. (C) i- Giemsa staining of i-untreated biofilms, ii- biofilms with sodium 
succinate 7.6mg/ml, iii- biofilms with 1.4mg/ml HCHS, iv- biofilm with 22.8mg/ml HCHS. 
Data represent the mean ± SD of three biological replicates. One-way ANOVA, **p < 0.01; 
***p < 0.001; ****p < 0.0001; SD, standard deviation, CFU- colony forming units, HCHS- 




Confocal scanning laser microscopy 
We then did Live/Dead staining and confocal scanning laser microscopy to analyse the 
effect of HCHS on S. aureus ATCC 25923 biofilms. At the higher concentrations (11.4 
mg/ml and 22.8 mg/ml of HCHS) tested, there was evidence of clumping and change in 
morphology of the biofilms. The arithmetic mean intensity showed an increase in both the 
live and dead staining as the concentration of HCHS increased to 5.7 mg/ml and thereafter 
showed a decrease as the concentrations increased (Fig. 21, Table. 2) 
 
Figure 21:Confocal scanning laser microscopy of S. aureus ATCC 25923 biofilms after 
LIVE/DEAD BacLight staining 
Untreated control and Sodium succinate control compared to biofilms grown at different 
concentrations of HCHS (1.4mg/ml, 5.7mg/ml, 11.4mg/ml, and 22.8mg/ml as marked on 
the picture). The green cells represent the live bacteria, red cells represent dead bacteria. 
HCHS, hydrocortisone 21 hemisuccinate, Succ.7.6mg/ml – Sodium succinate 7.6mg/ml, 
Control- maximum bacterial growth with no treatment 
Table 2: Arithmetic mean intensity of live (CH-1) and dead (CH-2) staining. HCHS, 
hydrocortisone 21 hemisuccinate 






Control (no HCHS) 94.9 44.08 
1.4 121.66 65.86 
5.7 242.44 149.7 
22.8 86.2 49.75 
 
Effect of HCHS on S. aureus ATCC 25923 Minimal Inhibitory Concentration (MIC) of 
antibiotics: 
None of the tested concentrations of HCHS shifted the MIC for any of the seven tested 
antibiotics. However, compared to control, increased planktonic growth rates of the bacteria 
were observed with subinhibitory concentrations of ciprofloxacin, doxycycline, 
erythromycin and gentamicin in the presence of the two concentrations of HCHS tested (p < 





Figure 22:MIC of planktonic S. aureus 25923 compared to its MIC in the presence of 
different concentrations of HCHS. 
Data represent the mean ± SD of three biological replicates. two-way ANOVA, ****p < 
0.0001; SD, standard deviation, OD595- optical density, HCHS- hydrocortisone 21 
hemisuccinate; NO AB- no antibiotic. 
Effect of HCHS on S. aureus ATCC 25923 Minimal biofilm inhibitory concentration 
(MBIC) of antibiotics: 
We then wanted to assess whether differences in metabolic activity and phenotype affected 
the susceptibility of S. aureus biofilms to antibiotics. Following treatment with different 
antibiotics, the MBIC value was represented as the concentration which gave more than 
90% biofilm killing. In the absence of HCHS, ATCC 25923 biofilms were susceptible to all 
the 7 antibiotics tested at different concentrations. In the presence of 1.4mg/ml HCHS 
however, bacteria within the biofilm were resistant at the highest concentration tested for 
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5/7 antibiotics. In contrast, when incubated with HCHS at 22.8mg/ml, the MBIC 
demonstrated a consistent decrease for all the antibiotics tested and none were found to be 
resistant to any of the antibiotics tested (Table 3). 
Table 3: MBIC of S. aureus 25923 biofilms compared to MBIC in the presence of different 
concentrations of HCHS. 
Antibiotic  MBIC (μg/ml) 
MBIC (μg/ml) with 
1.4mg/ml HCHS 
MBIC (μg/ml) with 
22.8 mg/ml HCHS 
Percentage killing >90% >90%  >90% 
Ami 8 >32 2 
Amox 2 16 1 
Cip 1 >32 0.5 
Dox 0.5 >32 0.25 
Ery 2 >32 0.5 
Gen 1 >32 0.5 
Van 8 8 2 
 
Effect of S. aureus ATCC 25923on the degradation of HCHS 
High-performanceliquid chromatography (HPLC) analysis was done on the media in the 
presence of HCHS with and without S. aureus ATCC 25923 to determine if S. aureuswas 
capable of metabolizing HCHS. HCHS in media degraded into cortisol (active compound) 
when incubated at 370C for 48 hours (26% and 7% cortisol for 1.4 mg/ml and 22.8 mg/ml 
HCHS respectively). In the presence of bacteria, there was a manifest increase in the 
relative cortisol production (65% and 23% cortisol for 1.4 mg/ml and 22.8 mg/ml HCHS 
respectively) (Table 4) 




The concentration of remaining HCHS and the active metabolite, cortisol was averaged for 
two samples. 
Sample  
Concentration (mg/ml), at 





1.4 0.67  0.24 
1.4 + bacteria  0.3  0.57  
22.8 15.53  1.27  
22.8 + bacteria  10.93   3.4  
 
Enhancement of anti-inflammatory action of HCHS in the presence of S. aureus ATCC 
25923: 
Given the increased production of cortisol in the presence of S. aureus, we evaluated 
whether the anti-inflammatory effect of HCHS was enhanced in the presence of S. aureus. 
The exposure of HNECs to poly (I:C) elicited a strong induction of IL-6 production, as 
expected.(212)The addition of both low and high concentrations of HCHS (1.4mg/ml and 
22.8mg/ml respectively) decreased IL-6 production which was significant at the high 
concentration (p=0.0001). Compared to HCHS, adding the supernatants of S. aureus treated 
with identical HCHS concentrations, IL-6 production was further reduced which was 




Figure 23: IL-6 secretion in the absence or presence of poly (I:C) LMW and different 
concentrations of HCHS or supernatants of S. aureus treated with identical HCHS 
concentrations 
IL-6 secretion by Primary Human Nasal Epithelial Cells (HNECs) in the absence (media) or 
presence of poly (I:C) LMW and different concentrations of HCHS or supernatants of S. 
aureus treated with identical HCHS concentrations. Data represents the mean ± SD of three 
biological replicates; IL-6, Interleukin 6; HNEC, Human nasal epithelial cells; HC &HCHS, 
hydrocortisone hemisuccinate; Media, 10μl nutrient broth + 90μl of HNEC media-
PneumaCult-EX Plus basal medium; SD, standard deviation 
 
 
Lactate Dehydrogenase (LDH) assay: 
Cell viability was assessed by measuring LDH release from HNEC- cultures. A 24-hour 
exposure of different concentrations of HCHS or supernatants of S. aureus treated with 
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identical HCHS concentrations showed no significant increase in LDH release in HNECs (p 
> 0.05) (Figure24). 
 
Figure 24: Cell viability using LDH assay 
Cell viability using LDH assay after 24-hour treatment with bacterial supernatants in the 
presence (1.4mg/ml HC +bacteria, 22.8mg/ml HC+ bacteria) and absence (1.4mg/ml HC, 
22.8mg/ml HC) of HCHS and bacterial supernatants.  Negative controls included untreated 
cells and positive controls; cells exposed to Triton X-100. Data represents the mean ± SD of 
three biological replicates.; LDH, lactate dehydrogenase; HC &HCHS, hydrocortisone 21 
hemisuccinate; SD, standard deviation 
 
3.6 Discussion: 
The use of corticosteroid as an oral or topical agent in chronic and acute infections remains 
controversial. Steroids have been shown to be beneficial and at times life-saving in certain 
infections while their use have also been associated with an increase in infection severity 
leading to life threatening complications.  
In this in vitro study, we demonstrate that HCHS increases the metabolic activity of S. 
aureus ATCC25923 in a dose-dependent way accompanied with increased aggregation of 
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planktonic and biofilm bacteria. An increased CFU count was observed when treating S. 
aureus ATCC25923 biofilms with 1.4 mg/ml HCHS, however, a gradual decrease in CFU 
counts was seen with increasing HCHS concentrations. The changes in metabolic activity 
were associated with changes in antibiofilm activity of antibiotics with a reduced 
susceptibility at 1.4 mg/ml and an increased susceptibility at the highest concentration of 
22.8 mg/ml HCHS. S. aureus ATCC 25923was capable of metabolizing HCHS, thereby 
increasing the cortisol production and boosting the anti-inflammatory properties of HCHS. 
An increasing metabolic activity with increasing steroid concentration which was then 
followed by a decrease in metabolic activity at the highest steroid concentration was also 
observed in the study done by Raab,(247)where he tested the action of methylprednisolone 
sodium-hemisuccinate and methylene prednisolone diethylamino acetate on S. aureus. This 
response differed depending on the organism and the glucocorticoid tested. Pseudomonas 
aeruginosa under similar conditions showed an increase in metabolic activity with 
increasing steroid concentration, without a drop at the highest concentration tested, which 
they attributed to the esters in the steroid molecule. Steroid compounds like progesterone 
have been shown to both inhibit and promote the growth of Neisseria gonorrhoeae 
depending on the dosage of treatment. The promotion of bacterial growth is thought to be 
due to the subversion of the activity of the host serine-threonine kinase Akt by the 
gonococcal phospholipase D.(248)In another study, HCHS injected intra-allantonically to 
chick embryo infected with intra-allantonic Staphylococcus epidermidis increased the 
mortality at doses of HCHS 10μg and above. This was,  however, attributed to the 
teratogenic effect as HCHS did not affect the growth or virulence of the bacteria. 
Interestingly, at the lower HCHS dose of 1μg, the increased mortality was associated with 
an increase in the tissue concentration of bacterial strains.(249) 
We observed that the planktonic S. aureus 25923 and its biofilms showed an increase in 
aggregation as the concentration of HCHS increased. A similar finding was reported where 
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pathogenic and non-pathogenic Pseudomonas species were incubated in a tobacco 
suspension.(250)Microscopy showed a decrease in the free-floating bacteria with an increase 
in the bacterial aggregates and this phenomenon required the presence of both bacteria and 
plant cells. Treatment with streptomycin inhibited this aggregation, suggesting that bacterial 
protein synthesis is required for this response. Extracellular polysaccharides and cell wall 
proteins are factors which are necessary for bacterial aggregation which is considered to be 
an important step in biofilm formation.(251)Bacterial aggregation has also been shown to be 
influenced by the number of bacterial cells in the media. Although this phenomenon is 
linked to bacterial adaptation and virulence development, these aggregates also develop in 
the presence of compounds like nickel where this is considered to be mechanism to reduce 
the surface area and circumvent nickel toxicity.(252)The size of the aggregates increased and 
their number decreased with higher concentration of nickel and it was vice versa with lower 
test concentrations.  In this current study we could not establish the viability of all the cells 
in the aggregates nor the molecular mechanisms involved in the formation of the aggregates 
in the presence of HCHS. Namely, we observed an increase in the CFU of biofilms till a 
concentration of 1.4mg/ml HCHS and there after a decrease with the higher concentrations 
of HCHS even though the metabolic activity was increased at higher concentrations. It 
could be that the bacterial aggregates were not able to be dispersed adequately with 
sonication and a proper dilution and hence an accurate CFU was not attained.  
The anti-inflammatory action of steroids and its benefits in a vast number of infections have 
been well described. McGee et.al(237)reviewed 190 trials using steroids along with 
antibiotics in conditions where infections play a major role and showed that steroid therapy 
improved survival, provided long term benefit and also relieved symptoms in a large 
number of infections. The benefit was seen more so in the most severe infections with 
greater morbidity. In some viral infections however, steroid therapy was either ineffective or 
at times harmful. Hydrocortisone was the steroid used in 4 % of these trials with the dose 
135 
 
varying from 10mg prednisolone equivalent to more than 1300mg administered as a single 
dose to more than 400 days in certain infections.  In clinical settings, hydrocortisone can be 
used intravenously for infections like severe community- acquired pneumonia as bolus 
doses up to 200mg followed by infusions at 10mg/hr for several days.(253)Hydrocortisone is 
also used as a topical agent in haemorrhoids (5mg/g to 25mg), inflammatory bowel diseases, 
inflammatory conditions in dermatology, ophthalmology and otology at concentrations 
ranging from 1% 2%, 10% as drops, creams, ointments or foams.(254-257)These 
concentrations are comparable to the ones used in our study.  Gong et.al,(239)in their study 
observed a decrease in the skin colonization of S. aureus in eczema and atopic dermatitis 
with both corticosteroid-antibiotic ointment and corticosteroid ointment alone. The results 
of our study showed that the increased biofilm metabolic activity at highest tested HCHS 
concentrations (clinically relevant doses) also increased the S. aureus biofilm susceptibility 
to antibiotics thus further supporting its use in specific infections. A similar action with 
cortisone and hydrocortisone acetate was seen in a Mycobacteriumlepraemurium infected 
rat study, where the steroid treatment decreased the bacterial infection in the spleen of these 
rats.(258)In contrast, systemic administration of glucocorticoids has been shown to increase 
the relative risk of developing certain bacterial, fungal and viral infections in a population-
based study.(259)Bacterial aggregation and biofilm formation have been associated with an 
increased tolerance to antibiotics. In the current study, we found this to be true at the low 
steroid concentration. However, at higher concentration, the biofilms were more susceptible 
to antibiotics and this we propose could be due to molecular mechanisms linked to the 
increased metabolic state in biofilms in the presence of HCHS, providing optimal conditions 
for the antibiotics to act.   
We also observed that in the presence of S. aureus 25923, there was an increase in the 
dissociation of the compound HCHS into the active metabolite cortisol, as well as an 
increased anti-inflammatory action as evidenced by a decrease in the inflammatory marker 
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IL-6. Analysis of the degradation of hydrocortisone 17-butyrate in the presence and absence 
of microorganisms by Rabouan-Guyon et al(202)showed an increased steroid degradation 
with bacilli compared to cocci like S. aureus and controls. Bacteria have been shown to 
utilise steroids as growth substrate and multiply. Enzymes involved in 21-dehydroxylation 
or 16𝛼-dehydroxylation of steroids such as corticosteroids and sex hormones have been 
identified in intestinal microbiota.(260)A metabolomic study demonstrated a reduction in 
steroid metabolites from the gut of streptomycin treated mice, suggesting that the reduction 
in faecal bacteria may be responsible for this.(261)Apart from this, literature shows that many 
soil and aquatic bacteria have specialised mechanisms by which they metabolise steroids. A 
study done to delineate the distribution of aerobic steroid catabolism pathways using both 
hidden Markov models and reciprocal BLAST identified 265 putative steroid degraders 
within Actinobacteria and Proteobacteria.(200)The strain S. aureus 25923 in our study was 
capable of degrading/utilising HCHS and producing cortisol, however the complex 
mechanisms involved in this process was beyond the scope of this study.  
 
3.7 Conclusion: 
This study identified for the first time the effect of HCHS on increasing the metabolic 
activity and aggregation capacity of S. aureus ATCC 25923 biofilms. HCHS affected the 
susceptibility of the biofilms, but not planktonic cells, to antibiotics. This is the first report 
on the potential of S. aureus to metabolise HCHS thereby potentiating the anti-inflammatory 
action of HCHS. Whilst further studies are required, testing the relevance of our findings 
using clinical isolates in the in vivo setting, our findings suggest that the clinical benefit of 
using steroids as adjuvants in infections might depend on the concentration of the steroid 
used and influenced by the host microbiome composition.  
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4 Chapter 4: The clinical and microbiome outcomes of medical 
treatments in chronic rhinosinusitis: A randomised double 
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The mainstay of treatment in chronic rhinosinusitis (CRS), a complex disorder of infection 
and inflammation, is topical steroid, oral steroid, antibiotic or a combination of these. The 
clinical outcomes vary among patients and are possibly dependent on these therapies as well 
as the initial phenotypic presentation. Among the different parameters implicated in the 
disease progression is sinonasal microbial dysbiosis. This double blinded, randomised 
placebo-controlled trial investigates the effect of the three different medical therapies in 
CRS on the clinical outcomes and explores the associated microbiome shifts.  
Methods 
Fifty eligible CRS patients were randomised into 3 active treatment arms consisting of oral 
prednisolone, topical Pulmicort or antibiotic, each arm with appropriate placebo. Patient 
symptom scoring, endoscopic grading, microbiome swabs and bacterial swabs were 
performed on enrolment (time_0), at the completion of treatment (time_3) and at week 6 (3 
weeks after the completion of treatment). 43 patients completed the trial and were included 
in the final analysis. Microbial communities were characterized using 16S ribosomal RNA 
(rRNA) gene-targeted amplicon sequencing. Analysis of bacterial abundance, diversity and 
stability were done using Quantitative Insights In to Microbial Ecology (QIIME 2) platform.  
Results 
There was significant improvement of clinical outcomes in all subjective and objective 
patient assessment scores in both the prednisolone and topical pulmicort arms at treatment 
completion, but not sustained at 6 weeks [sinonasal outcome test 22 (SNOT 22) p=0.012, 
p=0.008; Lund Kennedy score (LKS) p=0.013, p=0.025 respectively]. Similar improvement 
was seen also on the sub group analysis with a more pronounced difference in CRS with 
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nasal polyp patients (SNOT 22 p=0.06, prednisolone; p=0.013, pulmicort). Antibiotics, on 
the contrary, worsened symptoms. An increase in Corynebacterium was seen in Pulmicort 
and antibiotic and decrease with Prednisolone. There was an increase in Faiths phylogenetic 
diversity at 3-weeks (not at 6 weeks) in the Pulmicort arm. Microbial stability assessed 
using Rank variability and Difference variability was suggestive of an unstable microbiome 
in the antibiotic arm.  
Conclusion 
This study shows comparable clinical improvement with oral prednisolone and pulmicort 
topical rinses. Topical nasal rinses are, however, recommended as it can be given longer and 
is devoid of systemic side effects. Although microbiome changes were observed with the 
different treatments, we could not ascertain its consistency and clinical significance. In the 
light of our findings, and based on the potential local and systemic effects on microbiome 
and the emergence of multidrug resistant bacteria that is associated with antibiotic use, we 
do not recommend it in the routine treatment of CRS patients especially those presenting 
with polyposis.  
 
Short title:  Impacts of medical therapies in sinusitis.  






Chronic rhinosinusitis (CRS) is a disease of multifactorial aetiology where infection and 
inflammation often co-exist in the sinonasal cavity. The triggers of sinonasal mucosal 
inflammation in the context of CRS vary and may include epithelial barrier dysfunction, 
immune dysfunction, sinus outflow obstruction caused by anatomical variations and allergy 
and colonisation with pathogenic bacteria.(18, 19)The resultant clinical manifestation of CRS 
is variable however, with polyps evident in some patients, while purulence and oedema 
predominate in others. 
There is a growing interest and mounting evidence in literature to the contribution of the 
resident microbiome to health and disease state. Studies performed on the microbiome of 
the upper airway are relatively small in number, underpowered and differ in terms of 
sampling technique and site as well as bioinformatic analysis. This has led to a discrepancy 
in the results obtained with no real consensus achieved on the specific microbiome in health 
or disease. However, a relatively consistent observation is that of relative reduction in the 
markers of bacterial biodiversity, richness and evenness in CRS patients compared to 
controls. (74, 107, 110, 113, 262)The present-day consensus of expert opinion is rather than specific 
genera or species being directly associated with the development of CRS, CRS patients 
more often exhibit overall shift away from an apparent “healthy microbiota” into a state of 
dysbiosis. It is unclear as to whether the dysbiotic state changes over time, and in particular 
how factors including current medical treatments influence this change. (118)Oral antibiotics 
and corticosteroids, represent the pillars of the medical management of CRS. Rhinosinusitis 
is the most common disease for which antibiotics are prescribed.(263)The literature on the 
usefulness of antibiotics in CRS, however, is unclear with some reporting benefits on short 
term antibiotics and others reporting no added benefits over other modalities of medical 
management.(264, 265)Oral antibiotics have been shown to influence microbiome composition 
of the gastrointestinal tract affecting the host immune system and at times with deleterious 
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effect(266)Antibiotic use has also been associated with depletion of specific bacteria in the 
gastrointestinal tract and this in turn has been associated with the development of diseases 
like type-1 diabetes mellitus, bronchial asthma and obesity in animal and human 
studies(267)Whilst the effects of antibiotic use on the gut microbiome have been studied 
extensively, only a few small studies have evaluated the microbiome changes in the 
paranasal sinuses in response to antibiotic therapy. Liu et al(140)demonstrated a decrease in 
the bacterial diversity following antibiotic therapy in recalcitrant CRS patients while 
Merkley et al(268)contrastingly observed an increased diversity and decreased abundance 
following antibiotic therapy. It is important to note that these studies were conducted in 
post-operative patients or patients undergoing sinus surgery. Given that sinus procedures 
have been shown to influence microbial ecology, this confounding factor may need to be 
considered when interpreting the above studies’ findings.(92) 
Oral and topical corticosteroids exert their clinical benefit in CRS patients through anti-
inflammatory action, which is mediated through glucocorticoid receptors present within the 
host cells(235, 236)In addition to  their direct anti-inflammatory action, corticosteroids can also 
potentially influence inflammation by acting on the bacterial growth either directly(187), or 
through the excipients used in their commercial preparation(269)Little research has been 
performed however into the influence of corticosteroids on the sinonasal microbiome and 
the resultant clinical outcomes. 
Literature provides ample evidence for symptom improvement with topical steroid use and 
short term benefits with oral steroid therapy in CRS patients, particularly those with nasal 
polyps(270, 271)Antibiotics on the other hand, despite being associated with development of 
allergic diseases and chronic inflammation in the paranasal sinuses on long term use(90, 
272)continue to be routinely used in clinical practise of CRS management. 
The primary aim of this study is to evaluate the independent influence of commonly 
prescribed medications, namely oral steroids, topical steroids and oral antibiotics on the 
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sinonasal microbiome in un-operated patients with CRS. We secondarily examined the 
effect of each of these medical treatments on symptom and endoscopic scores. To the best 
of our knowledge this is the first randomised double-blinded placebo-controlled trial 
evaluating the microbiome changes in CRS patients receiving maximal medical therapy and 






An informed written consent was obtained from all the study participants enrolled, in 
accordance with the declaration of Helsinki. This study was approved by the Central 
Adelaide Local Health Network Ethics Committee (HREC/15/TQEH/177).  
Study design 
This was a randomised double-blinded placebo-controlled trial, recruiting patients with 
chronic rhinosinusitis (CRS) who attended the ENT out-patient department between 
December 2016 and December 2018. Randomisation was performed centrally by The 
Queen Elizabeth Hospital (TQEH) Pharmacy Clinical Trial department.  The pharmacist 
used a computer-generated table of random permutation of 20 numbers to randomise into 
permuted blocks of 9 to the 3 different treatment interventions.  The permuted block size or 
the active agent prescribed was not known to the investigator. All clinical trial medication 
(active and placebo) for the study was prepacked prior to study commencement by TQEH 
Pharmacy Clinical Trial pharmacists in a double-blind fashion.  This ensured allocation 
concealment of randomisation.  Allocated pack numbers corresponding to the randomisation 
list were then available to dispense to trial participants with the allocation numbers provided 
to participants in the order of enrolment into the study. All parties remained blinded until 
final data analysis and statistical testing. 
Study participants 
Patients who were diagnosed with CRS as per the criteria outlined in the European Position 
Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2012(4)were randomised into three 
different medical treatment groups. All patients self-administered their oral and irrigation 
medication daily for 3 weeks. All the patients were given 3 ‘treatments’ with one being the 
active medication they were allocated. 
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The first group received oral prednisolone (Panafcortelone, Aspen Pharmacare, St Leonards, 
NSW), oral placebo for antibiotic and 2 times daily 240ml Neilmed saline sinus irrigations 
(Santa Rosa, CA) with placebo representing budesonide respules added to the rinse. The 
second group received oral placebo (representing oral prednisolone in tapering dose), oral 
placebo (representing antibiotic) and 2 times daily Budesonide, 0.5mg/2mL (Pulmicort 
respules, AstraZeneca AB, Sodertalje, Sweden) diluted in 240ml Neilmed saline sinus 
irrigations. The third group received oral placebo (representing oral prednisolone in tapering 
dose), oral doxycycline (Doxylin, Alphapharm, Millers Point, NSW) and 2 times daily 
240ml Neilmed saline sinus irrigations with placebo representing budesonide respules added 
to the rinse. Contents of each treatment arm is represented in Table 5. The placebo oral 
medication was prepared by Professional Pharmaceutical Packaging Pty, Ltd (VIC, 
Australia) and the placebo for Pulmicort respules was 2mL water for injections (Pfizer, 
Brooklyn, USA). The treatment was randomised and repacked by the pharmacology clinical 
trials unit at TQEH. Neilmed saline sinus irrigation was used as the base nasal irrigation for 
all three groups with patients getting the sachets they had to add to the rinses. The inclusion 
and exclusion criteria for the study is outlined in (Table 6). The patients were followed up at 
3 weeks (treatment completion) and at 6 weeks (3 weeks after treatment completion). 
Patient symptom scoring, endoscopic grading, microbiome swabs and bacterial swabs were 
performed on enrolment (time_0), at week-3 at the completion of treatment (time_3) and at 
week 6 (3 weeks after the completion of treatment) (time_6). Radiological severity of CRS 







Table 5:Contents of each treatment arm of the RCT 
Oral steroid Topical steroid Oral antibiotic 
Panafcortelone ® (25mg/day 
for 1 week then 12.5mg/day 
for 1 week then 12.5 mg 
every other day for 1 week)  
 
+ 240ml isotonic saline with 
water for injection (2ml 
respules) as placebo 
delivered intranasally 2 
times a day  
 
+ oral placebo for antibiotic 
2 tablets on day one, 
followed by one tablet once 
daily for 3 weeks 
 
Pulmicort ® (0.5mg/2ml 
respules) washes of the nasal 
cavities and sinuses 
delivered intranasally 2 
times a day in 240 ml 
isotonic saline  
 
+ oral placebo for antibiotic 
2 tablets on day one, 
followed by one tablet once 
daily 
 
+ placebo for oral steroid in 
tapering doses for three 
weeks 
 
Oral Doxylin® (antibiotic) 
tablets 2 tablets on day one, 
followed by one tablet once 
daily 
 
+ placebo for steroid in 
tapering doses 
 
 + 240ml isotonic saline 
with water for injection (2ml 
respules) as placebo 
delivered intranasally 2 









Table 6:Inclusion exclusion criteria of the RCT 
Inclusion  Exclusion  Withdrawal 
1.Have symptoms 
and signs of CRS 
and require medical 
management AND 
2.are over 18 years 
of age AND 
3.are able to give 
written informed 
consent AND 
4.are local patients 
who will be 




1.Requirement for a 
specific corticosteroid 
or antibiotic treatment 
based on 
symptomatology 






5.on other CYP450 
inhibiting drugs  
6.liver disease 
 
1.Patients who do not return to this centre 
for follow up 
2. who exhibit an allergic reaction to any 
test treatments 
3. who requests withdrawal from the study; 
no reason will be required 
4.development of pus (confirmed secondary 
bacterial infection) in patients from groups 
1 or 2 (patients will be commenced on an 
antibiotic and withdrawn from the study).  
5.increasing size of nasal polyps causing a 
worsening of nasal blockage (patients will 
be commenced on steroids and withdrawn 




The patient symptoms were scored using the validated Adelaide disease severity score(274) 
Sinonasal outcome test-22 (SNOT-22).(275)Endoscopic assessment was performed using the 




A guarded flexible nasopharyngeal flocked swab (Copan Italia S.p.A., Brescia, Italy) was 
used under endoscopic guidance to prevent contamination from the rest of the nasal cavity. 
The swab was rotated in the middle meatus 7 times for maximum bacterial yield. Following 
this the swab heads were immediately transferred into a sterile container, transported on ice 
to the laboratory and stored at -800C. 
DNA extraction 
For DNA extraction from collected swabs, we used the Qiagen DNeasy Blood and Tissue 
kit (Hilden, Germany) with modifications. Briefly, using sterile forceps, the swabs are held 
by the remaining part of the shaft and with sterile scissors the swab head cut into small 
pieces, allowing the pieces to drop into a 2 ml microcentrifuge tube. Lysozyme (Sigma-
Aldrich, St Louis, Missouri, USA) was added to the lysis buffer at a concentration of 20 
mg/ml. From this,180 µl was transferred into to each tube and left at room temp overnight. 
The following day, a 5 mm stainless steel bead, Qiagen was added to each tube. The Qiagen 
Tissue Lyser was used to beat the swabs with the steel bead for 20 seconds at 15 Hz. The 
steel beads were   removed from the tubes and replaced with 50mg of 0.1 mm glass beads 
(Sigma Aldrich) A second round of bead beating was performed in the Tissue Lyser for 5 
mins at 30 Hz. To this, 25 µl proteinase K and 200 µl Buffer AL (without ethanol) were 
added and mixed by vortexing. Samples were incubated at 56oC for 30 mins. Tubes were 
pulsed briefly in a centrifuge after incubation to collect the beads and the supernatant was 
transferred to a new tube. The protocol was continued according to the manufacturer’s 
instructions and the DNA eluted in 100 ul elution buffer. Samples were quantified using the 
NanoDrop spectrophotometer (ThermoFisher scientific, Massachusetts, USA).  
PCR amplification of 16S rRNA gene and pyrosequencing 
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Polymerase chain reaction (PCR) amplification and sequencing was performed by the 
Australian Genome Research Facility. By amplifying the V3 to V4 (341F–806R) 
hypervariable region of the 16S rRNA, gene libraries were generated. PCR amplicons were 
generated using the primers CCTAYGGGRBGCASCAG in the forward sequence and 
GGACTACNNGGGTATCTAAT in the reverse sequence, using AmpliTaq Gold 360 
Master Mix (Life Technologies, Mulgrave, Australia) and following the local protocol. The 
resulting amplicons were measured by fluorometry (Invitrogen Picogreen; Thermo Fisher 
Scientific, Waltham, MA) and normalized. The equimolar pool was then quantified by 
quantitative PCR (KAPA Biosystems, Capetown, South Africa) and set up for sequencing 
on the Illumina MiSeq (Illumina Inc., San Diego, CA) with 300 base paired end chemistry. 
Bioinformatic pipeline 
Demultiplexed fastq files were received from the sequencing facility. We used the new 
QIIME 2 (version 2018.11)(277)for our bioinformatics pipeline. Forward and reverse reads 
were joined using PEAR(278)through the QIIME 2 plugin q2-pear 
(https://github.com/bassio/q2-pear). Joined sequences were then quality-filtered using the 
QIIME 2 plugin q2-quality-filter(279)with minimum quality parameter of 20. Denoising and 
Amplicon Sequence Variant (ASV) formation were done using deblur(280)through the q2-
deblur plugin with setting “trim-size” = 435 and with otherwise default parameters. 
Taxonomy assignment was done against the Greengenes 16S reference database (the 99% 
clustered similarity sequences),(281)version 13.8 (August 2013) using the BLAST-based 
classifier implemented in QIIME 2 (q2-feature-classifier)(282)and which implements a 
Lowest Common Ancestor (LCA) consensus algorithm. The SATé-enabled phylogenetic 
placement (SEPP) technique(283)was used for insertion of the ASVs into the high-quality tree 
generated from the 99% OTUs Greengenes reference database. 
A rarefaction depth cut-off was chosen at 400 before downstream analysis. Taxa were 
compared at the genus level with additional species-level analyses for Staphylococcus 
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aureus and epidermidis. The taxonomic assignment of the two DNA-negative control 
samples containing extraction reagents only was explored. The bacterial genus 
Flavobacterium was common to both samples and was present in relatively low abundance 
in many samples, so this genus was excluded before downstream statistical analyses. Mean 
relative abundance as well as prevalence of the genera were calculated for each group. 
Shannon’s diversity and Faith’s phylogenetic diversity index(284)were used for alpha 
diversity. Diversity metrics were generated through sci-kit bio version 0.5.3. 
Microbiome stability studies were conducted according to methods described by Martí et al. 
Rank variability (RV) is a per-sample index, and a surrogate for microbiome stability. It is 
defined by Martí et al. as “the absolute difference between each taxon rank and the overall 
rank”.(285)Differences variability (DV) is another index defined as “the absolute difference 
between each taxon rank at a given time and the value it had in the previous time step, 
averaged over all taxa present”. These were calculated using a Python implementation of the 
equations described in the original paper. 
Statistical analysis 
We analysed outcomes using a “longitudinal analysis of covariance” (longitudinal 
ANCOVA) model specification, which controls for baseline value of the outcome measure 
as a covariate, as specified in the methods of Twisk et al(286)A Repeated measures model 
without the treatment variable, but with the interaction between treatment and time specified 
as a covariate, was used to corroborate the longitudinal ANCOVA results and to compare 
the outcome values at baseline “time_0” to outcomes at follow-up timepoints after 
randomization and administration of treatment(s), and allow plotting of all three timepoints 
(including baseline). Estimated marginal means, standard errors (SEs), 95% confidence 
intervals, and contrasts between study groups were extracted from model results using the R 
package “emmeans”.(287)For all models mentioned, a linear mixed modelling approach was 
used (through the R packages lme4 and lmerTest)(288, 289)to adjust for the dependency of 
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repeated observations within each patient enrolled in the trial by specifying the patient 
variable as a random effect, following the paper of Twisk et al. All statistical analyses were 
performed using R(290)(R Foundation for Statistical Computing, Vienna, Austria) and the 





A total of 178 patients referred from general practitioners with a preliminary diagnosis of 
chronic rhinosinusitis were screened for recruitment from the outpatient clinic of the Queen 
Elizabeth Hospital, Adelaide between the period Dec 2016 and Dec 2018. Among these, 69 
patients met the eligibility criteria with 50 agreeing to be enrolled in the trial with 
randomization into the three treatment arms. The patient recruitment and flow chart details 
are summarized in (Figure 25).  From this randomized cohort, 5 patients were excluded due 
to withdrawal or non-compliance with the prescribed treatment. Analysis after unblinding 
revealed that 1 of these patients was from the active oral steroid arm, 1 from the active nasal 
steroid irrigation arm and 3 from the oral antibiotic arm. All the patients who completed the 
trial reported compliance to the 3-week therapy. The demographics and baseline clinical 
characteristics of the 45 patients who participated in the trial are summarized in Table7. 
Post-trial follow-up was possible for 43 patients with only 2 patients, both from the active 
oral antibiotic arm lost to follow up following their 3-week trial visit. Of the patients who 
were followed up for at least 6 months post trial completion 33 desired and proceeded to 
surgical intervention. There was however no between the treatment group in proceeding to 
surgery (p= 0.39). There were also no statistically significant differences between the three 




Figure 25: CONSORT flowchart 
 
Table 7:Patient Demographics 
 Oral steroid Topical steroid Oral antibiotic P value 
Number (n= 45) n=16 n=16 n=13  









Male/Female 9/7 12/4 8/5  
CRSsNP/CRSw
NP 






































11 (68.75%) 12 (75%) 10 (90.9%) 0.399 
 
 
CRSsNP; Chronic rhinosinusitis without polyps, CRSwNP; Chronic rhinosinusitis with 
polyps, SNOT 22; Sinonasal outcome test 22, ADSS; Adelaide disease severity score, LKS; 
Lund Kennedy score, LMS; Lund Mackey score, SD; Standard deviation. 
Clinical response of each treatment arm: 
Symptom Scores: We observed a decrease in the SNOT 22 and ADS scores in all the 
treatment arms with a significant reduction in the oral and topical steroid group. A repeated 
measures model was used for estimation of treatment effects of each arm across different 
timepoints, in comparison to baseline. These comparisons revealed a reduction (from 
baseline) of the SNOT-22 mean score of 12.9 [CI 3.0, 22.7] (p = 0.012) for oral 
prednisolone and 14.4 [CI 3.9,24.9] (p = 0.008) for Pulmicort rinse immediately post 
treatment at 3-weeks. In comparison, the 3-week score for oral doxycycline decreased only 
4.6 [CI -7.4, 16.5]. These improvements were not sustained at 3-week post treatment, with a 
recurrence towards baseline in all groups. (Figure: 26A & B). Changes in the Adelaide 
Disease Severity Score mirrored that of the SNOT-22. (Figure: 26D). 
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Endoscopic Scores: Similarly for the Lund-Kennedy score, we notice some improvement in 
the scores immediately post treatment at 3 weeks for the oral prednisolone (1.1 [CI 0.2, 1.9], 
p = 0.013) as well as the Pulmicort rinse arms (1.0 [CI 0.1, 1.9], p = 0.025), while the oral 
doxycycline arm had a comparatively negligible reduction (0.3 [CI -0.7, 1.3]). Again, this 
observable improvement in LKS for the first two treatments arms at the first follow-up 
appointment was not sustained at 3-week post treatment, with a movement toward baseline. 
(Figure: 26C) 
Comparison of clinical response to treatment between groups: 
Difference between the three treatment arms at 3 weeks were compared using longitudinal 
ANCOVA. There was a clinically significant reduction in SNOT-22 between treatment with 
oral prednisolone versus oral antibiotic (-8.7, CI [-23.9, 6.4], p = 0.253) and between 
treatment with Pulmicort rinse versus oral doxycycline (-11.1, [CI -26.7,4.5], p = 0.159) at 





Figure 26: Clinical outcomes of the trial 
 
Clinical outcomes of the trial: the oral and topical steroid groups showed some temporary 
improvement at 3 weeks, while there were poorer outcomes for the oral antibiotic group. 
Data represented as means (circles) and Standard Errors (error bars). (A) SNOT-22 scores: 
unadjusted raw data at baseline (time_0) and values as inferred from longitudinal ANCOVA 
at follow-up timepoints time_3 and time_6. (B) SNOT-22 scores as inferred from repeated 
measures model, demonstrated as change from baseline. (C) Lund-Kennedy scores as 
inferred from repeated measures model, demonstrated as change from baseline. (D) 
Adelaide disease severity scores (ADSS) as inferred from repeated measures model, 
demonstrated as change from baseline. SNOT-22 = Sinonasal outcome test-22; ADSS = 
Adelaide disease severity score; LKS = Lund Kennedy score; time_0 = baseline (day 0); 
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time_3 = immediate post therapy at 3 weeks; time_6 = 3-week post treatment completion; 
ANCOVA; Analysis of covariance.  
Microbiome outcomes: taxonomy 
We observed a differential abundance trends across the follow-up timepoints with different 
treatments. Corynebacterium and Staphylococcus species were the most common taxa in all 
3 patient groups at all assessed time points. In the oral antibiotic treatment arm, a tendency 
towards an increase in the relative abundance of Corynebacterium and Staphylococcus was 
observed immediately after treatment.   At 3 weeks post oral antibiotic treatment, the 
tendency for increased relative abundance of Corynebacterium persisted 17.4% [CI -1.6, 
36.4], while the relative abundance of Staphylococcus returned to pre-treatment levels. 
In patients randomised to the Pulmicort irrigation treatment arm, a tendency towards an 
increase in the relative abundance of Corynebacterium was also observed immediately post 
treatment and at 3 weeks post treatment it remained high at 16.7% [CI -0.3, 33.8]. Similar 
trends to increases in the relative abundance of Staphylococcus were also observed in this 
treatment arm at both measured time points with 9.8% [CI -7.2, 26.8] at 3 weeks post 
treatment.)  Figure 27 
 
Figure 27: Relative abundance of Corynebacterium and Staphylococcus 
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Relative abundance of Corynebacterium and Staphylococcus, showing an increasing 
Corynebacterium with topical Pulmicort and oral doxycycline and decreasing 
Corynebacterium with oral prednisolone at 3 and 6 weeks. Data represented as means 
(circles) and Standard Errors (error bars). (A) Relative abundance of Corynebacterium, as 
inferred from repeated measures model, demonstrated as change from baseline. (B) Relative 
abundance of Staphylococcus, as inferred from repeated measures model, demonstrated as 
change from baseline. time_0 = baseline (day 0); time_3 = immediate post therapy at 3 
weeks; time_6 = 3-week post treatment completion 
Microbiome outcomes: diversity and stability studies 
We measured Faith’s Phylogenetic Diversity index (Faith’s PD) and Shannon’s index as 
measures of phylogenetic and non-phylogenetic alpha diversity, respectively for all three 
treatment groups. Pulmicort rinses increased Faith’s PD immediately after treatment, a 1.1 
increase [CI 0.1, 2.1], compared to baseline), but with a rebound towards baseline value at 
the 6-week timepoint. No significant changes were observed in Shannon’s index for 
Pulmicort rinses and the oral steroid arm, while there was a trend towards a slight decrease 
in Shannon’s index at 6-weeks with oral antibiotic treatment. (Figure: 28) 
We used Rank variability (RV) and Differences variability (DV) as surrogates for assessing 
microbiome stability according to Martí et al.(285) When a large number of bacterial taxa 
change their ranking in terms of abundance compared to the average, the RV and DV 
becomes higher (and the microbiome becomes, supposedly, more labile i.e. less stable). In 
our trial, the oral steroid and topical steroid rinse arms demonstrated a (temporary) 
reduction in RV at the 3 weeks marks. Comparatively speaking, oral antibiotic treatment 






Figure 28: Microbiome alpha-diversity and stability comparisons 
 
Microbiome alpha-diversity and stability comparisons. Data represented as means (circles) 
and Standard Errors (error bars). (A) Faith’s PD, as inferred from repeated measures model, 
demonstrated as change from baseline. (B) Shannon’s index, as inferred from repeated 
measures model, demonstrated as change from baseline.  (C) Rank Variability, as inferred 
from repeated measures model, demonstrated as change from baseline. (D) Difference 
Variability (DV) raw scores at time_3 and time_6 follow-up timepoints. Faith’s PD = 
Faith’s phylogenetic diversity index; RV = Rank Variability; time_0 = baseline (day 0); 





Subgroup analyses: polyps versus non-polyps 
To investigate effect of nasal polyps on outcomes, we conducted separate repeated measures 
models for the CRSsNP and CRSwNP subgroups. The improvement in SNOT-22 scores for 
CRSsNP at 3 weeks compared to baseline were: 11.0 [CI -1.9, 23.9] for the oral steroid 
group; 7.9 [CI -6.1, 21.8] for the topical steroid group; and 6.6 [CI -6.9, 20.0] for the oral 
antibiotic group. On the other hand, the improvement at 3 weeks was more pronounced in 
the CRSwNP subgroup for the oral steroid (15.8 [CI -0.8, 32.4], p = 0.06) and the topical 
steroid groups (21.3 [CI 5.1, 37.6], p = 0.013), while the antibiotic had an overall average 
worsening of symptoms at 3 weeks. Again, a rebound phenomenon was observed for both 
steroid groups 3 weeks after completing the treatment course. (Figure 29) 
Figure 5 also shows that there appears to be no consistent explanation or association of the 
symptomatic outcome with the microbiomic parameters at any particular time point in our 










Subgroup analysis demonstrating SNOTT 22 score improvement on treatment with oral and 
topical steroids, and a worsening with oral antibiotics in CRSwNP patients at 3 weeks. Data 
represented as means (circles) and Standard Errors (error bars) and the results inferred from 
a repeated measures model. The maroon dotted line indicates minimal clinically important 
difference (MCID)(293)SNOT-22 = Sinonasal outcome test-22; CRSsNP= Chronic 
rhinosinusitis without polyps; CRSwNP= Chronic rhinosinusitis with polyps; Faith’s PD = 
Faith’s phylogenetic diversity index; time_0 = baseline (day 0); time_3 = immediate post 
therapy at 3 weeks; time_6 = 3-week post treatment completion. 
4.6 Discussion 
 
The pursuit of defining a healthy and diseased microbiome in the paranasal sinuses has led 
to the present day understanding of microbial dysbiosis in disease development and 
progression in CRS. Our study, further investigates this, to better understand the changes in 
microbial communities and their effect on clinical outcomes in response to currently 
recommended medical therapies for the treatment of CRS.  
To our knowledge, this is the first double blinded, randomised placebo-controlled trial to 
compare the clinical outcomes in the three different medical therapies in CRS and explore 
the microbiome shifts with these treatments. We observed an immediate post-treatment 
significant improvement in the subjective (SNOT-22 & ADSS) and objective (LKS) clinical 
scores of CRS patients treated with either oral or topical steroids for 3 weeks. This 
improvement however, was not sustained and the clinical symptoms returned to base line at 
3 weeks post cessation of treatment. No such improvement in any clinical parameters were 
observed following 3 weeks of oral doxycycline treatment. With regard to the microbiome 
outcomes in these patients, we observed that the group which received topical steroid 
showed a tendency towards increasing relative abundance of Corynebacterium and 
Staphylococcus at the end of 3 and 6 weeks. However, we could not conclusively associate 
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this with the improving clinical outcome as, the antibiotic group also demonstrated a similar 
increase in Corynebacterium while the oral steroid group decreased relative abundance of 
Corynebacterium and Staphylococcus. A further subgroup analysis differentiating patients 
with and without nasal polyps, demonstrated an improvement of clinical symptoms with 
topical or oral steroids and worsening with oral antibiotics in CRSwNP patients. These 
outcomes also did not appear to have any specific association with the microbiome 
outcomes.  
In the treatment for CRS, steroids seemed to outperform antibiotics in terms of clinical 
improvement and objective reduction in endoscopic inflammation. The anti-inflammatory 
action of steroids by modulation of inflammatory gene transcription is well documented in 
literature(235, 236). This along with the possible indirect and direct antibacterial effects of 
steroids is probably responsible for the immediate post therapy clinical benefits observed in 
our study(187, 294). Most antibiotics on the other hand act by eliminating the pathogen and 
thereby the infection. The antibiotic doxycycline, apart from its broad-spectrum anti-
infective property have also been shown to decrease inflammation by modulating gene 
expression of proinflammatory cytokines.(138)The increased benefit with steroids over 
doxycycline in our trial could be due to the fact that steroids have a more potent anti-
inflammatory property and also that the antibiotic treatment was not culture directed.  
 
A number of RCT’s have reported improvement in symptoms with the use of topical 
steroids in CRSsNP. The systematic review and meta-analysis of nine RCT’s by Kalish et 
al. investigating the effect of topical steroids on CRSsNP, suggests that although there is 
insufficient evidence to demonstrate an overall clinical benefit, topical steroids should be 
included in management protocols of CRSsNP as they appear to be safe and provides some 
symptomatic benefits.(295-298)Contrary to this, Parikh et al(299)in their double blinded, placebo 
controlled RCT, could not find any difference in clinical symptoms with the use of topical 
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fluticasone and placebo and so do not advocate their use in routine treatment of CRS. In this 
study, however, the patient sub-classification into those with and without polyps was not 
defined which might attribute to their findings. In CRSwNP, a systematic review  and 
metanalysis by Rudmick et al(300)on 19 randomised placebo controlled studies using topical 
steroids showed that mometasone, fluticasone, and budesonide provided reduction in 
symptoms in these patients. The duration of treatment in the studies ranged from a minimum 
of 4 weeks to 270 weeks and outcome measured as improvement in nasal symptoms. 
Fluticasone propionate nasal drops in a 12-week double blinded RCT on CRSwNP patients 
showed a decrease in the number of patients going in for surgery when compared to the 
placebo group. However, the assessment in this study was done immediately post therapy 
and hence do not account for further recurrence of symptom. (173)The use of oral steroids in 
CRSsNP is not sufficiently supported in literature (297, 298, 301).In CRSwNP oral steroids have 
been shown to reduce the inflammatory markers, radiological scores, endoscopic scores and 
the size of the polyps, thereby improving patient symptoms on an immediate (2 week) 
follow up(270) as well as lasting to up to 12 weeks with oral steroid taper, followed by 
maintenance with intranasal corticosteroids(271, 301, 302). In our trial we found that budesonide 
rinses, although not approved by the U.S food and drug administration (FDA) for use in 
CRS, had comparable clinical benefits to oral steroids. This was also observed in our 
subgroup analysis with a significant improvement in patient symptomatology in the 
CRSwNP group. A number of studies including double blinded placebo-controlled trials 
have investigated the effect of budesonide in CRS symptoms in post and pre surgical 
patients. These studies with follow up ranging from 3 months to one year have consistently 
demonstrated benefits with budesonide rinses.(303-305) Studies evaluating the safety profile of 
budesonide rinses also demonstrated that there was no evidence of hypothalomo-pituitary-
axis suppression (follow up of 38.2 months), changes in intraocular pressure or 
adrenocorticoid hormones levels (follow up of one year).(305, 306) Despite the having 
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significantly higher chances of systemic side effect, oral steroids are FDA approved for use 
on CRSwNP patients whereas topical budesonide rinses remains off label.(4)  
Oral doxycycline (non-culture directed) compared with oral steroid in a double blinded trial 
in CRSwNP have shown a comparable reduction in polyp size, inflammatory markers and 
most of the nasal symptom scores till a 12 week follow up.(155) Our study failed to 
demonstrate clinical improvement in terms of symptoms and endoscopy with doxycycline in 
the CRS cohort as well as in the CRSwNP group. This could be due to the comprehensive 
patient well-being assessment with SNOT 22 used in our study. Antibiotics continue to be 
used in the management of CRS with a low level of evidence and many of the available 
studies define cure rates as eradication of original pathogen with or without recolonization 
with non-pathogenic flora.(4, 301). Based on our findings and the fact that antibiotics have 
potential local and systemic side effects on local and remote microbiomes, we could not 
recommend antibiotics as routine in maximum medical therapy of CRS.  
The microbiome changes with the different treatments had differential outcomes in our 
study. The pre-treatment microbial communities were predominated with Corynebacterium 
and Staphylococcus as has been observed in previous studies. The topical steroid showed a 
tendency towards increasing relative abundance of Corynebacterium and Staphylococcus at 
the end of 6 weeks, oral antibiotic showed similar increase in Corynebacterium while the 
oral steroid group demonstrated a trend of decreasing Corynebacterium and Staphylococcus 
at 6-weeks. A very recent study by Jain et  al (307) observed similar effects of oral steroids 
and oral doxycycline on the Corynebacterium and an opposite effect on Staphylococcus 
average relative abundance in CRS microbiome. Unlike our trial, this study did not show 
any difference between the patient symptom scores across the treatments. The CRS patients 
in their cohort however, was not double blinded and received treatment only for 7 days 
which could account for the difference seen from our study. Despite this, similar to our 
results, their study also did not show any bacterial taxa that significantly corelated with 
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SNOT 22 or Lund Kennedy scores. A pilot study by Ramakrishnan et.al(308) aiming  to look 
at the microbiome changes associated the use of  intranasal corticosteroids (INCS) or topical 
antibiotic in non CRS volunteers observed an  increase in the relative abundance of 
Corynebacterium, Staphylococcus & Gonordia and a decrease in streptococci and 
Moraxella spp with INCS. Although a similar shift in microbial diversity was observed in 
our trial, this did not persist after treatment cessation as observed in their study.  
Ramakrishnan et al’s study however, included only 5 patients with 4 in INCS arm and 1 in 
topical mupirocin arm and was non blinded or randomized. Despite our findings on the 
bacterial changes with the different treatment modalities, the exact influence of the 
individual bacteria and its potential changes in abundance or diversity, and its association 
with clinical outcomes, could not be explained in our study. Furthermore, the inability of 
current sequencing technology to allow accurate speciation below the genus level is a 
significant limitation of microbiome research at present. With improvement in bioinformatic 
pipelines and analysis techniques, higher resolution and speciation may become possible 
and yield more useful information in this area. 
A relatively new concept in healthy and diseased state is microbial stability or variability 
over time. This theory, based on Taylors law was applied to explore the temporal stability of 
the microbiotas under different conditions to understand how this is related to the health 
status of the subjects by Martí el al. (285)They found statistically increased microbial 
variability for grade III obese patients, subjects taking antibiotics, subject who had a 
salmonella infection, subject who had travelled abroad, and the patients with a diagnosis of 
inflammatory bowel disease. In our study we observed an increasing trend in the Faiths 
phylogenetic diversity at 3weeks for the topical (not sustained at 6 weeks) and oral steroid 
groups, and a trend towards a decrease in the Shannon’s index in the antibiotic group at 
6weeks. Most interestingly, the RV and DV index of microbial stability suggested the 
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development of a progressively unstable microbiome with oral antibiotic use at 3 and 6 
weeks which was not seen in the steroid groups. 
The major drawback of our study is the small sample size. The patients were already 
diagnosed with CRS before they visited our tertiary hospital, and a number of them were 
already on medical therapies when assessed for eligibility and hence could not be recruited.  
Although topical and oral steroid groups showed similar clinical outcomes in our study, 
their bacteriological profiles with regards to Corynebacterium and Staphylococcus were 
different, suggesting that the immediate clinical benefits are mostly due to anti-
inflammatory action of steroids. However, the lower RV index with steroids (oral and 
topical) demonstrated in our study, suggests that the microbial stability could also contribute 
to clinical outcomes.  With the data we have available and the limitations of our study, we 
cannot ascertain with certainty whether the microbiome changes we have observed do have 
any clinical significance. In fact, we could perhaps argue that our results make us believe, 
with the limits of current technology, that symptomatic improvement was somehow 
"independent" of these changes that we looked at in the microbiome. e.g. steroids mainly 
work because of their anti-inflammatory action. 
4.7 Conclusion 
 
The report from our study show that steroids (topical and oral) provide symptomatic 
improvement, in a cohort of CRS patients, as long as they continue to be given. Although 
there were some associated microbiome changes with the various treatments, we could not 
ascertain the consistency of these and whether they do have a clinical significance at all.  
Budesonide nasal rinse reduced the symptoms to a similar extend in patients with and 
without polyps and could possibly be used for longer durations without the dangers of 
systemic side effects of oral steroids. Oral antibiotic on the other hand, failed to bring 
symptomatic benefits, and in patients with CRSwNP worsened the symptom scores. In the 
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light of our findings and based on the fact that antibiotics have potential local and systemic 
side effects on local and remote (e.g. gut) microbiomes, we could not recommend 
antibiotics as a routine in the maximum medical treatment of CRS patients especially those 
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The thesis begins with a detailed and systematic review into the literature on chronic 
rhinosinusitis, its etiopathogenesis, current recommended medical therapies and especially 
focuses on microbiome in CRS and the factors influencing it (chapter 1).  Chronic 
rhinosinusitis (CRS) is a common complex clinical syndrome of multifactorial aetiology 
where infection and inflammation coexist. It commonly presents with symptoms of nasal 
obstruction, discharge, facial pain and altered sensation of smell. CRS can further be 
classified into two phenotypes based on nasal endoscopy as CRS without nasal polyps 
(CRSsNP) and CRS with nasal polyps (CRSwNP). Among the various proposed factors in 
the etiopathogenesis of CRS, the most prominent ones are bacterial infection and host 
immune responses and these have been extensively researched. Literature reviews have 
shown an association between microbiome profiles in healthy and diseased states in a 
number of chronic inflammatory disorders. It is proposed that complex interactions between 
the resident microbes as well as between the microbe and host immune system are 
responsible for normal and healthy state of the various bodily functions. Along with the 
different factors associated with disease development, surgical or medical interventions 
could also potentially alter this harmony leading to local or remote microbial dysbiosis. 
Studies have shown this to be true in many conditions like inflammatory bowel disease, 
bronchial asthma, diabetes and obesity where newer treatment modalities are targeted 
towards restoring microbial harmony. According to the current understanding, a similar 
process is believed to underlie the etiopathogenesis and disease progression in CRS.  
The medical management in CRS is mostly directed against the inflammation and infection 
with oral steroids, topical nasal steroids, oral antibiotics or a combination of these. 
Rhinosinusitis has been found to be the most common condition for which antibiotics are 
prescribed in general practice. Despite this, a large number of patients, respond inadequately 
to medical therapies and eventually require multiple surgical interventions and prolonged 
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medical management. The response to medical therapies varies among patients, depending 
on the treatment, its duration and initial phenotypic presentation in CRS. It is often observed 
in literature that, despite having proven bacterial colonization and biofilms in the mucosa, 
CRS patients respond well to topical steroid therapies. Corticosteroids have well established 
anti-inflammatory mechanisms by which they bring about the clinical benefits. The complex 
interactions between corticosteroids and microbiome in the sinuses of patients and the 
influence of these interactions on the disease outcome is, however, not clearly understood. 
An insight into this would ultimately, lead to a greater understanding of the way in which 
medications influence the microbial species that contribute to disease pathogenesis and this 
could lead to tailored therapeutic approaches and improved outcomes in patients with CRS. 
The first part of this project investigated the effect of a commercial nasal steroid (pulmicort) 
and the individual components used in its preparation on methicillin sensitive and 
methicillin resistant Staphylococcus aureus (S. aureus and MRSA respectively) which are 
common pathogens in CRS, in an in vitro study (chapter 2). We observed that pulmicort, 
which contains the corticosteroid budesonide and excipients, inhibited the biofilm formation 
of S. aureus and MRSA strains tested. Interestingly, the excipient EDTA, which is a 
component present in commercial topical nasal steroid preparations, also inhibited the 
biofilm formation at FDA approved concentrations and concentrations much below. The 
presence of the excipients also influenced the antimicrobial activity of antibiotics 
differentially and were also found to be non-toxic to human nasal epithelial cells. This study 
showed that commercial nasal steroid preparations, apart from the anti-inflammatory action 
of its active ingredient steroid, probably possessed properties which inhibited biofilm 
formation, which was mediated through the excipients present in them, to bring about the 
clinical benefits in patients. This understanding is important because it could potentially 




The second part of the project (Chapter 3) focused on evaluating how corticosteroid on its 
own, influenced the various metabolic responses and growth dynamics that occur in S. 
aureus This invitro study was done using a water-soluble corticosteroid hydrocortisone 
hemisuccinate (HCHS). We found a differential growth response in the bacteria depending 
on the concentration of HCHS. There was an increase in the metabolic activity and 
aggregation of S. aureus planktonic forms as well as biofilms in the presence of HCHS in a 
dose dependent manner. At the highest HCHS concentrations (clinically relevant), the 
biofilms were found to be more susceptible to all the antibiotics tested, while the presence 
of intermediate HCHS concentrations rendered the biofilms tolerant to antibiotics even at 
the highest antibiotic concentration tested. Yet another finding in this study was the 
increased dissociation of HCHS into the active metabolite cortisol in the presence of S. 
aureus, which in turn resulted in a greater drop in the levels of the inflammatory marker IL-
6 induced in primary human nasal epithelial cells. This suggests that S. aureus was probably 
capable of utilizing steroid as a growth substrate, thereby causing dissociation of HCHC, 
and eventually potentiating its anti-inflammatory action. The information on the usefulness 
of corticosteroids in infections in the literature is controversial. While it has been shown to 
be beneficial and at times life-saving when used in certain infections there are also studies 
demonstrating increase in serious and opportunistic infections especially with long term 
steroid use.  Our study had demonstrated for the first time that corticosteroids can variably 
affect the bacterial metabolic and growth responses in human pathogenic bacteria, 
depending on the steroid concentration and the bacterial strains tested.  This expands our 
understanding on the possible causes for the differential responses of steroid therapy in 
infections. This project provides new scope of research where steroids could be utilized in 
specific concentrations with antibiotics to contain a number of chronic inflammatory 
infections in humans.  
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For the final part of this project (Chapter 4), we conducted a double-blinded randomized 
placebo-controlled trial (RCT), aiming to evaluate and compare the clinical and microbiome 
outcomes of various medical treatments commonly employed in the “maximal medical 
therapy” of CRS patients. The three treatment arms included oral prednisolone, topical 
budesonide nasal rinses (pulmicort) and oral doxycycline, along with appropriate placebo, 
administered for a of duration of 3 weeks. Patients were evaluated at baseline, then followed 
up at 3 weeks post intervention, / and thereafter 3 weeks after completion of treatment. 
Patient’s symptom scoring, endoscopic grading, microbiome swabs were done at all these 
visits. We observed an immediate and significant improvement in the subjective (SNOT-22 
& ADSS) and objective (LKS) clinical scores of CRS patients treated with either oral or 
topical steroids for 3 weeks. The changes were not sustained at 6weeks.There was no 
improvement in the scores at any time point in the doxycycline group.  
With regard to the microbiome outcomes in these patients, we observed that the group 
which received topical steroid showed a tendency towards increasing relative abundance of 
Corynebacterium and Staphylococcus at the end of 3 and 6 weeks. However, we could not 
conclusively associate this with the improving clinical outcome as, the antibiotic group also 
demonstrated a similar increase in Corynebacterium while the oral steroid group decreased 
relative abundance of Corynebacterium and Staphylococcus. A further subgroup analysis 
differentiating patients with and without nasal polyps, demonstrated an improvement of 
clinical symptoms with topical or oral steroids and worsening with oral antibiotics in 
CRSwNP patients. These outcomes also did not appear to be have any specific association 
with the microbiome outcomes. There were also no statistically significant differences in 
Shannon’s and Faith's diversity indices between the three treatment groups, although the 
doxycycline group had slightly lower diversity indices. Rank Variability (RV) and 
Difference Variability (DV) which are indices of microbial stability suggested the 
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development of a progressively unstable microbiome with oral antibiotic use at 3 and 6 
weeks, which was not seen in the steroid groups.  
This research enhances our current knowledge on the association between the clinical 
outcomes of CRS patients with the most widely used medical therapies and the changes that 
occur in the microbiome communities in the sinuses. Steroid therapies could potentially 
alter the microbial pattern in CRS patients, without causing a reduction in the bacterial 
diversity and show clinical improvement during the time of administration. Antibiotics 
however, could decrease the bacterial diversity thus potentially leading to microbial 
destabilization with unclear clinical benefit. Literature provides ample evidence on the 
harmful effects of antibiotics on local and remote microbial communities in the human body 
and also on the deleterious results of multidrug resistant bacteria emerging due to unjustified 
antibiotic use. Oral steroids, on the other hand, while providing reasonable clinical benefits 
in CRS, is associated with a number of complications when used for a prolonged period. 
Topical steroids, however, have been shown to be safe and bring about excellent symptom 
relief in CRS patients. Based on the above facts, and the findings from this PhD research we 
encourage the use of topical steroid nasal rinses as first line medical therapy in CRS patients 
and discourage the routine use of antibiotics in these patients especially those presenting 
with polyps. The outcomes from the studies conducted in this project informs daily clinical 
practice, and would help to tailor, modify and potentially develop better topical nasal 
therapeutic agents in CRS which would efficiently control infection and inflammation while 
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Participant Information Sheet 
 
Title: The Effect of Topical and Oral Corticosteroids on the Sinonasal Microbiome. 
    
HREC number: HREC/15/TQEH/177     
Ethics Application / Approval Number:  
 
INVITATION TO PARTICIPATE 
 
We invite you to participate in a research project which we believe is of potential 
importance. You are being invited because you require medical management of chronic 
rhinosinusitis symptoms. However, before you decide whether or not you want to 
participate, we need to be sure that you understand why we are doing it, and what it 
would involve if you agreed. We are therefore providing you with the following 
information. Please read it carefully and be sure to ask any questions you have. The Doctor 
conducting the research will discuss it with you and answer any questions that you may 
have. You are also free to discuss it with outsiders, (i.e. family, friends and / or your local 
doctor) You do not have to make an immediate decision. Your participation is purely 
voluntary. Should you agree to enter the trial, you may change your mind and withdraw at 
any stage. 
 
PARTICIPATION IS VOLUNTARY 
 
Participation in any research project is voluntary. If you do not wish to take part, you are 
not obliged to. If you decide to take part and later change your mind, you are free to 
withdraw from the project at any stage without providing a reason. Your decision to take 
part, not to take part or to withdraw will not affect your position on the surgical waiting 
list, your routine treatment, your relationship with those treating you, or your relationship 
with this institution. 
 
BACKGROUND TO THE STUDY 
 
What is the research about? 
Chronic inflammation of the sinuses and nose (“chronic rhinosinusitis” or “chronic 
sinusitis”) causes headache, pain over the face, blockage of the nose and discharge from 
the nose. The cause of this condition is not fully understood. Finding out what factors are 
important in triggering the inflammation, and the body’s response to the inflammation is 
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important to enable the development of new treatments. Corticosteroids (or steroids) are 
the main medical treatment for chronic rhinosinusitis.  
 
 
The aim of our study is to determine the effect of steroids (either as oral tablets, or as a 
nasal wash) on the bacteria living on the mucosal lining of the nose and sinuses (the 
sinonasal microbiome). The information gained from this research can then be used to 
guide new treatment approaches. 
 
Why is the research being done? 
Disorders such as inflammation of the nose and sinuses are not easy to live with. These 
disorders can be seen in different forms in the population and there are many factors 
contributing to the severity of the disease. One of the causes of severe sinus disease is 
microbial infections. Unfortunately, for many people with these disorders, current 
treatments do not work very well.  
 
The Ear, Nose & Throat Department at The Queen Elizabeth Hospital is actively working to 
try to better understand the nature of the microbes (including bacteria and fungus) living 
in the sinuses and their effect on sinus health and disease. From our previous research 
work into microbes, our department has found new treatments to be used in chronic 
sinusitis, which are being tested and developed. 
 
To study the microbiome in chronic rhinosinusitis, the doctors working in the Ear, Nose & 
Throat Department need to obtain nasal swab samples from the lining of the nose. These 
swab samples will be taken while you are in clinic. The samples will be then taken to the 
laboratory and studied to identify the microbes in it. 
 
If you consent, your samples will be collected and stored in the ENT Department and used 
in studies approved by the Ethics Committee. The donated samples will only be used for 
research within the Ear, Nose & Throat Department at The Queen Elizabeth Hospital 
laboratories, and the department will not transfer its ownership to other institutions. 
Occasionally, the department may need to send some of your stored samples to 
specialized labs for certain tests (for example, to characterize the bacteria from your nose). 
If some of your samples are transferred to other labs for special tests, this will happen only 
in a way that will not reveal your identity, so your privacy will always be protected. No 
genetic information about your DNA will be studied. 
 
Who is sponsoring it, and are they paying the researcher or his/her department to do the 
research? 
There is no commercial sponsor. This research is part of the activities of the Ear, Nose & 
Throat (ENT) Department at The Queen Elizabeth Hospital and the University of Adelaide. 
The department is supported by research grants from the Government and private 
Research Foundations.  
 
How and why have I been chosen as a possible participant in the research? 
Your doctor is currently seeing you in the outpatient clinic because you are suffering from 
sinus symptoms. As part of this study, we require samples from individuals who have 




How many other people have been asked to consider participating? 
Every individual attending the outpatient clinic and is diagnosed with chronic sinusitis will 
be asked to participate. A total of 45 patients will be involved in the trial. 
 
PROCEDURES AND TREATMENT 
 
What treatment will I get if I do take part? Will this be different from the treatment I 
would get otherwise? If so, how and in what ways? 
After signing the consent form, you will be randomly allocated into one of three groups to 
receive one of the routine treatments for chronic rhinosinusitis: 
 
Doxylin® (also known as doxycycline) – an antibiotic that is effective against many types of 
microbes, which may be contributing to your current symptoms. It is a commonly-used 
medication in tablet form that has been shown to be effective against chronic 
rhinosinusitis symptoms, and is approved by the Therapeutic Goods Administration (TGA). 
 
Pulmicort® (also known as budesonide) – the same type of medication found in steroid 
spray(s) you may have used previously such as Rhincort® or Nasonex®. Budesonide is a 
steroid solution that is TGA-approved to treat asthma symptoms in asthmatic patients. 
 
Panafcortelone® (also known as prednisolone) – a member of the same family of 
medications as Pulmicort®/budesonide (i.e., steroids). Prednisolone is a steroid tablet that 
is TGA-approved to treat a variety of conditions including asthma. 
 
You will be provided with the Consumer Information leaflets for each of these treatments.  
 
The treatment will be provided to you in a way such that you will not know which 
treatment you are receiving and which treatment group you belong to. This way of 
research while “not knowing” is called blinding. 
 
We will see you at the end of the 3-week treatment period, and then again 3 weeks later, 
which is the standard review time. 
 
Your confidentiality is of utmost importance and will not be compromised. There will be no 
other changes to your care. 
 
Will I have to come back to the clinic more often or remain in hospital for longer than 
would normally be the case? 
No. You will be asked to attend the clinic at three weeks after your first appointment, then 
after six weeks, which is the normal standard of care. Nasal swab samples will be collected 
at each visit. 
 
What will I be asked to do at each visit? 
Initially, we will take CT images of your nasal cavities and sinuses and do an examination 
with a small telescopic camera (endoscope) in order to ascertain the severity of your 
disease. We will also ask you to complete a questionnaire about your nose or sinus 
condition, medications that you are taking, past history and allergies, as another measure 
of this. At each visit (initial, 3- & 6-week reviews), we will use an endoscope to take a swab 
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of the tissue surface inside your nose. We anticipate that the extra time that this will take 
during each clinic visit will be 10 minutes.  
 
How long will my participation in the study last? 
The study will finish after the 6-week visit, and medical management of your condition will 
continue as normal. 
 
What procedures will I be asked to submit to including exposure to radiation and what 
will be the likely effects? 
The extra procedures you will have are 3 swabs taken of the tissue surface inside your 
nose. This is a very gentle procedure and we do not expect any adverse effects.  
 
If I decide not to take part what other treatments are available to me? 
The main medical treatment received in each group is considered part of the routine 
treatment administered for chronic rhinosinusitis. 
 
In the event that patients in group 2 and 3 develop pus (confirmed secondary bacterial 
infection), you will need a specific oral antibiotic therapy, and will therefore be 
commenced on an antibiotic and excluded from the study. 
 
If the need arises for steroid treatment in group 1 participants (for example, increasing size 
of nasal polyps causing a worsening of nasal blockage, or worsening of sinusitis symptoms), 
then you will be commenced on steroids and you will be withdrawn from the study. 
 
Will the decisions about my treatment be made by my usual doctor or by someone else? 
Your usual treating doctor will still make all the treatment decisions with you. 
 
Are there any factors, which would exclude me from participating, like pre-existing 
illness, the possibility of becoming pregnant or other drugs being taken? 
Your surgeon will have screened you for any medications or conditions that would make 
the participation risky or inappropriate for you. 
 
In general, these are the criteria that would exclude you from participating: 
 
- the use of corticosteroids and/or antibiotics in the period of 6 weeks prior to 
study initiation 
- the need for the use of a specific form of steroid (either oral or topical nasal 
corticosteroids) for specific indication (e.g. continued severe growth of nasal 
polyps) during the study period 
- the need for the use of oral or topical nasal corticosteroids for other indications 
(for example, asthma or allergic rhinitis) during the study period 
- the need for the use of antibiotics during the study period- either for presence of 
pus/secondary infection in the nose upon endoscopic examination, or for other 
indications 
- history of previous sinus surgery 
- pregnancy/breastfeeding 
- age < 18 years 




MEDICINES AND DRUGS 
 
What are the names and amounts of the drugs which I will be given? 
Group 1. Oral antibiotics (200mg on day 1 then 100mg daily thereafter) and placebo 
for steroid, + 240ml isotonic saline delivered intranasally 2 times a day for 3 
weeks 
Group 2. Oral placebos for antibiotic and steroid, + 0.5mg topical steroid in 240ml 
isotonic saline delivered intranasally 2 times a day for 3 weeks 
Group 3. Oral placebo for antibiotic, and steroid (25mg/day for 1 week then 
12.5mg/day for 1 week then 12.5 mg every other day for 1 week) + 240ml 
isotonic saline delivered intranasally 2 times a day for 3 weeks 
 
Note: The placebo is a capsule similar in appearance to the steroid and antibiotics but does 




What would happen if I were to feel severe discomfort or pain?  
In the unlikely event that you experience pain or severe discomfort please contact your 
treating doctor or the researchers to discuss the situation. If you feel more comfortable 
seeing your GP this is also an option, as is the emergency department of the QEH or any 
other hospital. 
 
DISCOMFORTS, RISKS AND SIDE EFFECTS 
 
Will there be any discomforts, such as additional needles, biopsies, or pain?  
A nasal swab will be taken in clinic and this is a minimally invasive procedure with no side 
effects and is done safely in clinics or on the wards. All samples will be taken by your 
doctor under the guidance of the endoscope camera for increased safety. All samples will 
be obtained after a nasal local pain-killer spray is sprayed into your nose, to minimize any 
discomfort or pain. 
 
Are there likely to be side effects from the research procedures, and if so what are they? 
There are no overt risks perceived to be associated with this project to participants 
randomized to receive either antibiotic therapy (group 1) or steroid therapy (groups 2 and 
3). These treatments are considered part of the routine medical therapy for chronic 
rhinosinusitis. 
 
Specific side effects 
 
Doxycycline: The most likely side effect of doxycycline (Doxylin®) use is increased 
sensitivity to UV light – this is why it is important that you avoid sun exposure during the 
study. Other potential side effects of doxycycline include nausea, vomiting, diarrhoea, 
stomach burning, tooth discolouration, and reduced growth of tooth enamel. Less 
common side effects include rashes, inflammation in the mouth, bone deformity, fungal 
overgrowth. Rare side effects include lifting off of the skin or nails and nail discolouration, 
oesophageal ulcers (due to partly swallowed tablets – thus you will be asked to refrain 
from lying down after taking medications), fever, abdominal cramping/pain, dehydration, 
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inflammation and fat accumulation in the liver, increased pressure in the head, allergic 
reactions such as anaphylaxis, & joint stiffness. 
 
Budesonide: There are some side effects which may occur, these include: Nose/throat 
dryness or irritation, cough, sneezing, headache, nosebleeds, and unpleasant taste/smell, 
ear infections, respiratory infections, viral infections, gastroenteritis, vomiting, diarrhoea, 
abdominal pain, conjunctivitis. The product information sheet provided by AstraZeneca 
(the manufacturer of Pulmicort®) indicates an adverse reaction rate of about 3% or more. 
Tell your doctor immediately if any of the following rare, but serious side effects occur: 
vision problems, loss of taste or smell, pain/sores in your nose, or signs of too much 
corticosteroid (such as unusual acne, menstrual period changes, puffy face). 
 
Prednisolone: The prednisolone medication (Panafcortelone®) used in this study is unlikely 
to cause any problems during short term use. Possible side effects of prednisolone include 
reduced adrenal function, increased susceptibility to infection, masking of signs of 
infection, sodium and water retention, swelling, high blood pressure, low blood potassium, 
high blood sugar, changes in blood lipid levels, osteoporosis, fractures, increased appetite, 
indigestion, delayed wound healing, skin atrophy, bruising, facial flushing, hair growth, 
growth retardation in children, muscle weakness and wasting, fat redistribution, weight 
gain, menstrual irregularity, amenorrhoea, psychiatric effects, posterior subcapsular 
cataracts. These effects are more common with long-term treatment courses, whereas for 
this study, you will take prednisolone for 3 weeks only. As for budesonide, tell your doctor 
immediately if you notice any of the rare but serious side effects noted above. 
 
Who should I contact if I am worried about any effects that I experience? 
You can contact the treating doctor, the researchers or your GP. 
 
Would I be withdrawn from the study if my condition became worse or if any extra risks 
came to light during the course of it? 
If there were any concerns you would be withdrawn from the study and your condition 
monitored closely. 
 
In the event that patients in group 2 and 3 develop pus (confirmed secondary bacterial 
infection), you will need a specific oral antibiotic therapy, and will therefore be 
commenced on an antibiotic and excluded from the study. 
 
If the need arises for steroid treatment in group 1 participants (for example, increasing size 
of nasal polyps causing a worsening of nasal blockage, or worsening of sinusitis symptoms), 
then you will be commenced on steroids and you will be excluded from the study. 
 
Pregnancy and breastfeeding 
There are no known harmful effects of these treatments to pregnant women or the unborn 
child; however we have chosen to exclude pregnant and breastfeeding women at this 
stage of the trial. If you are breastfeeding, may be pregnant, or are planning to get 
pregnant please kindly inform us. 
 
 
Are there any activities I should refrain from during and in the period following the 
research and for how long, e.g., blood donations, taking other medication, sexual activity 
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(with or without attempting to achieve a pregnancy) exposure to sunlight, driving, taking 
part in other studies?  
We encourage participants to practice protected sex during the duration of this study for 
the reason outlined above. Women of childbearing age should use effective contraception. 
Because the antibiotic used in this study is sometimes associated with skin sensitivity, you 
are advised to avoid exposing your skin to the sun while taking these medications. Also, we 
will ask that you refrain from lying down (e.g., going to bed) for a period of time after 
taking your medications to avoid problems from incomplete tablet digestion. 
 
WHAT WILL HAPPEN TO THE INFORMATION COLLECTED? 
 
How will my confidentiality be protected – will the information and results be de-
identified? 
You will be assigned a code which will be attached to all the study forms thus de-
identifying your study results. A list of patient’s names matching the allocated codes is kept 
in a locked research area of the ENT department and only accessible to the researchers. 
Your name will not be identified in any written results from the trial. 
 
Will I be informed about the results of the study? 
If you are interested, you are welcome to have access to the results of the study once they 
have been collected, analysed and published. Please contact Dr Psaltis on the number 
below (see WHAT IF I HAVE A QUESTION ABOUT THE STUDY?). 
 
How long will my information be stored for? 
Your information will be stored for 15 years before being destroyed. 
 
What are my rights? 
If you become injured during this study, and your injury is a direct result of the effects of 
study procedures, The Queen Elizabeth Hospital will provide reasonable medical 
treatment. Your participation in this study shall not affect any other right to compensation 
you may have under common law.  
 
How can I obtain more information? 
If you have any specific questions about your legal rights you may ask the researchers or 
the executive officer of the ethics committee – contact details are below.  
 
Is there any payment for participation? 





BENEFITS OF THE RESEARCH 
 
Is there any chance that the proposed research will be of benefit to me personally, or to 
future patients with the same condition? 
It is unlikely that there will be an immediate benefit to you for participating.  However, as 
research provides a better understanding of sinus disease, the eventual development of 
new treatments in the future may benefit other people in the community suffering from 
sinus disease.  
 
WHAT IF I HAVE A QUESTION ABOUT THE STUDY? 
 
If you wish to speak to one of the research team about this study you can contact a 
member of the Research Team (lisamarycherian@gmail.com) or Dr Psaltis at TQEH on (08) 
8222 7158, or after hours on (08) 8222 6000. 
 
All research in Australia involving humans is reviewed by an independent group of people 
called a Human Research Ethics Committee (HREC). The ethical aspects of this research 
project have been approved by the Central Adelaide Local Health Network HREC. 
 
This project will be carried out according to the National Statement on Ethical Conduct in 
Human Research (2007) incorporating all updates. This statement has been developed to 
protect the interests of people who agree to participate in human research studies. 
 
Should you wish to speak to a person not directly involved in the study about it, you may 
contact The Executive Officer of the HREC, on (08) 8222 6841. 
 
Participants or other concerned individuals who would like to make a complaint about this 
study should contact the HREC Secretariat 
 
 Ph:   
 Email:  hrec@adelaide.edu.au 
 Post:  Human Research Ethics Secretariat 
  c/- Research Branch 
  The University of Adelaide 
  SA 5005 
 
INSTRUCTIONS – SINUS RINSE 
 
Step 1: Wash your hands. Fill the clean bottle with the designated volume (240mL) of 
previously boiled water. 
 
Step 2: Cut the SINUS RINSE mixture packet at the corner and pour its contents into the 
bottle. Tighten the cap and tube on the bottle securely. Place one finger over the tip of the 
cap and shake the bottle gently to dissolve the mixture. 
 
Step 3.  Select one plastic Budesonide 0.5mg/placebo plastic vial and squeeze the contents 




Step 4: Standing in front of a sink, bend forward to your comfort level and tilt your head 
down. Keeping your mouth open, without holding your breath, place the cap snugly 
against your nasal passage. SQUEEZE BOTTLE GENTLY until the solution starts draining 
from the OPPOSITE nasal passage. Some may drain from your mouth. For a proper rinse, 
keep squeezing the bottle GENTLY until 1/2 (120 mL) of the bottle is used. Do not swallow 
the solution. 
 
Step 5: Blow your nose very gently, without pinching nose completely to avoid pressure on 
eardrums. If tolerable, sniff in gently any residual solution remaining in the nasal passage 
once or twice, because this may clean out the posterior nasopharyngeal area, which is the 
area at the back of your nasal passage. At times, some solution will reach the back of your 
throat, so please spit it out. To help drain any residual solution, blow your nose gently 
while tilting your head forward and to the opposite side of the nasal passage you just 
rinsed. 
 
Step 6: Now repeat steps 4 and 5 for your other nasal passage. 
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Title: Effect of Steroids on the Sinonasal Microbiome  Protocol Number:  
 
I, the undersigned  ................................................................................................  
hereby consent to my involvement in the research project explained above. 
 
• I have read the Participant Information Sheet or someone has read it to me in a 
language that I understand.  
 
• I understand the purposes, procedures and risks of the research described in the 
project. 
 
• I have had an opportunity to ask questions and I am satisfied with the answers I 
have received. 
 
• I freely agree to participate in this research project as described and understand 
that I am free to withdraw at any time during the project without affecting my 
future care. 
 
• I understand that I will be given a signed copy of this document to keep. 
 
• I give permission for my general practitioner to be informed of my participation in 
this study 
 
I do/do not have an allergy to steroids (please circle) 
I do/do not have an allergy to tetracycline antibiotics (please circle) 
PATIENT SIGNATURE ..............................................  DATE ……./……./……. 
INVESTIGATOR DECLARATION  I have given a verbal explanation of the research 
project, its procedures and risks and I believe that the participant has understood that 
explanation. 
 





Screening Visit Assessments and Checklist 
 
At Recruitment: 
☐ Review of inclusion and exclusion criteria 
☐ Confirm informed consent form signed 
☐ Swab for bacterial culture 
☐ Endoscopic evaluation and completion of Modified Lund-Kennedy questionnaire 
☐ Microbiome swab 
☐ Lund-Mackay CT scoring 
☐           Book for CT scan if not previously done 
☐ Review appointment booked  
 
Pre-Treatment Checklist 
☐ Recording demographic information and contact details 
☐ Review of medical history 




☐ Phone call review after week 1: Check drug administration, dosing & compliance, 
symptom relief/persistence, adverse events 
☐Phone call review at week 3: Check drug administration, dosing & compliance, symptom 
relief/persistence, adverse events, reminder for follow up. 
☐Phone call review at week 6: Check drug administration, dosing & compliance, symptom 
relief/persistence, adverse events, reminder for follow up. 
 
 
Post-Treatment at 3- and 6-weeks Checklist 
☐ Has the participant returned all treatment agent (used and unused vials) 
☐ Physical examination 
☐ Review symptom relief/persistence and adverse event 
☐ Completion of SNOT22 
☐ Repeat microbiome and bacteriology nasal swabs to be taken 









Inclusion & Exclusion Criteria Review 
Inclusion Criteria Criteria Met Date 
Each participant must meet the following criteria to be 
enrolled: 
Yes No  
1.Participant must have had at least two of the following 
symptoms of chronic rhinosinusitis that has been 








Day-1     
Week-3     
Week-6     
 
 
   
2. Participant must show evidence of chronic sinusitis by 
direct endoscopic examination. 
 
   
3. Participant must show evidence of chronic sinusitis on 
CT scan  
   
4. Participant must have the ability to take oral drugs and 
administer nasal lavage twice daily for the duration of 
the treatment period. 
   
5. Participant must be between the ages of 18 and 70 
years. 
   
6. Participant must be able to give written informed 
consent. 
   
7. Participant must have the ability and willingness to 
attend several visits to the study center 
Participant must be willing to present to study center at 
Day 21 AND Day 42 of recruitment? 
   
8. Participant must be willing for nasal microbiome swab 
and bacterial culture swab at the time of 
recruitmentand at Day 21 AND Day 42 of recruitment 
   
If the answer to any of the inclusion criteria is No, the 
participant is not eligible for participation. 
   
 
ADELAIDE SYMPTOM SEVERITY SCORE Symptoms∗ Nasal obstruction, Rhinorrhoea, Post-nasal drip, 
Headache or facial pain, Sense of smell, (all scored 1 to5), Quality of life† How do your symptoms affect 
your quality of life? Scale of 0 to7 ∗1 = no symptoms, 2 = mild, 3 = moderate, 4 = severe, 5 = extreme. † 0 = 







Exclusion Criteria Criteria Met Date 
Each participant must NOT meet the following criteria to be 
enrolled: 
Yes No  
1. Participant who have used oral steroid and/or oral 
antibiotic and/or nasal steroid spray within the period 
of 6 weeks prior to study 
   
2. Female participant who is pregnant or breast-feeding.    
3. Participant who is immunocompromised.    
4. Participant who is an active smoker    
5. Participant who is taking any CYTP450 inhibitors    
6. Participant with liver disease    
7. Participant with a previous history of sinus surgery    
8. Participant has a clinically significant laboratory 
abnormality. 
   
9.  Participant with known allergy to Doxycycline, 
Prednisolone or Budesonide 
   
10. Participant is unlikely to comply with the study 
protocol or, in the opinion of the investigator, would 
not be a suitable candidate for participation in the 
study. 
   
If the answer to any of the exclusion criteria is Yes, the 
participant is not eligible for participation. 
   
 
Staff Initials: ___________________________   Date (DD/MM/YYYY): _____/_______/_________ 
 
 
I have reviewed all Inclusion/Exclusion criteria and it is in my medical judgment that the 
participant is eligible for participation in the study. 
 
Assigned to Cohort #:    
 
Signature Principal Investigator/Sub-investigator:       
 






Scoring and collection 
 
CT -Lund – Mackey score   
Was a CT scan taken? 
               And 
 
             Scored 
 
Sinus Left  right 
Maxillary    
Ant/ethmoid    
Post/ethmoid   
Frontal    
Sphenoid   
OMC   





DD            MM          YYYY 
 
Bacterial Culture Swab  









☐ Yes ☐ No 
 
☐ Yes ☐ No 
 
☐ Yes ☐ No 






DD/MM/YYYY    (HH:MM) 
Microbiome swab   









☐ Yes ☐ No 
 
☐ Yes ☐ No 
 
☐ Yes ☐ No 






















Date of Visit:  _________/_________/__________ 
                              DD           MM           YYYY 
 
Date of Birth:  _________/_________/__________ 
                              DD           MM           YYYY 
 
Gender: ☐ Male ☐ Female 
 
UR number:  
 
Race:  ☐ American Indian or Alaskan Native 
  ☐ Asian 
  ☐ Black or African American 
  ☐ Native Hawaiian or other Pacific Islander 
  ☐ White 
  ☐ Other/Mixed Race (specify)_________________________________ 
 
Phone number:  
 








Medical History (List current or past condition that occurred in the last 5 years) 
 
 
Duration of chronic rhinosinusitis:  
 
Number of episodes per year: 
Frequency of medication use: 
Antibiotics: 
Oral steroid: 
Nasal steroid spray/douching: 
Antihistamines: 
Others: 
Date of last treatment taken:  
 
ODIFIED LUND-KENNEDY SCORING SHEET 




   




No polyps 0 No polyps 0 
Polyps in middle meatus only 1 Polyps in middle meatus only 1 




No discharge 0 No discharge 0 
Clear, thin discharge 1 Clear, thin discharge 1 
 Polyp  Discharge Oedema 
 R L R L R L 
Day 1 
 
      
3 weeks 
 
      
6 weeks 
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Absent 0 Absent 0 
Mild 1 Mild 1 
Severe 2 Severe 2 
 
SNOT-22 
Time of assessment: Day 1 Pre-treatment, 3-week, 6-week 
 
 
Considering how severe the problem 
is when you experience it and how 
frequently it happens, please rate 
each item below on how ‘bad’ it is by 
circling the number that corresponds 
























































1.    Need to blow nose 0 1 2 3 4 5  □ 
2.    Sneezing 0 1 2 3 4 5  □ 
3.    Runny nose 0 1 2 3 4 5  □ 
4.    Cough 0 1 2 3 4 5  □ 
5.    Nasal obstruction 0 1 2 3 4 5  □ 
6.    Loss of smell or taste 0 1 2 3 4 5  □ 
7.    Post-nasal discharge 0 1 2 3 4 5  □ 
8.    Thick nasal discharge 0 1 2 3 4 5  □ 
9.    Ear fullness 0 1 2 3 4 5  □ 
10.  Dizziness 0 1 2 3 4 5  □ 
11.  Ear pain 0 1 2 3 4 5  □ 
12.  Facial pain/pressure 0 1 2 3 4 5  □ 
13.  Difficulty falling asleep 0 1 2 3 4 5  □ 
14.  Wake up at night 0 1 2 3 4 5  □ 
15.  Lack of good night’s sleep 0 1 2 3 4 5  □ 
16.  Wake up tired 0 1 2 3 4 5  □ 
17.  Fatigue 0 1 2 3 4 5  □ 
18.  Reduced productivity 0 1 2 3 4 5  □ 
19.  Reduced concentration 0 1 2 3 4 5  □ 
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